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1 Introduction
Diabetic nephropathy is one of the leading causes of end-stage renal disease
and an important sequela of diabetes mellitus. Currently, an estimated 347
million people suffer from diabetes. The number of diabetic patients has doubled
within a timespan of about thirty years (DANAEI et al., 2011) and the number
of unreported cases is likely to be substantial. Predictions by the World Health
Organization (WHO) suggest that diabetes might become the seventh leading
cause of death in the year 2030 (WHO, 2011). By far the most important form
of diabetes is type 2 diabetes mellitus, which accounts for 90% of cases (WHO,
1999). While insulin treatment can enable patients to live almost normal lifes, the
sequelas associated with diabetes pose a serious risk to the continued health of
the patients. About 20-40% of diabetics develop diabetic nephropathy (DN) as a
sequela. Untreated, this condition eventually leads to renal failure, requiring renal
replacement therapy in the form of dialysis or transplantation (COLLINS et al., 2012).
So far, the underlying molecular mechanisms of diabetic nephropathy (DN) are only
insufficiently understood. Animal models have been instrumental in the research
of diabetes and its associated diseases. Mice are especially suited to the research of
pathophysiological processes because of the large number of genetically modified
animals available today, and their fast succession of generations. However, so far
it has only been possible to recapitulate the early stages of diabetic nephropathy
in mouse models. The development of mouse models that better display the later
stages of diabetic nephropathy is of tantamount importance (BREYER and QI, 2010;
BROSIUS et al., 2009). Several studies have demonstrated the influence of the genetic
background on the susceptibility to diabetes-associated renal lesions in mice (BETZ
and CONWAY, 2014; GURLEY et al., 2010, 2006). So far, many new models of diabetic
nephropathy are only evaluated on one background, irrespective of its suitability
for the evaluation of renal lesions. Many mouse models of diabetic nephropathy
might resemble the human disease more closely, if transferred to a suitable genetic
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background. One promising model of DN with a dominant inheritance pathway are
mice expressing dominant negative glucose-dependent insulinotropic polypeptide
receptors (GIPR) under the transcriptional control of the rat proinsulin gene
promotor (HERBACH et al., 2005). Glucose-dependent insulinotropic polypeptide
(GIP) plays an important role in the regulation of blood glucose levels. GIPRdn-
transgenic mice on an outbred CD1 background have already been shown to
be a suitable model of diabetes mellitus and diabetic nephropathy (HERBACH
et al., 2009). Clinical presentation, pancreas morphology and renal lesions closely
resemble important aspects of human diabetes. A study performed on GIPRdn
transgenic mice of CD1 and BALB/c background has already shown significant
differences between the strains (POPPER, 2013). Discrepancies in mean glomerular
volume, the degree of glomerular hypertrophy and podocytes numbers and volume
per glomerulus correlate well with the severity of glomerulosclerotic lesions and
proteinuria displayed by the two examined strains (POPPER, 2013). The FVB/N
and C57BL/6J strains are popular throughout the scientific world, and are often
used as genetic backgrounds for many models of diseases. The aim of this study
was the determination of strain dependent differences on the development of
diabetes mellitus, and how strain-dependent features influence the susceptibility to
diabetes-associated kidney alterations in GIPRdn-transgenic FVB/N and C57BL/6J
mice.
2
2 Scientific background
2.1 Diabetes mellitus
2.1.1 Classification of types of diabetes mellitus
Diabetes mellitus (D.m.), from the greek “to pass through” (first written record
by Aretaios of Cappadocia, 100 a.d.) and the latin “honey-sweet” (Thomas
Willis, 1675), was among the first diseases to be described, i.e. in the Ebers
papyrus, Egypt, 1500 b.c.. D.m. is comprised of a large, heterogenic group of
metabolic diseases characterized by abnormal glucose metabolism. The deficient
carbohydrate metabolism leads to hyperglycemia and is often accompanied by
abnormalities in the metabolism of fats and proteins. Four categories of diabetes
are differentiated currently (AMERICANDIABETESASSOCIATION, 2014). The first
group, diabetes mellitus type 1, consist of cases in which hyperglycemia is caused
by a destruction of the beta-cells, leading to an absolute insulin deficiency in
humans. In humans, the destruction of the beta-cells is the result of an autoimmune
reaction, with autoantibodies targeting a variety of structures and metabolism
products. However, rare cases of idiopathic diabetes with a high heritability are
also included in this group. Diabetes mellitus type 2 is caused by insulin resistance
with relative insulin deficiency, or a primary low or impaired insulin secretion,
and is responsible for approximately 90% of cases. Both genetic susceptibility and
lifestyle choices play a role in the development of type 2 diabetes. A large number
of genetic variations are associated with either a heightened or lowered risk of
diabetes and patients often carry several genetic risk factors at once (SCHWENK
et al., 2013). The risk of contracting diabetes increases further, when other risk
factors like obesity, lack of physical activity or high blood pressure are also present.
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Epigenetic alterations can also influence the risk of contracting diabetes mellitus,
as maternal high fat diet has been shown to lead to an increased body mass index
and decreased insulin sensitivity in offspring in mice (DAHLHOFF et al., 2014;
SCHWENK et al., 2013). The third group includes all other specific types of diabetes.
Gestational diabetes mellitus makes up the fourth group and is defined as a glucose
intolerance first diagnosed during pregnancy, which does not fall under any of the
other categories.
Types of diabetes mellitus (AMERICANDIABETESASSOCIATION, 2014)
1. Type 1 diabetes
a) Immune mediated
b) Idiopathic
2. Type 2 diabetes
3. Other specific types
a) Genetic defects of β-cell func-
tion
i. Chromosome 12, HNF-1α
(MODY3)
ii. Chromosome 7, glucoki-
nase (MODY2)
iii. Chromosome 20, HNF-4α
(MODY1)
iv. Chromosome 13, insulin
promoter factor-1 (IPF-1;
MODY4)
v. Chromosome 17, HNF-1β
(MODY5)
vi. Chromosome 2, NeuroD1
(MODY6)
vii. MODY7-11
viii. Transient neonatal dia-
betes
ix. Permanent neonatal dia-
betes
x. Mitochondrial DNA
xi. Others
b) Genetic defects in insulin ac-
tion
i. Type A insulin resistance
ii. Leprechaunism
iii. Rabson-Mendenhall syn-
drome
iv. Lipoatrophic diabetes
v. others
c) Diseases of the exocrine pan-
creas
i. Pancreatitis
ii. Trauma/pancreatectomy
iii. Neoplasia
iv. Cystic fibrosis
v. Hemochromatosis
vi. Fibrocalculous pancre-
atopathy
vii. Others
d) Endocrinopathies
i. Acromegaly
ii. Cushing’s syndrome
iii. Glucagonoma
iv. Pheochromocytoma
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v. Hyperthyroidism
vi. Somatostatinoma
vii. Aldosteronoma
viii. Others
e) Drug or chemical induced
i. Vacor
ii. Pentamidine
iii. Nicotinic acid
iv. Glucocorticoids
v. Thyroid hormone
vi. Diazoxide
vii. β-adrenergic agonists
viii. Thiazides
ix. Dilantin
x. γ-Interferon
xi. Others
f) Infections
i. Congenital rubella
ii. Cytomegalovirus
iii. Others
g) Uncommon forms of immune-
mediated diabetes
i. “Stiff-man” syndrome
ii. Anti-insulin receptor anti-
bodies
iii. Others
h) Other genetic syndromes
sometimes associated with
diabetes
i. Down syndrome
ii. Klinefelter syndrome
iii. Turner syndrome
iv. Wolfram syndrome
v. Friedreich ataxia
vi. Huntington chorea
vii. Laurence-Moon-Biedl
syndrome
viii. Myotonic dystrophy
ix. Porphyria
x. Prader-Willi syndrome
xi. Others
4. Gestational diabetes mellitus
MODY: Maturity onset diabetes of the young
2.1.2 Clinical manifestation and diagnosis of diabetes mellitus
The most prevalent form of diabetes mellitus is diabetes mellitus type 2. Unless
hyperglycemia is diagnosed during routine examinations, type 2 diabetes mellitus
often remains undetected over long periods of time, before clinical symptoms like
polydypsia and polyuria occur. Other symptoms include poor wound healing,
weight loss occasionally accompanied by polyphagia, heightened susceptibility to
infections or impaired vision. While common in type 1 diabetes, hyperglycemic
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ketoacidosis is rare in type 2 diabetics. The related hyperosmolar hyperglycemic
state (HHS), which leads to severe dehydration, is far more common and can lead
to coma or even death, if it remains untreated (CORWELL et al., 2014). According
to the American Diabetes Association, the criteria, of which at least one must be
fulfilled for diagnosing diabetes mellitus in a patient, are (AMERICANDIABETESAS-
SOCIATION, 2013):
1. Symptoms of diabetes and casual plasma glucose concentration ≥ 200mg/dl
2. Fasting plasma glucose ≥ 126mg/dl after at least 8h of fasting
3. Glucose≥ 200mg/dl two hours after a glucose load of 75g anhydrose glucose
(oral glucose tolerance test)
4. Glycated hemoglobin (HbA1c) ≥ 6.5% confirmed by repeated testing and
standardized assays
Diagnosing diabetes by measuring HbA1c remains somewhat controversial, as
several other conditions besides hyperglycemia can influence the glycation of
hemoglobin, i.a. anemia, iron deficiency, vitamin B(12) deficiency or folate defi-
ciency (HARDIKAR et al., 2013).
2.1.3 Diabetes mellitus-associated diseases
Sequela of diabetes mellitus can be roughly divided into complications caused
by microvascular or macrovascular damage due to persisting hyperglycemia and
complications independent of blood vessel damage or dependent on both micro-
and macrovascular lesions. The pathogenesis of D.m.-associated vascular damage
is complex. Studies have shown loss of pericytes and development of a pro-
inflammatory milieu, which in turn leads to basement membrane thickening,
endothelial dysfunction and loss of barrier function (LI et al., 2012; KERN, 2007; VON
TELL et al., 2006). The consequences of vascular damage include arteriosclerosis,
thrombosis, tissue hypoxia due to decreased blood flow and leakage of protein into
the interstitium.
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Microvascular complications of diabetes: diabetic retinopathy, diabetic
cardiomyopathy, diabetic neuropathy and diabetic nephropathy
Diabetic retinopathy is a very common complication of diabetes mellitus and
has a non-proliferative phase, followed by a proliferative stage. During the non-
proliferative phase, persistent hyperglycemia is known to cause damage to the cap-
illaries in the retina (GERALDES et al., 2009). In some cases, exudate leaks through
compromised capillaries into the macula, causing macular edema. Concomitantly,
hyperglycemia also damages neuronal cells in the retina (RAJASHEKHAR et al.,
2014). During the proliferative phase, neovascularisation occurs in the fundus
oculi, increasing the risk of vitreous hemorrhages. Symptoms range from impaired
vision to blindness.
Diabetic cardiomyopathy, first described in 1972 (RUBLER et al., 1972), is a conse-
quence of microangiopathy with endothelial dysfunctions, abnormal metaboliza-
tion (AVOGARO et al., 2004), oxidative stress, cardial autonomic neuropathy and
alterations of calcium ion transients (PEREIRA et al., 2006). Patients present with
cardiomegaly and diffuse myocardial fibrosis in the absence of significant coronary
obstruction.
Diabetic neuropathy does not present with one clearly defined clinical picture,
but rather a collection of different syndromes all caused by the same underlying
processes, neuronal dysfunction and ischemia caused by insufficient blood flow
through damaged capillaries (WILLIAMS et al., 1980). Both axonal degeneration
and segmental demyelination of nerves can occur in diabetic neuropathy (VITAL
et al., 1973). Metabolism changes have been implicated in the pathophysiology of
diabetic neuropathy in animal models, but could not be substantiated in studies
with human patients. Clinical presentation depends on which nerves are afflicted
in each patient. Described diabetic neuropathies include amyotrophy, a wasting of
sceletal muscle accompanied by muscle pain. Another form that often occurs in
diabetics is the autonomic neuropathy or autonomic polyneuropathy, with a large
collection of symptoms, depending on the exact location of the lesions. Common
symptoms include orthostatic hypotension, gastroparesis, nausea, diarrhea, urine
incontinence or retention, and pollakisuria. Correspondingly, mononeuropathy
and polyneuropathy of various nerves, both sensoric and motoric, occur.
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Diabetic nephropathy, more extensively described in chapter 2.2, is a progressive
condition first described by Kimmelstiel and Wilson (KIMMELSTIEL and WILSON,
1936) that leads to chronic kidney insufficiency and failure. Patients with advanced
diabetic nephropathy often require dialysis or an organ transplant. In 2008, 44%
of US patients developing kidney failure were diabetic (CDC, 2011). Diabetic
nephropathy seems to increase the risk of cardiovascular events and subclinically
increased urine albumin excretion has been associated with a higher mortality rate
in diabetic patients (MULLER, 1998; JARRETT et al., 1984).
Macrovascular complications of diabetes: stroke, cardiac infarction,
peripheral arterial disease and diabetic myonecrosis
Atherosclerosis as a macrovascular complication in diabetic patients leads to an
increased risk for strokes, myocardial infarctions and peripheral arterial disease
(VAZQUEZ-BENITEZ et al., 2015). As hyperglycemia and elevated levels of fatty
acids promote the formation of atherosclerotic plaques (LUSIS, 2000), diabetics
have a 2-4 times higher risk for coronary artery disease and ischemic stroke.
Cardiovascular disease is the leading cause of death among diabetics and accounts
for 65-75% of deaths, shortening the life expectancy of diabetics by several years
compared to non-diabetics of the same age group (MOSS et al., 1991). Peripheral
arterial disease (PAD) is defined as atherosclerotic occlusion of lower extremities,
and usually presents with intermittent claudication, rest pain, ulcers or even
gangrene. As such, it is a risk factor in the development of diabetic foot, and
it serves as a marker for systemic vascular diseases. While PAD also occurs in non-
diabetic patients, the aetiopathology in diabetic patients seems to be different due
to changes in arterial structure and function (AMERICANDIABETESASSOCIATION,
2003).
Diabetic myonecrosis is a rare, but serious condition that usually occurs in patients
already suffering from diabetic retino- or nephropathy. Caused by the infarction of
muscle tissue, it is most often found in the thigh and patients present with sudden
unilateral pain and edema (BHASIN and GHOBRIAL, 2013).
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Diabetic foot ulcer, diabetic encephalopathy and diabetic neuropathic
arthropathy
Diabetic foot ulcers develop from a combination of diabetic neuropathy, which
decreases sensitivity and pain reception, and peripheral vascular disease. Addition-
ally, diabetics suffer from impaired wound healing and a compromised to abnormal
immune system, which further complicates the treatment of wounds, and often
makes limb amputation necessary (MOURA NETO et al., 2013).
Cognitive impairments in diabetics, referred to as diabetic encephalopathy, include
memory loss, dementia, seizures and coma. Both vascular and metabolic changes,
especially persisting hyperglycemia and hypoxia, are suspected to play a role in
the development of brain damage (SINHA et al., 2014; MENG et al., 2013).
Diabetic neuropathic arthropathy is a progressive degeneration of the ankle joint
and another rare sequela of diabetes with unclear aetiology. Denervation, caused
by vascular damage and repeated trauma due to the decreased sensitivity of the
limb appear to play a role in the progression of the disease (BAKER et al., 2007).
Only approximately 1-2% of patients with peripheral neuropathy seem to develop
Charcot arthropathy. Proinflammatory cytokines, increased osteoclast activity,
neuropeptides and microvascular hyperemia are implicated in the development of
diabetic arthropathy, and a genetic predisposition seems to be likely (MASCAREN-
HAS and JUDE, 2013). Contrary to the development of diabetic foot, peripheral
arterial disease seems to have a protective effect on the development of diabetic
arthropathy (KAYNAK et al., 2013).
2.2 Diabetic nephropathy (DN)
2.2.1 Clinical stages of diabetic nephropathy
Diabetic nephropathy in humans is defined by a diabetic condition, albuminuria
and increasingly declining glomerular filtration rate (GFR) (MOGENSEN et al.,
1983). During stage 1, characterized by hyperfunction of the kidney, GFR and
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albumin excretion are increased. Following stage 1 is a silent second stage, where
the GFR is normal to increased, but albumin excretion returns to normal levels
under good glycemic control. Stage 3, incipient diabetic nephropathy, is marked
by persistent microalbuminuria (15-300 µg/min), that slowly increases and a rise
in blood pressure. Stage 4, known as overt diabetic nephropathy, is characterized
by macroalbuminuria, slightly increasing plasma creatinin concentrations and
decreasing GFR. In stage 5, end-stage renal failure, patients additionally develop
uremia and low GFR (MOGENSEN et al., 1983).
2.2.2 Composition and function of the glomerular filtration
barrier as relating to the pathogenesis of diabetic
nephropathy
The glomerular filtration barrier (Figure 2.1, p.12 and Figure 2.2, p.13) consists of
three layers: the glomerular endothelium, the glomerular basement membrane and
the slit diaphragm formed between podocyte foot processes. The fenestrated,
thin endothelium lines the inside of the glomerular capillaries (KONDO and
USHIKI, 1985). Approximately 30-50% of the endothelial surface are fenestrated
(DEEN et al., 2001). The fenestration and flattening of the endothelial cells is
induced via podocyte-derived vascular endothelial growth factor A (VEGF-A)
and transforming growth factor β1 (TGF-β1) (LIU et al., 1999; KITAMOTO et al.,
1997). A glycocalix, composed mainly of proteoglycans and sialoproteins (PRIES
et al., 2000), covering the endothelium and extending into the fenestrae, and a
layer of surface glycoproteins makes the endothelium semipermeable and allows
the retention of as much as 95% of plasma proteins (HJALMARSSON et al., 2004;
OHLSON et al., 2001). This glycocalix contributes little to the hydraulic resistance
of the filtration barrier (DRUMOND and DEEN, 1994). The glomerular basement
membrane (GBM) contains type IV collagen formed from a triple helix of α3, α4
and α5 chains that differs from the type IV collagen present in the glomerular
mesangium (HARVEY et al., 1998). The type IV collagen forms a regular meshwork
with round to oval pores (ISOGAI et al., 1999). The podocyte foot processes (pedicels)
form a 30-40nm wide membrane-like slit diaphragm between their interdigitating
processes. The podocytes attach themselves to the GBM by connecting their actin
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cytosceletons with cell surface adhesion proteins, namely α3β1 integrin and α-
dystroglycan (KOJIMA and KERJASCHKI, 2002; KRETZLER, 2002), which enables
the slit diaphragm to withstand the high filtration pressure (EL-AOUNI et al.,
2006). The slit diaphragm, essentially a cell-cell connection between pedicels, is
the most selective part of the filtration barrier. The proteins podocin and nephrin,
both produced by the podocytes, are integral to maintaining the slit diaphragm
architecture (ROSELLI et al., 2004; WARTIOVAARA et al., 2004; KHOSHNOODI et al.,
2003). The glomerular basement membrane and the slit diaphragms each provide
roughly half of the hydraulic resistance of the filtration barrier (DRUMOND and
DEEN, 1994). The components of the glomerular filtration barrier retain blood
particle components in a size- and charge-dependent manner.
2.2.3 Morphology and pathogenesis of glomerular and tubular
lesions in diabetic nephropathy
In 1936, Kimmelstiel and Wilson first described eight cases of patients presenting
with hyalinization of the glomeruli. They noted that the homogeneous mass they
observed did not contain amyloid or fat, and that it belonged to the intercapillary
connective tissue. Marked arteriosclerosis and fatty degeneration of arterioles were
found in all cases. Further observations included slightly thickened glomerular
basement membranes, decreased number of capillaries and hyalin-like masses
lying between the bowman’s capsule and the glomerulus. Kimmelstiel and Wilson
noted that all patients reported long standing diabetes in their histories, and
showed albuminuria and signs of renal insufficiency (KIMMELSTIEL and WILSON,
1936). The lesions described by Kimmelstiel and Wilson are now referred to as
mesangial expansion and glomerulosclerosis. Glomerulosclerosis is now defined
as a degenerative process with scarring of glomerulus. Microscopically, mesangial
expansion, thickening of the glomerular basement membrane, adhesion of the
glomerulus to the bowman’s capsule or hyalinosis of the arterioles can be observed
(LIZICAROVA et al., 2014). In humans, glomerulosclerosis often presents as a
nodular sclerosis of the glomerulus. This nodular sclerosis is commonly called a
Kimmelstiel-Wilson lesion (BERKMAN and RIFKIN, 1973).
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Figure 2.1 Schematic drawing of the glomerulus
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1: Macula densa, 2: afferent arteriole, 3: efferent arteriole, 4: GBM (black), 5:
endothelial cells (green), 6: Bowman’s capsule, 7: podocyte (red), 8: mesangium
(turquoise), 9: proximal tubule. Picture courtesy of Dr. Andreas Blutke, Institute of
Veterinary Pathology, LMU München.
Several factors play a role in the development of glomerular lesions associated with
diabetes mellitus. One important feature in the development of DN is podocyte
and glomerular injury through various metabolic changes. High glucose concen-
trations, nonenzymatically glycated proteins, mechanical stress and proteinuria
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Figure 2.2 Schematic drawing of the glomerular filtration barrier
A: Podocyte foot process, B: Slit diaphragm, C: Nephrin, D: Podocin, E: α3β1-
Integrin, F: Laminin, G: Dystroglycan, H: Glomerular basement membrane,
I: Glomerular endothelial cell. Picture courtesy of Dr. Andreas Blutke, Institute of
Veterinary Pathology, LMU München.
can stimulate angiotensin II production. Locally high angiotensin II concentrations
induce a reduction in nephrin production and induce the production of TGF-
β1, a fibrogenic growth factor which can promote renal hypertrophy (ZIYADEH
13
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Table 2.1 Pathologic classification of DN in humans by TERVAERT et al. (2010)
Class Description Inclusion Criteria
I Mild or nonspecific LM changes
and EM-proven GBM thickening
GBM >395nm in female and
>430nm in male individuals 9 years
of age and older
IIa Mild mesangial expansion Mild mesangial expansion in >25%
of the observed mesangium
IIb Severe mesangial expansion Severe mesangial expansion in
>25% of the observed mesangium
III Nodular sclerosis (Kimmelstiel-
Wilson lesion)
At least one convincing Kimmelstiel-
Wilson lesion
IV Advanced diabetic glomerulo- Global glomerular sclerosis in >50%
sclerosis of glomeruli
DN: diabetic nephropathy, LM: light microscopical, EM: electron microscopical,
GBM: glomerular basement membrane
and WOLF, 2008; SHARMA and ZIYADEH, 1994) and increases the production of
podocyte-derived vasoendothelial growth factor (VEGF). TGF-β1 has great impact
on podocyte metabolism and has been shown to suppress the genes coding for
nephrin and podocin in the podocytes and can induce podocyte apoptosis (MITU
et al., 2007) via MAP kinase p38 and caspase 3 (SCHIFFER et al., 2001). Changes
in podocyte metabolism have a profound effect on podocyte morphology and
function. TGF-β1 can also decrease podocyte adhesion to the GBM by reducing
α3β1 integrin production (DESSAPT et al., 2009). Combined with podocyte foot
process effacement as a result of the reduction in nephrin production, decreased
adhesion to the GBM increases the likelihood of podocyte loss. Podocyte loss
through either detachment, apoptosis or necrosis is the most important aspect in
the progressive destruction of the glomerular filtration barrier, eventually leading to
the proteinuria and renal failure that is characteristic for the clinical presentation of
DN. Podocyte hypertrophy and thickening of the glomerular basement membrane
(GBM) has been shown to precede the development of glomerular hypertrophy
and glomerulosclerosis in mice (TERVAERT et al., 2010; HERBACH et al., 2009). A
thickening of the GBM, as a consequence of increased matrix protein deposition, is
associated with ultrasturctural changes in GBM architecture that make the GBM
more, rather than less, porous (ISOGAI et al., 1999). Hyperglycemia can induce
increased glomerular matrix protein deposition in the glomerulus through various
metabolic pathways, with transforming growth factor β1 (TGF-β1) as one of the
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most important downstream mediators (ZIYADEH, 2004; SHARMA and ZIYADEH,
1994; ZIYADEH et al., 1994). The accumulation of extracellular matrix might be
associated with a decrease in the capillary surface area available for filtration
(MAUER et al., 1984). Glomerular hypertrophy also leads to reduced relative
podocyte density, forcing the podocytes to further increase in size to maintain
the glomerular filtration barrier. One of the most important risk factors for the
development of glomerular lesions in human patients, aside from hyperglycemia, is
hypertension (GANGADHARIAH et al., 2014; MOGENSEN, 1998). Diabetics suffering
from DN are more likely to report a family history of hypertension, than diabetics
who do not develop DN (ROGLIC et al., 1998). Increased intracapillary pressure
in the glomerulus is thought to lead to hyperfiltration and subsequent scarring of
the glomerulus as a result of endothelial and mesangial injury (BRENNER et al.,
1988; BRENNER, 1983). The cases of two patients suffering from both diabetes
mellitus and unilateral renal artery stenosis seem to support this theory, as both
developed signs of DN in the initially healthy kidney, but not in the kidney affected
by renal artery stenosis (BERONIADE et al., 1987; BERKMAN and RIFKIN, 1973).
Common features of DN also include protein reabsoption into the proximal tubular
epithelial cells, tubular hypertrophy, tubular basement membrane thickening and
tubular atrophy (AN et al., 2015; HABIB, 2013). Most tubulointerstitial lesions
are related to proteinuria and hyperfiltration, as protein erroneously filtrated into
the interstitium has been shown to have a nephrotoxic effect (MARSHALL and
WILLIAMS, 1998; REMUZZI et al., 1995; BRENNER, 1983). Renal interstitial fibrosis,
mediated by TGFβ1 via multiple cytokines like tumor necrosis factor (TNF-α) and
connective tissue growth factor (SAKAI et al., 2013) and epithelial-mesenchymal
transformation (EMT) of tubular epithelial cells into myofibroblasts, are important
features of human DN that animal models largely fail to reproduce. In kidneys
with advanced DN, mononuclear cell infiltration as an inflammatory response to
proteinuria can be observed and contributes to the progression of DN (TESCH, 2007;
CHOW et al., 2004a,b).
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2.3 Murine models of diabetes mellitus
In the following chapter, some of the most widely-used mouse models of diabetes
mellitus on commonly used genetic backgrounds will be described. Mouse models
of diabetes mellitus include genetically modified animals, spontaneously mutated
animals and mice with dietary induced diabetes mellitus. Genetically modified
mice can be subdivided into transgenic mice, knockout mice and mouse mutants.
In transgenic mice, an exogenous gene (transgene) has been inserted randomly
into the mouse genome. Mice in which a gene has been inactivated, are called
knockout mice. Mouse mutants are generated by exposing the germ cells of male
mice to mutagenic substances (i.e. ethylnitrosourea), causing random mutations in
the genome of their offspring. The range and severity of symptoms displayed by
different mouse models can vary drastically, depending on the genetic modification.
The genetic background on which the different mutations and and knocked out
genes are examined has been shown to have a great influence on the severity of
the symptoms (BROSIUS, 2010; GURLEY et al., 2010; XU et al., 2010; BROSIUS et al.,
2009; QI et al., 2005). Some mouse strains are more susceptible to the development
of diabetic lesions, while other mouse strains carrying the same mutation display
only mild diabetes mellitus. So far, no single mouse model of diabetes displays the
entire range of symptoms, or the same severity of the disease, as human patients
(BROSIUS et al., 2009; BREYER et al., 2005b). Mouse models of DN are described in
chapter 2.4.
2.3.1 Streptozotocin-induced diabetes
Streptozotocin-induced diabetes mellitus is a popular model of diabetes mellitus
type 1. Streptozotocin (STZ) is an antibiotic naturally produced by Streptomyces
achromogenes, with a high toxicity for pancreatic beta cells (LEITER, 1982). Any
genetic background can be used in this model of diabetes, though strains differ
in their susceptibility to STZ. Disadvantages of the STZ-model include suspected
non-specific toxicity of STZ and the need for different STZ regimes depending
on the mouse strain and its susceptibility. To lower the risk of non-specific
toxic effects, using low-dose STZ regimes instead of high-dose STZ regimes
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is often recommended (BREYER et al., 2005b). Low-dose and high-dose STZ
treatments induce comparable levels of hyperglycemia in males of the same genetic
background, but the level of hyperglycemia varies both in respect to gender and
mouse strain (LEITER, 1982; ROSSINI et al., 1977). High-dose STZ regimes lead
to albuminuria even in C57BL/6J mice, while low-dose STZ treatment leads to
comparatively lower levels of albuminuria, depending on the background strain
(compare Table 2.2, p.31).
2.3.2 Obese mouse (ob/ob)
The ob/ob mouse carries a spontaneous recessive autosomal mutation of the leptin
gene, leading to leptin deficiency, occurring in an animal at the Jackson Memorial
Laboratory in 1950 (INGALLS et al., 1950). Leptin is a small adipokine that lowers
appetite by binding to leptin receptors in the hypothalamus. On a C57BL/6J
background, animals present with massive adipositas, mild hyperglycemia and
hyperinsulinemia. On other available backgrounds, the obesity is observed to
be less severe while diabetic symptoms are massively increased (BREYER et al.,
2005b).
2.3.3 Diabetes mouse (db/db)
Db/db mice carry a point mutation of the leptin receptor and are available on
the C57BL/6J, the C57BLKS/J and the DBA/2J background. They begin to
develop hyperinsulinemia as early as 10d of age, with hyperglycemia beginning
at approximately 1m of age. The progression to pancreatic islet cell degeneration
takes between 5-6m. While it is possible to use db/db mice as a model of DN on
the C57BLKS/J background, C57BL/6J mice display no noticeable signs of kidney
insufficiency. More severe hyperinsulinemia and hyperglycemia develops on the
DBA/2J background compared to the C57BL/6/J and C57BLKS/J (BREYER et al.,
2005b).
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2.3.4 Kuo Kondo mouse (KK/Ta)
Thought to be a polygenetic model of diabetes, the KK mouse was established by
Kondo et al. in 1957 from native japanese mice. These mice exhibit obesity, mild
insulin resistance and hyperglycemia, and increased pancreatic islet volume and
number. Symptoms develop slowly over several months before stabilizing and
finally reverting to normal at approximately one year of age. KK mice seem to be
predisposed to renal lesions resembling DN, like mesangial expansion, mesangial
cell proliferation and arteriole hyalinization (TOMINO et al., 2005).
2.3.5 Nagoya-Shibata-Yasuda mouse (NSY)
The inbred NSY mouse was created from outbred Jcl:ICR (ICR mice bred by CLEA
Japan, Inc.) mice selected for glucose intolerance, and males reproducibly develop
age related diabetes type 2. Unlike most mouse models of non-insulin-dependent
diabetes mellitus, NSY mice are only moderately obese and hyperinsulinemic and
do not show pancreatic islet hypertrophy. They display defects in both insulin
secretion and insulin resistance (UEDA et al., 1995).
2.3.6 New Zealand obese mouse (NZO)
The NZO mouse is a polygenetic model of type 2 diabetes bred from two agouti
mice, chosen from a mixed colony. It was first described in 1953. Animals
present with obesity, insulin resistance, islet hypertrophy and hypercholesterolemia
(BIELSCHOWSKY and BIELSCHOWSKY, 1956).
2.3.7 High fat diet (HFD) induced diabetes mellitus type 2
Different mouse strains exhibit diverging metabolic responses to HFD and sev-
eral strains may develop glucose intolerance (MONTGOMERY et al., 2013; SIMS
et al., 2013; ANDRIKOPOULOS et al., 2005; NOONAN and BANKS, 2000). HFD-fed
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C57BL/6J, FVB/N and DBA/2J display only mild hyperglycemia and glucose
intolerance. The 129X1 strain is the most glucose intolerant (MONTGOMERY
et al., 2013) of all investigated mouse strains, when fed a HFD, and displays an
increase in blood glucose concentration of 284% compared to control mice during
an intraperitoneal glucose tolerance test. On the other hand, the C57BLKS/J strain,
though closely related to the C57BL/6J mice, reacts to high fat diets by becoming
more physically active and feeds self-restrictively. Thus, C57BLKS/J mice do not
gain weight as quickly or develop insulin resistance (SIMS et al., 2013). The BALB/c
strain is another strain that is unresponsive to HFD. BALB/c mice fail to develop
adipositas or hyperglycemia (MONTGOMERY et al., 2013).
2.4 Murine models of diabetic nephropathy
In the following chapter, some of the most promising mouse models of diabetic
nephropathy will be described shortly. While db/db and KK/Ta mouse models
of diabetes mellitus type 2, described in chapter 2.3, can be utilized as models of
DN, crossbreeding to create mouse models with several mutations or backcrossing
of promising genetic variations on strains especially prone to the development
of kidney lesions can be useful to better mimic human DN in the mouse model
(BROSIUS et al., 2009; BREYER et al., 2005a). Mice with fasting blood glucose
concentrations of more than 200-300mg/dl, depending on the source (MARRERO
et al., 2013; FOX, 2007), are considered to be diabetic. No definition of DN in mice
currently exists. Generally, mice display albuminuria, hyperfiltration and a varying
collection of the histopathologic changes present in human patients with DN. No
mouse model of DN achieves renal failure, which may point to either an insufficient
duration of diabetes at the time of examination or an intrinsic resistance to kidney
disease in the currently used mouse strains.
2.4.1 Bradykinin receptor deficient Ins2Akita/+ mouse
Ins2Akita/+ mice are a model for Mutant Ins-Gene Induced Diabetes of Youth
(MIDY]. MIDY is a form of of permanent neonatal diabetes (LIU et al., 2010). These
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mice develop hyperglycemia and albuminuria due to a spontaneous mutation
in the Ins2 gene, which causes misfolding of insulin. They also show many
signs of DN, like glomerulosclerosis and tubulointerstitial fibrosis, thickening
of the glomerular basement membrane and detachment of podocyte foot processes
(CHANG and GURLEY, 2012). Ins2Akita/+ mice are available on a number of different
genetic backgrounds. Ins2Akita/+ on a FVB/N background display average blood
glucose levels of 798±58 mg/dl, insulin levels of 0.11±0.08 µmol/l, a systolic blood
pressure of 115±2 mmHg and 9.8 times higher albumin excretion compared to a
control group. They display interstitial fibrosis scores of approximately 0.4, and
glomerulosclerosis indices of 1 (KAKOKI et al., 2010).
Ins2Akita/+ with a homozygous deletion of the Bdkrd2 gene (B2R-null Akita) on a
C57BL/6J or C57BLKS/J background are used as a model of bradykinin 2 receptor
(B2R) deficiency. BRKO(bradykinin receptor knockout mice)-Ins2Akita/+ lack both
B2R and B1R and display even more severe lesions of the kidney. Bradykinin is an
endogenous polypeptide produced by the vascular kinin-kallikrein system that acts
as a vasodilatator by stimulating the release of NO, prostacyclin or endothelium-
derived hyperpolarizing factor. Additionally, B2R activation has a negative effect
on the collagen I and IV synthesis stimulated through hyperglycemia, TGFβ
and epithelial growth factor (BLAES et al., 2012) Clinical findings in B2R-null
Akita deficient include stable blood pressure, comparable blood glucose and
insulin levels, increased oxidative stress compared to Ins2Akita/+ retaining both
bradykinin receptors. Albuminuria is increased 1.8-fold in B2R-null Akita and
2.7-fold in BRKO Akita compared to Ins2Akita/+. Semiquantitative measurements
of interstitial fibrosis and glomerulosclerosis, are severely increased compared to
wild-type controls. The interstitial fibrosis scores are approximately 1.4 and 3.3
and glomerulosclerosis indices approximately 1.5 and 2.3 respectively for B2R-null
and BRKO Akita. All histological signs of DN present in the Ins2Akita/+ mouse are
found increased in severity in BRKO mice (KAKOKI et al., 2010).
2.4.2 Renin-overexpressing mouse with STZ-induced diabetes
Currently, several models of renin-overexpression exist on the 129S6/SvEvTac co-
isogenic background. The genetic variations RenTgARE, RenTgKC and RenTgMK
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display higher than normal plasma renin levels, leading to cardiovascular disease
and nephropathy. Diabetes mellitus is induced either through low-dose STZ
treatment or the Ins2Akita/+ mutation (BREYER et al., 2005b). Blood glucose levels
are dependent of the manner of diabetes induction. Albumin excretion varies
from normal up to 10-fold increased, systolic blood pressure can reach up to
150mmHg. Histological observations include normal to severe glomerulosclerosis
indices with inflammatory cell infiltration and tubulointerstitial fibrosis, according
to unpublished observations (S.B.G. et al, found in (BROSIUS et al., 2009).
2.4.3 OVE26-transgenic FVB/N (FVB-OVE26) mouse
OVE26-transgenic FVB/N mice overexpress a calmodulin mini gene regulated by
the rat insulin 2 promotor. The overexpression of calmodulin in the pancreatic β
cells causes β cell toxicity, leading to severe early-onset type 1 diabetes. Due
to a small population of surviving β cells, FVB-OVE 26 mice are not insulin
dependent. Two month old FVB-OVE26 display average blood glucose levels
of 594±11 mg/dl. Systolic blood pressure does not exceed 100mmHg. FVB-
OVE26 develop pronounced albuminuria. At the age of nine months, albumin
excretion exceeds 15000 µg/d, compared to approximately 2000µg/d in F1 hybrids
of FVB-OVE26 and C57BL/6J mice. GFR, measured by FITC inulin clearance,
decreases from 600µl/min at 3m, to just above 500µl/min at 9m (ZHENG et al.,
2004). Histological alterations include glomerular hypertrophy, glomerulosclerosis,
considerable tubulointerstitial fibrosis and GBM thickening (BREYER et al., 2005b).
Mesangial volume is increased by factor 4 compared to the non-diabetic control in
10m old animals (ZHENG et al., 2004).
2.4.4 eNOS−/− mouse
Vascular endothelial nitric oxide synthase (eNOS) acitivity is lowered in this mouse
model through polymorphisms in the NOS3 gene. Nitric oxide (NO) plays an
important role in the management of vascular permeability and vasodilatation.
Low NO levels lead to severe alterations in the kidneys of diabetic mice. This
model has been established both on a C57BL/6J and C57BLKS/J background, with
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diabetes being induced through various STZ-regimes. High-dosage STZ-diabetic
B6-eNOS−/− develop more robust glomerulosclerotic and tubulointerstitial lesions,
however, this is likely due to a direct toxic effect of the STZ on the kidneys. To
avoid direct nephrotoxic effects, low-dosage STZ-regimes should be used (BREYER
et al., 2005b). Although C57BL/6J-Ins2Akita/+eNOS−/− die shortly after weaning,
(C57BL/6J x 129SvEv)F1 hybrids carrying eNOS−/− and Ins2Akita/+ are viable and
show similar clinical alterations. As a model of type 2 diabetes, BKS-eNOS−/−
mice have been crossbred with BKS-db/db mice (BREYER et al., 2005b). After
a low-dose STZ-regime, 30w old eNOS deficient C57BL/6J develop severely
increased blood glucose levels of about 650mg/dl, an increased systolic blood
pressure of ca. 127mmHg and a 10-fold increase in albuminuria compared to
wild.type controls. Unlike wild-type STZ-treated mice, eNOS−/− mice do not
develop hyperfiltration. All mice displayed mild glomerular mesangial expansion,
cell proliferation and mesangiolysis, 4.6% displayed global glomerulosclerosis
(KANETSUNA et al., 2007).
2.4.5 Kuo Kondo - Agouti (KK-Ay/Ta) mouse
Established in 1969 by Nishimura et al., the KK-Ay was bred from KK mice and mice
heterozygous for a mutation of the agouti gene called mouse lethal yellow (Ay).
Ay mice are obese and insulin resistant (MICHAUD et al., 1994; HELLERSTROM
and HELLMAN, 1963) KK-Ay/Ta mice display obesity, hyperinsulinemia and
hyperglycemia, but no increase in blood pressure. Blood glucose levels average
at 447±19 mg/dl casual and 84±2 mg/dl fasting blood glucose at the age of
20w. KK-Ay develop albuminuria with >400mg/g urinary albumin to creatinin
ratio (WILLIAMS et al., 2007). Symptoms of DN like glomerular hypertrophy,
moderate GBM thickening, podocyte fusion, podocyte loss, interstitial fibrosis
and glomerulosclerosis are present, but no stereological data was made available
(TOMINO, 2012; MACEDO et al., 2007; ITO et al., 2006; CHEN et al., 2002).
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2.4.6 NONcNZO10/LtJ mouse
The NONcNZO10/LtJ is a congenic strain (definition in chapter 2.5) bred from
nonobese nondiabetic mice (NON/LtJ) and the New Zealand obese mouse
(NZO/HlLt) and is a polygenic model of type 2 diabetes. NONcNZO10/LtJ mice
are only moderately obese compared to ob/ob or db/db mice. After weaning,
NONcNZO10/LtJ mice are fed a diet containing 10% fat to promote the devel-
opment of diabetes mellitus. Blood glucose levels of 24w old NONcNZO10/LtJ
mice are averaging at approximately 466±35 mg/dl. The mice develop mild
glomerulosclerosis and show increased PAS staining of the GBM (LEITER and
REIFSNYDER, 2004). Though the renal alterations displayed by this strain can
be severe, several features such as intracapillary glomerular lipid deposits and
immunoglobulin deposits occur in the NON strain as well as in NONcNZO10/LtJ
mice and are unrelated to diabetes (BREYER et al., 2005b; WATANABE et al., 1991).
2.4.7 Decorin deficient (Dcn−/−) mouse with STZ-induced
diabetes
The small leucine-rich proteoglycan decorin has the ability to bind to TGF-β and
other growth factors that play a role in the development of mesangial expansion.
In the tubulus, decorin can bind to the insulin-like growth-factor I receptor and
prevent apoptosis of tubular epithelium caused by hyperglycemia (SCHONHERR
et al., 2005). Decorin deficient mice are available on the C57BL/6J background. Mice
are treated with standard STZ-regimes to induce diabetes mellitus. Blood glucose
levels do not differ from those of wild-type STZ-induced diabetic mice. Compared
to wild-type mice, Dcn−/− mice show 50% increased albuminuria, starting 6m after
STZ treatment, and renal function is decreased by 23%. TGF-β levels are increased,
and mononuclear infiltration can be observed. Mesangial matrix expansion is 1.5
times higher compared to wild-type diabetics and apoptosis of tubular epithelium
can occur. Nodular glomerular sclerosis or tubulointerstitial fibrosis does not occur
in this model (MERLINE et al., 2009; WILLIAMS et al., 2007).
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2.4.8 Mice expressing a dominant negative glucose-dependent
insulinotropic polypeptide receptor (GIPRdn-tg mice)
Function of glucose-dependent insulinotropic polypeptide (GIP) and the
GIP receptor
Glucose-dependent insulinotropic polypeptide, originally named gastric inhibitory
polypeptide, is an incretin synthesized by K cells in the duodenum and proximal
jejunum (BUCHAN et al., 1978). It consists of 42 amino acids, derived from
its preprohormone precursor by proteolytic processing (GALLWITZ et al., 1996).
The amino acid sequence of GIP is highly conserved and shows 90% homology
for humans, pigs, cattle and rats. GIP is released after the consumption of
carbohydrates and lipids. The amount of GIP released is directly proportionate to
the amount of lipids and carbohydrates absorbed. The effectiveness of lipids in the
stimulation of GIP secretion depends on species and dietary habits, lipids being
a far more potent stimulant of GIP secretion in species with a high percentage of
fat in their diet (i.e. humans). GIP binds to the GIP receptor expressed mainly on
beta cells in the pancreas. The GIP receptor is a G-protein linked receptor of the
secretin/VIP receptor family with seven transmembrane domains. The binding of
the ligand to the N-terminal domain activates a heterotrimeric G-protein, and thus
an adenylat-cyclase (GELLING et al., 1997). The adenylat-cyclase produces cAMP,
which causes a Ca2+ influx through voltage-gated calcium channels. The increase
of intracellular Ca2+ stimulates insulin excytosis (LU et al., 1993). GIPR is present
in a variety of different tissues and cells, including pancreas, fat tissue, intestines,
heart, adrenal cortex, hypothalamus, hippocampus, pituary, olfactory bulb, bone
marrow stromal cells, osteoblasts and macrophages (NYBERG et al., 2005; KAPLAN
and VIGNA, 1994; USDIN et al., 1993). In the presence of high plasma glucose levels,
especially after oral administration, GIP stimulates insulin secretion from the beta
cells of the endocrine pancreas. If, on the other hand, plasma glucose levels are
low, GIP increases the secretion of glucagon. Thus it plays an important role in
stabilizing blood glucose levels in healthy individuals. GIP also seems to influence
beta cell number during post-natal islet neogenesis and apoptosis of beta cells in
mice, as mice and pigs expressing a negative GIP receptor display decreased beta
cell mass and decreased beta cell replication (HERBACH et al., 2011; RENNER et al.,
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2010). Research has shown, that in diabetics, the effect of GIP on insulin secretion
is impaired. Diabetic patients display a significantly decreased and delayed
postprandial early phase and almost missing late phase reaction to GIP (VILSBØLL
et al., 2002). Possible causes include impaired or missing GIP receptor functionality
or postreceptor defects. While variances in the genetic sequence of the GIP receptor
have been found, a clinical significance of the mutations is doubted. However,
a reduced effectiveness of GIP has been shown in 50% of first degree relatives
of diabetic patients (VILSBØLL et al., 2002). An inappropriate glucagon response
in the presence of hyperglycemia and hyperinsulinemia has been discussed as a
factor for the apparent reduced effectiveness of GIP in diabetics (CHRISTENSEN
et al., 2013; DUNNING and GERICH, 2007). Another factor that might play a role in
GIP effectiveness might be the by approximately 50% decreased amount of GIPR
mRNA present in the beta cells of diabetic animals with persistent hyperglycemia
(NOGI et al., 2012; XU et al., 2007). In the presence of insulin, GIP has a variety
of effects on fat tissue. It stimulates fatty acid synthesis and the incorporation of
fatty acids into triglycerides or adipose tissue, increases insulin receptor affinity for
insulin, and can exacerbate conditions like obesity and fatty liver syndrome (YIP
and WOLFE, 2000; YIP et al., 1998; WASADA et al., 1981). GIP receptor knockout
(GIPR−/−) mice do not display diet-induced obesity or insulin resistance, whereas
mice overexpressing GIPR are prone to it. Part of this effect might be caused by a
higher energy expenditure of GIPR deficient mice and a preference for using fat
as an energy source. As GIP seems to act in concert with insulin, it also works
contrary to glucagon and decreases glucagon-induced lipolysis. Furthermore, it
stimulates the secretion and activity of adipose lipoprotein-lipase (LPL), which in
turn further increases the uptake of triglycerides into adipose tissue. Additionally,
GIP has a profound effect on bone density. Age-related bone density loss correlates
with decreased GIPR mRNA in bone marrow stromal cells. GIPR−/− mice showed
reduced bone mass, transgenic mice overexpressing GIP showed increased bone
mass (DING et al., 2008).
GIPRdn-tg mice on the outbred CD1 background
GIPRdn-transgenic mice were generated on outbred CD1 stock and carry mutated
GIP receptor cDNA. The loss of function of the mutated human GIP receptor
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under the control of the rat proinsulin 2 promotor was demonstrated in vitro
previously (VOLZ, 1997). Transgenic GIPRdn-tg CD1 developed casual blood
glucose levels of over 700mg/dl by the age of 6m. The 24h urine volume of GIPRdn-
tg CD1 was about 6-fold increased compared to controls. Albumin excretion
per day was increased 7.7-fold compared to wild-types. Both GIPRdn-tg and
wild-type CD1 mice were endowed with 30000 nephrons and GIPRdn-tg CD1
showed no signs of pathological nephron loss. Glomerular basement membrane
thickness was significantly increased. GIPRdn-tg mice displayed moderate to severe
glomerulosclerosis and marked glomerular hypertrophy with mesangial expansion,
enlarged capillary diameter and podocyte hypertrophy (POPPER, 2013; HERBACH
et al., 2009).
GIPRdn-tg mice on the inbred BALB/c background
To better understand the influence of the genetic background on the development
of diabetes and DN, GIPRdn-CD1 mice were backcrossed unto the inbred BALB/c
strain. The BALB/c strain is one of the three most commonly used inbred mouse
strains and popular as a general purpose strain in many different disciplines of basic
research. GIPRdn-tg BALB/c displayed casual blood glucose levels of 700mg/dl
and higher by the age of 6m. BALB/c mice display a significantly higher baseline of
ca. 127mmHg systolic blood pressure irrespective of transgenic status, compared to
most other mouse strains (POPPER, 2013; SCHLAGER and WEIBUST, 1967). GIPRdn-
tg BALB/c produce only about one third of the 24h urine volume of GIPRdn-tg
CD1 mice. Only mild albuminuria, with 2.6 times increased albumin excretion
in 24h, was be observed in GIPRdn-tg BALB/c mice compared to GIPRdn-tg CD1
mice. The glomerulosclerosis index of GIPRdn-tg BALB/c mice was considerably
lower compared to GIPRdn-tg mice on a CD1 background. Nephron number was
lower in BALB/c mice compared to CD1 mice, but no difference between wild-type
and GIPRdn-tg BALB/c animals could be observed. No measurable increase in
glomerular basement membrane thickness was apparent in GIPRdn-tg BALB/c mice
vs. wild-type BALB/c mice. The mean glomerular volume of wild-type BALB/c
mice was approximately 50% smaller than that of wild-type CD1 mice. GIPRdn-
tg BALB/c mice also showed a smaller percentile increase in mean glomerular
volume compared to BALB/c-wt mice, than GIPRdn-tg CD1 mice vs. CD1-wt mice.
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The comparatively low glomerulosclerosis index displayed by GIPRdn-tg BALB/c
compared to GIPRdn-tg CD1 mice might be due to the lower mean glomerular
volume displayed by BALB/c mice compared to CD1 mice (POPPER, 2013).
2.5 Influence of the genetic background on the
susceptibility to diabetes mellitus and diabetic
nephropathy
2.5.1 Inbred and congenic mouse strains and outbred stock
A mouse strain is considered inbred if it can be traced to a single ancestral breeding
pair and has been mated brother to sister for at least twenty consecutive generations
(BECK et al., 2000). After those twenty generations, an average of 98.6% of loci
are homozygous in each mouse of that strain. As all mice share the two ancestors
initially used for breeding, they are also isogenic, which means they are virtually
genetically identical (MOUSEGENOMEINFORMATICS). Many long established
inbred mouse strains, i.e. C57BL/6J, FVB/N, BALB/c or DBA/2J, have been
bred for more than a hundred generations and are now homozygous in all loci.
Most inbred mouse strains have been bred for specific genotypes and the resulting
specific phenotypes. The degree of genetic relationship between inbred mouse
strains and substrains can differ significantly and depends on the subspecies of
mice used to create the original founding strains and the amount of time that has
passed since the divergence of substrains (WATERSTON et al., 2002; BECK et al.,
2000). The distinct groups are the C57-related mice (i.e. C57BL/6, C57BLKS), the
Castle’s mice which split of from the C57 group during the early 20th century
(i.e. 129/Sv, DBA/2), Swiss mice (i.e. FVB/N), mouse strains derived from Japan
and China (i.e. KK/Ta) and mice derived from wild mice. Two more groups
are comprised of “other” inbred strains with no relationship to each other or any
of the previously described groups (i.e. Ay) and mouse strains descended from
several inbred mouse strains (BECK et al., 2000). Genetic variation between inbred
mouse strains has been measured by determining the number of single nucleotide
polymorphisms (SNPs) present in various mouse strains. An average SNP density
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of 1 in 500-700bp in C57BL/6J vs. 129S1, C3H and BALB/c mice (WATERSTON et al.,
2002) was determined. Genealogically, C3H, 129S1 and BALB/c mice all belong
to the Castle group of mouse strains, which split off from the C57BL/6 group,
while FVB/N mice belong to the Swiss mouse group (BECK et al., 2000). The Swiss
group of mice have had no contact whatsoever with C57BL/6 or Castle mice since
they were founded (BECK et al., 2000). Considering the difference in contributing
subspecies between C57BL/6J and FVB/N mice and the almost nonexistent degree
of relationship, the number of SNPs of FVB/N versus C57BL/6J mice can be
assumed to be considerably higher. Another important feature to be kept in mind
when maintaining and using inbred mice is the high rate of genetic drift in a closed
off livestock. A colony of inbred mice separated from a founding colony for 20
generations, spontaneously occurring mutations, residual heterozygosity and copy
number variations can cause enough genetic drift to lead to substrain divergence.
If possible, mice from the livestock of the original provider of a colony’s animals
should be crossed into that colony on a regular basis to reduce genetic drift (BAILEY,
1977).
In mouse genetics, “congenic” is a term used to describe organisms with a high
genetical similarity. Congenic mice differ in only one locus, or even just one allele. If
an interesting allele present in one inbred mouse strain, the so-called donor mouse
strain, is supposed to be transferred to another inbred mouse strain, the recipient
mouse strain, a special breeding scheme called backcrossing is used to produce a
congenic mouse strain (GV-SOLAS, 2011). Conventional backcrossing requires
ten generations (N10), while speed-congenic backcrossing, using a marker assisted
selection protocol can reach the same level of homozygosity in seven generations.
These breeding methods enable the investigation of the impact of a certain allele
on different genetic backgrounds.
Outbred mouse stocks (i.e. CD1, NMRI) on the other hand, maintain genetic
diversity and heterozygosity. Outbred mouse stocks are defined as a colony of
genetically diverse mice closed off for at least four generations. For example,
HsdWin:NMRI are outbred NMRI mice from a colony maintained by Harlan
Sprague Dawley, Inc. (Hsd) since 1998. The founding animals of this colony were
obtained from the colony at Winkelmann Versuchstierzucht GmbH & Co (Win).
Crl:NMRI mice are outbred NMRI mice as well, but from a colony maintained by
the Charles River Laboratories and genetically different from HsdWin:NMRI mice.
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A rotational breeding scheme prevents to much inbreeding from occurring and
aims to create maximum heterozygosity. Unlike inbred mice, outbred mice can
vary greatly in phenotype as a reflection of their genetical heterozygosity.
2.5.2 C57BL/6J strain
All mice of the C57 group go back to the stock first bred by Miss Lathrop in
1921 (BECK et al., 2000) and have been inbred over many generations (current
generation: F226PF235). Like most laboratory mice strains, the C57BL/6J strain is
descended from several (sub)species of mice. Additionally to the usual subspecies
Mus musculus musculus, Mus musculus domesticus and Mus musculus castaneus,
remnants of genetic material of Mus spretus can be found in C57BL/6J mice
(D. H. PERCY, 2007). The genome of C57BL/6J mice has been almost completely
sequenced (WATERSTON et al., 2002) and the relationship to several other inbred
mouse strains has been evaluated. It is currently the most commonly used mouse
strain used in scientific research around the world. Several studies have noted
the failure of diabetic C57BL/6J mice to develop anything more than mild renal
lesions, even in the presence of severely increased blood glucose levels, but do not
offer any insight as to the cause of that apparent insusceptibility (GURLEY et al.,
2006). When fed a diet high in fat and carbohydrates, they are prone to develop
a non-insulin dependent diabetes mellitus and high blood pressure (MILLS et al.,
1993). According to data made available through the mouse phenome project,
blood glucose levels of male 12w old C57BL/6J mice after a four hour fasting
period average at 201mg/dl. The average systolic blood pressure of 10w old males
was 113.7mmHg±3.2 (DESCHEPPER et al., 2004). BL/6 mice are known for their
longevity (STORER, 1966).
2.5.3 FVB/N strain
FVB/N mice were bred from outbred albino swiss mice at the National Institute of
Health (USA) and are characterized by their sensitivity to the B strain of the murine
lymphoma virus (Friend virus). Unlike most strains of laboratory mice, swiss
mice seem to be almost exclusively descended from Mus musculus domesticus
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(D. H. PERCY, 2007). The large pronuclei of FVB/N mice make them ideal
candidates for the direct microinjection of DNA for the production of transgenic
animals (BECK et al., 2000). Several studies have noted that mouse models of DN
displayed a significantly higher albumin excretion on the FVB/N background
compared to almost any other genetic background. Severe albuminuria correlated
with homozygosity for the FVB/N genotype in peaks on chromosomes 11, 13
and 19 in FVB-OVE26 x C57BL/6J crosses of the N2 generation. Also notably
were the decreased mean glomerular volume and correspondingly decreased
mesangial expansion and interstitial fibrosis displayed by FVB-OVE26 x C57BL/6J
hybrids (XU et al., 2010). According to the Mouse Phenome Project Database
(phenome.jax.org), blood glucose levels of male 12 week old FVB/N mice after a
four hour fasting period average at 203mg/dl. The average systolic blood pressure
of 10 weeks old males was 122.2mmHg±3.2 (DESCHEPPER et al., 2004).
2.5.4 Influence of the FVB/N and C57BL/6J genetic background
on diabetes mellitus and diabetic nephropathy
The most likely factors to influence susceptibility to DN in transgenic mice are
the degree of hyperglycemia, blood pressure, kidney architecture and the location
and copy number of the inserted transgene. To investigate the influence of the
FVB/N and C57BL/6J genetic background on diabetes mellitus and associated
renal lesions, studies on DN using one or both of the strains were surveyed. The
findings of this survey are listed in Table 2.2, p.31. A clear trend is immediately
noticeable. Models of diabetes mellitus and DN using the FVB/N strain as a genetic
background unfailingly develop severe hyperglycemia and albuminuria, and
glomerulosclerosis is more severe compared to the same model on the C57BL/6J
strain. In models of diabetes mellitus and DN using the C57BL/6J strain as a genetic
background, the degree of hyperglycemia varies, with some models developing
only very mild hyperglycemia and B2R-/- Ins2Akita/+ C57BL/6J yielding the best
results. Albuminuria does not reach the aim of a tenfold increase compared to wild-
type controls in C57BL/6J mice, and only mild glomerular lesions were observed
in the majority of models. None of the listed studies further addressed possible
reasons for the observed differences in susceptibility to DN.
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Table 2.2 FVB/N and C57BL/6J mice in DN research
Genetic Mutations/diabetes Blood glucose Diabetes-associated Study
back- induction concentration renal lesions
ground (mg/dl)
FVB/N OVE26 803±30 (+) mesangial expansion ZHENG et al.
(+) glomerular hypertrophy CARLSON et al.
(+) increased GBM thickness BREYER et al.
(+) severe albuminuria (x121) XU et al.
db/db 300-400 (+) diffuse glomerular sclerosis CHUA et al.
(+) albuminuria (x10)
Ins2Akita/+ 700 (+) albuminuria (x10) CHANG et al.
STZ 570-610 (-) albuminuria (ACR) QI et al.
(+) albuminuria (UAE2)
(+) mild mesangial expansion
C57BL/6J db/db 170-190 (+) glomerular hypertrophy
(+22%)
HUMMEL et al.
(+) mild glomerular sclerosis SHARMA et al.
Ins2Akita/+ 500 (+) albuminuria (x2.8) GURLEY et al.
(+) glomerular hypertrophy
(+30%)
(+) mild glomerular glomerular
sclerosis (0.953)
B2R-/-, Ins2Akita/+ 798±58 (+) albuminuria (x4) KAKOKI et al.
(+) glomerulosclerosis (1.5)
eNOS-/-, STZ 650 (+) mild mesangial expansion KANETSUNA et al.
Os+/+ 4, STZ 340±60 (+) mild sclerosis (0.83±0.26) ZHENG et al.
(-) glomerular hypertrophy
STZ 334±35 (+) albuminuria (34%) GURLEY et al.
(+) mild glomerular sclerosis
(0.66±0.09)
HFD 138-259 none NOONAN and
BANKS
1 increase compared to control group
2 UAE: urinary albumin excretion (µg/24h)
3 glomerulosclerosis index, between 0 (no alterations) and 4 (glomerulosclerosis with total tuft
obliteration in all observed glomeruli).
4 Os: oligosyndactyly mutation, that causes a 50% decrease in nephron number
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3 Materials and methods
A list of the performed analyses and corresponding sample sizes is shown in Table
3.1, p.70. The animal experiments were conducted according to the specifications
of the local ethics committee and the regional government of Upper Bavaria (55.2-
1-54-2531.3-49-10).
3.1 Animals
3.1.1 Breeding
The C57BL/6J mice used for breeding were obtained from the Institute of Molecular
Animal Breeding and Biotechnology of the LMU Munich (Germany) and were
maintained in the Institute of Veterinary Pathology, LMU, München. Male GIPRdn-
transgenic mice on a CD1 background were breed to C57BL/6J wild-type females.
The resulting male transgenic offspring was backcrossed on C57BL/6J wild-type
females for six generations. GIPRdn-transgenic males and their male wild-type
litter mates of the sixth backcrossed generation (N6) were used for this study.
Approximately 1.6% of the diploid genome of the CD1 background remains in the
N6 generation of GIPRdn-transgenic C57BL/6J mice.
The FVB/NJ mice were generously donated by the Medical Research Council (UK),
via the University of North Carolina (USA) and the Laboratory for Functional
Genome Analysis (LAFUGA), Gene Center of the LMU Munich (Germany). Male
GIPRdn-transgenic mice on a CD1 background (N37) were breed to FVB/N wild-
type females (Figure 3.1, p.33). The resulting male GIPRdn-transgenic offspring
was backcrossed on FVB/NJ wild-type females over several generations to obtain
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congenic animals. The transgenic males and their sex-matched wild-type litter
mates of the N25 were used for this study. Approximately 2.98 x 10−4% of the
diploid genome of the CD1 background is still present in GIPRdn-transgenic FVB/N
mice of the N25.
Figure 3.1 Breeding scheme of GIPRdn-tg FVB/N and C57BL/6J mice by backcross-
ing
FVB/N or C57BL/6J GIPRdn-tg CD1
♀ ♂
♀tg ♀wt♂wt♂tg
♀
FVB/N or C57BL/6J
N1
N2
♂tg ♀tg ♂wt ♀wt
N6
N25
GIPRdn-tg C57BL/6J
GIPRdn-tg FVB/N
N1-25: number of backcrossed generations, wt: wild-type, tg: transgenic. Drawings
of mice courtesy of Dr. Andreas Blutke, Institute of Veterinary Pathology, LMU
München.
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3.1.2 Animal husbandry
Environmental conditions were realized according to the guidelines by the Society
for Laboratory Animal Science (BUSCH et al., 2014). A light cycle of 12 hours light,
followed by 12 hours of darkness was implemented. The light intensity did not
surpass 200 lux . The room temperature was kept within the range of 20◦ − 24◦C,
the air humidity between 45% and 65%. Standard cages type II and III (Makrolon,
Ehret, Germany) with hygienic animal bedding (Lignocel R©, J. Rettenmaier &
Söhne, Germany) were used to house mice. Environmental enrichment in the
form of nesting material (cellulose paper) was offered to all animals. Tap water
ad libitum and a standard diet for mice and rats (Altromin 1324, Germany) was
provided. At the age of 3 weeks, the mice were weaned from their dams, separated
by gender and marked through ear piercing.
3.1.3 Genotyping by polymerase chain reaction (PCR)
Genotyping was performed according to a protocol established in the Institute
of Veterinary Pathology, LMU München (HERBACH, 2002), in which transgenic
mice are identified via polymerase chain reaction from DNA extracted from tail tip
biopsies.
DNA extraction
Tail tip biopsies of approximately 0.5cm length, obtained prior to perfusion from
euthanized mice, were incubated with 400µl Mastermix in a heating block (Biometra
TB1 Thermoblock, Whatman, Germany) over night, at 55C. Two minutes of
centrifugation at 15.000 rpm (Sigma 1k15, Sigma, Germany) were used to separate
digested from undigested material. The supernatant was transferred into a fresh
1.5ml reaction cup (Eppendorf, Roche, Germany). The DNA was precipitated
by adding 400µl isopropanol (Roth, Germany) and vigorous shaking of the cups.
Then the resulting DNA pellet was washed twice with 900µl of 70% ethanol (Roth,
Germany). After the removal of the liquid phase, the pellet was dried at room
temperature. Depending on the size of the dried DNA pellet, 100-200µl of TE buffer
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were used to dissolve the DNA. Complete dissolution was ensured by storing the
samples at 4◦ for 24h.
Mastermix
Cutting buffer 375µl
SDS 20% (Roth, Germany) 20µl
Proteinase K (20mg/ml) (Boehringer Ingelheim, Germany) 5µl
Cutting buffer
1M Tris-HCl (pH 7.5, Roth, Germany) 2,5ml
0.5M EDTA (pH 8.0, Sigma, Germany) 5.0ml
5M NaCl (Roth, Germany) 1.0ml
1M DTT (Roth, Germany) 250µl
Spermidine (500mg/ml, Sigma, Germany) 127µl
Aqua bidest. ad 50ml
TE-buffer
10mM Tris-HCl (pH 8.0, Roth, Germany)
1mM EDTA
Storage at 4◦C
Polymerase chain reaction (PCR)
All components were cooled on ice. The Taq DNA polymerase (Taq PCR Master
Mix Kit, Qiagen, Germany) was stored at -20◦C and defrosted directly prior to
being added to the Mastermix. In PCR-analysis cups (Kisker, Germany), 1µl of
the dissolved DNA was added to 19µl of the Mastermix. As positive and negative
controls, DNA of mice of known status (wild-type and GIPRdn-transgenic) were
used. Distilled water served as an internal (no template) quality control. The PCR
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was performed in a Biometra R© Uno II Thermocycler (Biometra, Germany). Initially,
the samples were heated to 94◦C for 4min, followed by 35 cycles of 94◦C for 1min,
60◦C for 1min and 72◦C for 2min. After 10 more minutes at 72◦C, the thermocycler
cooled down the samples to 4◦C.
The following oligonucleotid primers were employed for the polymerase chain
reaction:
-5’-ACA GNN TCT NAG GGG CAG ACG NCG GG-3’ sense (Tra1)
-5’-CCA GCA GNC NTA CAT ATC GAA GG-3’ antisense (Tra3)
(Synthesis, Ludwig-Maximilians-Universität, Munich, Germany)
The primers bind to the mutated human GIP receptor, but also to the murine GIP
receptor. In the places where variations do occur, oligonucleotid synthesis, marked
“N” in the primer sequence, was used to allow all nucleotides to attach (HERBACH
(2002)). A difference in the number of base pairs allows for a differentiation of the
mutant human (140bp) and endogenous murine (500bp) receptor.
Mastermix (Taq PCR Master Mix Kit, Qiagen, Germany)
1mM dNTP 4µl
10x Qiagen PCR buffer 2µl
MgCl2 1.25µl
Primer sense (Tra1), 10pmol/µl 1µl
Primer antisense (Tra3), 10pmol/µl 1µl
RNase-free water 5.7µl
Q-solution 4µl
Taq-polymerase 0.125µl
Gel electrophoresis
The PCR products were separated by molecular size, weight and charge through
gel electrophoresis. A TAE agarose gel (1,5%, 1,5g agarose (Gibco BRL, Ger-
many)/100ml TAE buffer) in a Easy Cast R© gel chamber (PeqLab, Germany) was
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used. Both the TAE buffer used to make the gel and the TAE running buffer
contained 9µl/l ethidiumbromide (0.1%, Merck, Germany). 4µl of 6x loading dye
(MBI Fermentas, Germany) were added to each sample. The first well of each row
was filled with 12µl of a size standard (PUC Mix Marker, MBI Fermentas, Germany).
Remaining wells were each filled with 24µl of the samples. The electrophoresis was
run at 90 V and 200 mA (Biorad Power PAC 300, Biorad, USA) for 45 minutes. The
bands then were made visible under UV light (306 nm, Eagle Eye II, Stratagene,
Germany) and the result was documented.
TAE buffer
Tris base (Roth, Germany) 2.42g
Glacial acetic acid (Sigma, Germany) 0.571ml
EDTA 0.5M, pH 8.0 (Sigma, Germany) 1ml
Aqua bidest. ad 500ml
3.1.4 Blood pressure measurement
Noninvasive blood pressure measurements were performed on six months old
mice. Prior to the blood pressure measurement, the animals were acquainted
thoroughly to the automatic system over a timespan of two weeks. The system
consisted of an occlusion tail cuff and a pressure recording sensor (CODA System,
Kent Scientific, USA). The measurement of systolic, diastolic and mean blood
pressure were performed on three consecutive days, between 8am and 11am. The
results of one measurement cycle per day, consisting of 10 separate measurements,
were averaged.
3.1.5 Quantitative and semiquantitative determination of
glucose concentrations in urine and blood
All animals were tested for glucosuria, using diagnostic dipsticks for glucose
detection (Macherey-Nagel, Germany). Urine was collected by gently stroking
the animal’s abdomen to encourage spontaneous micturition and caught with a
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plastic cup (Eppendorf, Roche, Germany). The dipsticks were used according
to the manufacturer’s instructions. At six months of age, casual blood glucose
levels were determined. At 3pm, blood was drawn from the tail vein into a
10µl capillary (Hirschmann, Germany) by incising the tail tip. The samples were
immediately transferred into plastic cups (Eppendorf Roche, Germany) filled with
500µl haemolysing solution (Hitado, Germany). After calibration with a control
solution of known glucose concentration, all samples were analyzed with the Super
GLeasy automatic system (Hitado, Germany).
3.1.6 Serum parameter measurements: Creatinine, urea,
triglyceride, protein and ion concentrations
Serum was collected from 6 months old male mice by drawing blood from an
incision in the tail tip into a capillary (Brand, Germany). The drawn volume
(170-190µl) did not exceed 10% of the animals’ blood volume, calculated as 6.6% of
the animals’ body weight (MORTON et al., 1993; FURUHAMA and ONODERA, 1983).
The blood was transferred into a plastic cup (1.5ml Eppendorf, Roche, Germany)
and centrifugated for 10min at 10.000 x g (Sigma 1k15, Sigma, Germany). The
serum was separated from the solid phase and stored at -80◦C. Determination of
serum creatinine, urea, triglycerides, total protein, albumin, chloride and sodium
concentrations was graciously performed by the City Clinic Munich, Schwabing,
Germany (Architect ci8200 Autoanalyser, Abbott, Germany).
3.1.7 Cystatin C serum concentration
For the determination of cystatin C serum concentrations, the mouse cystatin C
ELISA kit (BioVendor, Czech Republic) was used according to the manufacturer’s
instructions. All steps were performed at room temperature. Next to a coated
microtiter plate, the kit contains all required solutions, standards, quality controls
and antibodies ready to use. First, 100µl each of the provided standards, high
and low quality controls and the samples (diluted 1:500 with dilution buffer), as
well as a blank (pure dilution buffer) were pipetted into their assigned wells in
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duplicate. The plate was incubated on a microplate shaker (Corning R© LSETM
digital microplate shaker) at 300rpm for 1 hour. Then, three rounds of washing,
using 350µl of washing solution, were performed. 100µl of biotin-labeled antibody
were added to the wells and again left to incubate the microplate shaker for 1 hour,
before repeating three washing steps. 100µl of streptavidin-horseradish-peroxidase
conjugate were added to each well to incubate for 30 minutes on the microplate
shaker. After another three washing steps, 100µl substrate solution were added and
incubated under an opaque cover for 10 minutes. 100µl stop solution were added
and the plate was immediately measured at a wavelength of 450 nm and 630 nm in
a microplate reader (Magellan, Tecan AG, Germany). A standard curve was plotted
automatically by the microplate reader program. Following to the manufacturer’s
manual, the reading at 630 nm was subtracted from the 450 nm measurement and
the results of the duplicate readings were averaged.
3.1.8 Urine parameter measurements
Urine creatinine, urea and ion concentrations
Urine collected over a time period of 24h was centrifugated for 10 min at 10.000 x g
(Sigma 1k15, Sigma, Germany) to remove impurities and stored at -80◦C. Creatinine,
urea, sodium and chloride concentration were determined with the Architect
ci8200 Autoanalyser (Abbott, Germany) in the City Clinic Munich, Schwabing,
Germany.
Urine albumin concentration
The mouse albumin ELISA kit Bethyl E90-134 (Bethyl, USA) was used in compli-
ance with the manufacturer’s recommendations to determine the urine albumin
concentrations. Urine samples of 6 months old mice were collected from metabolic
cages over a 24h period. First, the plate (Nunc C bottom Immunoplate 96 wells,
Nunc A/S, Denmark) was coated with goat anti-mouse albumin capture antibody
(1mg/ml A90-134A). 1µl of antibody was diluted with 100µl of coating buffer and
the plate was incubated at room temperature for 1h. Three rounds of washing were
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performed by pipetting and then aspiring 200µl of washing solution into each well.
Unspecific binding sites were blocked with 200µl of blocking solution left in the
wells for 30min. After the removal of the blocking solution, the plate was washed
three times. Standard dilutions of mouse albumin were produced according to the
manufacturer’s directions (7.8 - 500 ng/ml). The predicted albumin concentration
of the urine samples was used to calculate a dilution with a concentration that
would fall within the range of the standards. Ultimately, samples were diluted with
sample diluent between 1:200 and 1:6400. Every sample was analyzed in duplicate,
and the second sample was diluted by the factor two compared to the first sample.
100µl of standard and samples respectively were pipetted into the wells. Aqua
dest. served as a negative control. The plate was incubated for one hour and
then washed five times. 100µl of horseradish peroxidase conjugate (1mg/ml goat
anti-mouse albumin HRP-conjugate, A90-134P-22), diluted 1:100.000 in conjugate
diluent, were pipetted into each well and incubated under an opaque cover for
60min. Another five rounds of washing were performed. Then, 100µl of substrate
solution (TMB/H2O2, Kirkegaard and Perry, USA), an equal mixture of substrate
reagents A and B, were added. The plate was placed under a light-tight cover for an
incubation period of 7min. The reaction was stopped by adding 100µl of 1MH3PO4
(Roth, Germany). A computer-assisted microplate reader (Magellan, Tecan AG,
Germany) measured the light absorption at 450 nm. The results of the duplicate
readings were averaged and a standard curve (Magellan, Tecan AG, Germany)
calculated for each plate. The value of the water’s colour intensity was subtracted
from the averaged sample values. Only values within in the range of the linear
part of the standard curve were accepted.
Materials used for ELISA
Coating buffer
0.05M Carbonate-bicarbonate (Sigma, Germany) adjusted to pH 9.6
Washing solution
50mM TRIS (Roth, Germany)
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0.14M NaCl (AppliChem, Germany)
0.05% Tween 20 (Roth, Germany)
adjusted to pH 8.0
Blocking solution
50mM Tris (Roth, Germany)
0.14M NaCl (AppliChem, Germany)
1% Bovine serum albumin in Tris buffered saline (Sigma Chemical, Germany)
adjusted to pH 8.0
Sample- /conjugate diluent
50mM Tris (Roth, Germany)
0.14M NaCl (AppliChem, Germany)
1% Bovine serum albumin in Tris buffered saline (Sigma Chemical, Germany)
0.05% Tween 20 (Roth, Germany)
adjusted to pH 8.0
Urine albumin to creatinine ratio (UACR)
UACR (mg/g) was calculated by dividing the urine albumin concentration (mg/dl)
through the urine creatinine concentration (g/dl).
Estimated glomerular filtration rate (eGFR)
The glomerular filtration rate is calculated as the volume of the primary urine
divided by the time in which it was filtrated. The estimated glomerular filtration
rate uses creatinine clearance as a measure of actual GFR.
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Equation 1:
eGFR = ccrea urine×Vurineccrea serum×t
eGFR: estimated glomerular filtration rate
ccrea urine: creatinine concentration in the urine
Vurine: urine volume
ccrea serum: creatinine concentration in the serum
t: time in which the urine volume was produced
3.1.9 Food and water consumption and 24h urine collection
To determine the food and water consumption and collect 24h urine samples, 180d
old mice were kept in metabolic cages (Techniplast, Germany) over 24 hours. Before
the start and after the end of the 24 hours, the body weight of the mice and the
weight of feed and water were measured to the nearest 0.1g on a precision scale
(Kern 440-43, Kern & Sohn GmbH, Germany). The obtained urine samples were
stored at -80◦C, protected from evaporation.
3.2 Perfusion fixation and processing of kidneys
3.2.1 Vascular perfusion fixation of the kidneys
Orthograde vascular perfusion was performed on eight 6 month-old mice per group.
A system with two bottles containing buffer and paraformaldehyde, suspended
approximately 1.2m above the working space and connected via a three-way valve
to a perfusion needle, was used for the perfusion (Figure 3.2, p.43). Due to the set-
up, a constant hydrostatic pressure was maintained (WANKE, 1996). The animals
were killed by cervicocranial dislocation. The abdominal and thoracical cavities
were opened with scissors. A gauge 20 needle (Sterican R© Gr.1, B. Braun Melsungen
AG, Germany) was used to pierce the left ventricle (Figure 3.3, p.44). Approximately
2ml Lidocain (Lidocainhydrochloride 2%, bela-pharm, Germany), inserted via the
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three-way valve, were perfused first to dilate the vascular system. At the start of the
perfusion process, the Vena cava caudalis was severed within the thoracic cavity to
maintain a steady pressure and enable the perfusate to drain out. For the following
two minutes PBS (pH 7.4, 37◦C) was perfused by hydrostatic pressure, until all
blood was removed from the circulation and the perfusate discharge appeared
clear. The system was then switched to 4% paraformaldehyde (Serva, Germany)
dissolved in PBS (pH 7.4, 37◦C) for 5 minutes.
Figure 3.2 Cardial perfusion setup
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IV: intravenous. Picture courtesy of Dr. Andreas Blutke, Institute of Veterinary
Pathology, LMU München
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Figure 3.3 Perfusion of a mouse
Picture courtesy of Dr. Andreas Blutke, Institute of Veterinary Pathology, LMU
München
Materials used for kidney perfusion
Phosphate-buffered saline (PBS)
Sodium chloride (AppliChem, Germany) 8.0g
Potassium chloride (AppliChem, Germany) 0.2g
Potassium dihydrogen phosphate (AppliChem, Germany) 0.27g
Disodium hydrogen phosphate dihydrate (AppliChem, Germany) 1.78g
ad 1l Aqua dest.
adjusted to pH 7.4
4% Paraformaldehyde (PFA) in PBS (pH 7.4)
Paraformaldehyde (Serva, Germany) 40g
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PBS pH 7.4 1l
3.2.2 Kidney processing for histology, immunohistochemistry
and quantitative stereology
The entrails were removed and the carcass with the kidneys was submerged in
200ml 4% paraformaldehyde solution for 24 hours. The kidneys were blotted dry
on paper, stripped of their capsules and weighed separately to the nearest milligram
on a precision scale (Mettler AE200, Germany). A caliper gauge (Mannesmann,
Germany) was used to measure the longitudinal length of each kidney. Every
kidney was laminated vertically to the longitudinal axis by a microtome blade
with the help of a laminator (design: Dr. Andreas Blutke, Figure 3.4, p.46). To
facilitate the cutting of even, 1mm thick slices, the kidneys were embedded in agar
(BactoTM agar, BD, USA). With the help of a dot matrix and random numbers, three
locations in the cortex of each kidney were chosen by systematic random sampling
(NYENGAARD, 1999) for epon embedding (Figure 3.5, p.47). The tissue samples of
approximately 1mm diameter were obtained using a self-designed tissue punch
and stored in plastic cups (Eppendorf, Roche, Germany) filled with 4% PFA solution
in PBS (Figure 3.5, p.47). From each kidney, two slices were chosen randomly for
paraffin embedding and placed in embedding capsules (Engelbrecht, Germany).
They were fixed inside the capsules with pieces of sponge (Bio Optic, Italy). In the
same manner, all remaining slices went on to GMA/MMA embedding.
3.2.3 Paraffin embedding and detection of glomerular matrix
proteins and TGFβ1 by immunohistochemistry
After 24h of fixation in 4% paraformaldehyde, the samples were processed in a
Histomaster 2050 (Bavimed, Germany, protocol p.47) and embedded in paraffin
with the TBS 88 Paraffin Embedding System (Medite, Germany). Approximately
3-5µm thick sections were cut from the paraffin blocks with a HM 315 rotary
microtome (Microm, Germany), put in a water bath (60◦C, Daglef Patz, Germany)
to unfold, and mounted on coated glass slides (Starfrost, Engelbrecht, Germany).
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Figure 3.4 Lamination of kidneys
Finally, the sections were dried in a heating cabinet (Memmert, Germany) at 40◦C
for 24h. For the detection of laminin, fibronectin, collagen IV and TGFβ1, three
animals per group were selected randomly.
Dehydration and paraffin embedding of kidney sections
30min Aqua dest.
2 x 1.5h 70% Ethanol (Bundesmonopolverwaltung für Branntwein (BfB), Germany)
2 x 1.5h 96% Ethanol (BfB, Germany)
2 x 1.5h 100% Ethanol (BfB, Germany)
1.5h Xylol (SAV LP, Germany)
2h Paraffin (60◦C, Sherwood Medical, USA)
46
CHAPTER 3. MATERIALS AND METHODS
Figure 3.5 Sampling for epon embedding
Sampling of kidney slices with the help of a dot matrix and a
tissue punch
Push button
Ejection mechanism
Pressure spring
Die cutter
Tissue punch
Picture of the tissue puncher courtesy of Dr. Andreas Blutke, Institute of Veterinary
Pathology, Ludwig-Maximilians-Universität München
3h Paraffin (60◦C)
Materials used for immunohistochemistry
Tris buffer (TBS) pH
Tris (Roth, Germany) 6.05g
NaCl (AppliChem, Germany) 9g
Aqua dest. ad 1000ml
adjust to pH 7.6
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Detection of laminin and fibronectin by immunohistochemistry
After drying overnight in a heating cabinet (37◦C), the sections were deparaffinised
and rehydrated by being immersed in xylol for 20 minutes and passing through
a descending series of ethanol (100%, 96% and 70%) and Aqua dest. To block
the endogenous peroxidase in the samples, they were then rinsed in 1% H2O2
for 15min, then rinsed again in TBS for 10min. Proteinase K (Dako Diagnostika,
Germany) was used to facilitate tissue penetration (antigen retrieval) by completely
covering the sections with the ready-to-use solution. The sections in their humidity
chamber were placed in an incubator (Memmert, Germany) at 37◦C for 30min.
Another 10min of rinsing in TBS preceded the blocking of unspecific binding sites
with normal serum (pig serum, 10% in TBS) for 30 minutes. The sections were
tilted to remove the serum and then covered with the primary antibody (rabbit
anti-mouse laminin, 4.1g/l (DAKO, Germany) and rabbit anti-mouse fibronectin
5.1g/l (DAKO, Germany) respectively), diluted 1:100 in TBS. Again, the humidity
chamber with the sections was incubated at 37◦C for 2 hours. The slides were
washed in TBS for 10 minutes. Then, the section were covered with the secondary
antibody, polyclonal swine anti-rabbit IgG (Dako, Denmark), diluted 1:100 in TBS
containing 5% normal mouse serum. The sections were incubated at 37◦C for 1 hour.
Sections were rinsed in TBS for 10 minutes prior to target antigen detection with
3,3’-Diaminobenzidine (DAB, Sigma, Germany). Previously, the DAB pellet had
been dissolved in 5ml of Aqua dest. beneath an opaque cover. Immediately before
application, 1% H2O2 was added to the DAB. Depending on the strength of the
reaction, the DAB was left on the sections for up to 5 minutes, then it was washed
off in Aqua dest. for 2 minutes. The kidney sections were counterstained at room
temperature with Hemalaun diluted 1:10 in Aqua dest. for 20-60 seconds, rinsed off
briefly in cold tap water and dehydrated in 70%, 96% and 100% ethanol solutions.
After immersion in xylol, the sections were mounted with glass cover slides. As
a negative control, the primary antibody was replaced by TBS in an additional
section. A positive control was deemed unneccessary, as kidneys naturally contain
laminin and fibronectin.
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Detection of collagen IV by immunohistochemistry
The protocol for collagen IV is identical to the protocol for laminin and fibronectin,
except for antibodies and antibody concentrations. As a primary antibody, rabbit
anti-human placental type IV collagen (Quartett, Germany) was used in a dilution
of 1:40 in TBS. The secondary antibody (polyclonal swine anti-rabbit IgG, Dako,
Denmark) was diluted 1:50 with TBS containing 5% mouse normal serum. As
a negative control, the primary antibody was replaced by TBS in an additional
section. No additional positive control was considered necessary, as kidney tissue
can be used for that purpose.
Detection of transforming growth factor β1 (TGFβ1) by
immunohistochemistry
The avidin-biotin peroxidase method, coupled with tyramin amplification was
used to detect TGFβ1. All preparation steps up to the blocking with normal
serum were performed as described for the detection of laminin and fibronectin.
Instead of pig, 10% normal goat serum was used. The primary antibody, 200µg/ml
rabbit anti-TGFβ1 (Santa Cruz Biotechnology, USA), was diluted 1:400 in TBS.
Incubation at 37◦C lasted for 2 hours. After washing in TBS, the secondary antibody,
biotinylated goat anti-rabbit IgG (Vector Laboratories, USA) diluted 1:200 in TBS
with 10% normal mouse serum, was applied for 1 hour at 37◦C. The sections were
rinsed in TBS for 10 minutes, before avidin-biotin complex (Vectastain ABC kit,
Vector, USA) was added in a dilution of 1:100 for 30 minutes at room temperature.
Again, the sections were rinsed in TBS for 10 minutes. Biotinylated Tyramin (0.5%,
ProteoChem, USA) andH2O2 (1%) in TBS were added to the sections for 15 minutes.
Avidin-biotin complex (1:100 in TBS) was applied to the sections and left to incubate
at room temperature for 15 minutes. Antigen detection and counterstaining were
carried out as specified before. As a negative control, the primary antibody was
replaced by TBS in an additional section. Murine uterine tissue was used as a
positive control.
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Biotinylating of tyramin for TGF-β1 immunohistochemistry
NHS-LC-Biotin (ProteoChem, USA) 100mg
Borate buffer, pH 9.0 (Sigma, Germany) 40ml
Tyramine hydrochloride (Sigma, Germany) 30mg
shake for 12 hours
3.2.4 Glycolmethylacrylate and methylmethacrylate
(GMA/MMA) embedding and staining of GMA/MMA
sections
After fixation, the tissue samples destined for glycolmethacrylate and methyl-
methacrylate (GMA/MMA) embedding were routinely processed in a Citadel 1000
tissue processor (Shandon, Germany) according to the protocol listed below. The
embedding followed the protocol described by HERMANNS et al. (1981). All kidney
sections were first immersed in a 1:1 2-hydroxymethylmethacrylate (Flika Chemie,
Germany) : methylmethacrylate (Merck, Germany) solution and remained on a
shaking plate (model 4010, Köttermann, Germany) for 24h at 4◦C. Then the tissue
samples were transferred into solution A and left to saturate at 4◦C for 4 hours.
Next, they were transferred in polyethylene cups (LDPE, Diagonal, Germany)
and embedded in about 40ml of solution A, to which 60µl of dimethylanilin had
been added. The polyethylene cups were transferred into a water bath of 4◦C
overnight for polymerization. After the removal of the polyethylene cups, 1.0µm
thick sections were cut from the blocks with a Mikrom HM 360 rotary microtome
(Mikrom, Germany). Sections were allowed to stretch out in a water bath (60◦C,
Daglef Patz, Germany) and after mounting on glass slides (Engelbrecht, Germany),
were left to dry on a heating plate (OTS 40, Meditel, Germany). To ensure adherence
to the glass slides, the sections were kept in a heating cabinet (Memmert, Germany)
at 64◦C for a minimum of 24h before staining. Hematoxilin Eosin (HE) stain,
periodic acid Schiff (PAS) stain and a periodic acid silver methenamine stain were
performed according to the following listed protocols.
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Materials and protocols used for GMA/MMA embedding and staining of
GMA/MMA sections
Dehydration protocol for GMA/MMA embedding
3h rinsing solution
2x1h Ethyl alcohol 30% (BfB, Germany)
2x1h Ethyl alcohol 56% (BfB, Germany)
2x1h Ethyl alcohol 70% (BfB, Germany)
2h Ethyl alcohol 96% (BfB, Germany)
2x3h Ethyl alcohol 96% (BfB, Germany)
Rinsing solution
Cadodylic acid sodium-trihydrate (AppliChem) 16g
1N Hydrochloric acid (AppliChem) 6.23ml
Aqua dest. 1500ml
D+Saccharose (AppliChem) 105g
Calciumchloride dihydrate (Merck) 1.105g
Adjust to pH 7.2
Solution A
Benzoylperoxide (Merck, Germany) 338mg
Methylmethacrylate 20ml
Hydroxymethylmethacrylate 60ml
Ethyleneglycol monobutylether (Merck, Germany) 16ml
Polyethyleneglycol 400 (Merck, Germany) 2ml
HE staining
1. Mayer’s Hemalaun (AppliChem, Germany) 30min
2. Rinsing in tap water 10min
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3. 1% HCl-alcohol (Roth, Germany) 1s
4. Rinsing in tap water 10min
5. Drying on a heating plate (60◦C)
6. Eosine-Phloxin (Merck, Germany) 30min
7. Aqua dest. 3x1s
8. Drying on a heating plate (60◦C)
9. Xylol
10. Mounting with glass cover slides (Menzel GmbH & Co KG, Germany) with
Histofluid R© (Superior, Germany)
Periodic acid-Schiff reaction (PAS)
1. 1% Periodic acid (AppliChem, Germany) 15min
2. Aqua dest. 3x3s
3. Schiff’s reagent (Merck, Germany) 30-60min
4. Rinsing in tap water 30min
5. Drying on a heating plate (60◦C)
6. Mayer’s Hemalaun (AppliChem, Germany) 30min
7. Rinsing in tap water 10min
8. 1% HCl-alcohol (Roth, Germany) 1s
9. Rinsing in tap water 20min
10. Drying on a heating plate (60◦C)
11. Xylol
12. Mounting the slides with glass cover slides (Menzel GmbH & Co KG, Ger-
many) with Histofluid R© (Superior, Germany)
Periodic acid-Schiff methenamine silver stain (PAS-MS)
1. 1% Periodic acid (AppliChem, Germany) 5min
2. Aqua dest. 3x1s
3. Silvermethenamin 25min (65◦C)
4. Aqua dest. 3x1s
5. 0.1% Goldchloride 10-20s
6. Aqua dest. 3x1s
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7. 2% Sodiumthiosulfat 1min
8. Aqua dest. 3x1s
9. Drying on a heating plate (60◦C)
10. Schiff’s reagent (Merck, Germany) 60min
11. Rinsing in warm tap water 30min
12. Drying on a heating plate (60◦C)
13. Mayer’s Hemalaun (AppliChem, Germany) 30min
14. Rinsing in tap water 10min
15. Drying on a heating plate (60◦C)
16. Xylol
17. Mounting with glass cover slides (Menzel GmbH & Co KG, Germany) with
Histofluid R© (Superior, Germany)
3.2.5 Glycid ether (Epon) embedding, staining of glycid ether
sections and sample processing for disector analyses
and electron microscopy
The six tissue samples per animal (n=8 per group) selected for glycid ether em-
bedding were washed for 3h in Sörensen phosphate buffer at room temperature.
Next, they were postfixed in 1% osmium tetroxide (Merck, Germany) for 2h at
4◦C, followed by another three washing steps of 2min each in Sörensen phosphate
buffer at room temperature. Dehydration in acetone solutions (Roth, Germany) was
performed at 4◦C. The samples were first immersed in a 100% acetone and glycid
ether mixture at room temperature for one hour, and then in pure glycid ether
for one hour. The samples were then embedded in dried gelatin capsules (Plano,
Germany) with epon embedding mixture. The polymerization occurred over 48h
at 60◦C. Trimming of the blocks was performed with a TM60 Reichert-Jung milling
machine (Leica, Germany). 0.5 µm thick semithin sections were cut of the blocks
with a Reichert-Jung Ultracut E microtome (Leica, Germany). The sections were
stained with Azur II-Safranin according to the protocol listed below.
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Dehydration
30% Acetone (Merck, Germany) 15min
50% Acetone (Merck, Germany) 15min
70% Acetone (Merck, Germany) 15min
90% Acetone (Merck, Germany) 15min
100% Acetone (Merck, Germany) 3x30min
Sörensen phosphate buffer (0.067M, pH 7.4)
Solution I 80.8ml
Solution II 19.2ml
Adjust to pH 7.4
Solution I
Potassium dihydrogen phosphate (Roth, Germany) 9.08g
Aqua dest. ad 1000ml
Solution II
Disodium hydrogen phosphate dihydrate (Roth, Germany) 11.88g
Aqua dest. ad 1000ml
1% Osmium tetroxide solution
2% Osmium tetroxide (Merck, Germany) 5ml
Veronal acetate buffer (pH 7.6) 2ml
0.1M Hydrogen chloride (Merck, Germany) 2ml
Saccharose (Merck, Germany) 0.45g
Aqua dest. 1ml
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Veronal acetate buffer (pH 7.6)
Sodium veronal (barbitone sodium, Merck, Germany) 2.95g
Sodium acetate (Merck, Germany) 1.94g
Aqua dest. ad 100ml
Epon-embedding mix
Solution A 3.5ml
Solution B 6.5ml
Paradimethyl aminomethyl phenol (Serva, Germany) 0.15ml
Solution A
Glycid ether 100 (Serva, Germany) 62ml
2-Dodecenyl succiniacid anhydride (Serva, Germany) 100ml
Solution B
Glycid ether 100 (Epon 812, Serva, Germany) 100ml
Methyl nadic anhydride (Serva, Germany) 89ml
Azur II solution
Disodium tetraborate (Merck, Germany) 1g
Aqua dest. 100ml
Azur II (Merck, Germany) 1g
Stir for 2h
37% Formaldehyde (Roth, Germany) 250µl
Safranin O solution
Disodium tetraborate (Merck, Germany) 1g
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Aqua dest. 100ml
Safranin O (Chroma, Germany) 1g
Saccharose (Merck, Germany) 40g
Stir for 2h
37% Formaldehyde (Roth, Germany) 250µl
Azur II-Safranin staining protocol
1. Azur II solution (55◦C) 15-20s
2. Aqua dest. 3x1s
3. Drying on a heating plate (55◦C, Meditel, Germany)
4. Safranin solution (55◦C) 15-20s
5. Aqua dest. 3x1s
6. Drying on a heating plate (55◦C, Meditel, Germany)
7. Cover with glass cover slips (Menzel GmbH & Co KG, Germany), using
Histofluid R©
Preparation of glycid ether embedded samples for electron microscopy
Ultrathin sections were cut from epon embedded tissue samples with a nominal
thickness of 70nm with an Ultracut E microtome (Leica, Germany). The sections
were mounted on uncoated copper grids (SSI, Science Services, Germany) and
contrasted with lead citrate (Serva, Germany) in accordance with a long established
protocol (REYNOLDS, 1963), by floating the sections on droplets of lead citrate for
15-30min.
3.3 Glomerulosclerosis Index
To semiquantitatively evaluate the severity of glomerulosclerotic lesions, two
periodic acid-Schiff methenamine silver (PAS-MS) stained GMA/MMA sections
per animal (n=8 per group) were selected randomly. 108±6.6 (100 -120) glomerular
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profiles were analysed at a magnification of 400x. The glomerular profiles were cho-
sen for analysis through systematic meander sampling according to the unbiased
counting rule (GUNDERSEN, 1978). All profiles were classified according to the
score by EL NAHAS et al. (1991). The glomerulosclerosis index was calculated by
dividing the sum of the allocated scores by the total number of sampled glomerular
profiles (EL NAHAS et al., 1991).
Stages of glomerulosclerosis according to EL NAHAS et al. (1991)
Stage 0: Normal glomeruli, no visible alterations
Stage 1: Mesangial expansion/thickening of the basement membrane
Stage 2: Mild/moderate segmental sclerosis/hyalinosis of up to 50% of the glom. profile
Stage 3: Diffuse glomerular sclerosis/hyalinosis of more than 50% of the glom. profile
Stage 4: Diffuse glomerular sclerosis with total tuft obliteration and collapse
3.4 Quantitative stereological analyses
3.4.1 Determination of the total kidney volume
The total kidney volume was calculated by dividing the total kidney weight by the
specific mass density of paraformaldehyde perfusion-fixed murine kidney tissue
of 1.05mg/mm3 (WANKE, 1996).
3.4.2 Estimation of the total nephron number in both kidneys
The physical disector method was used to estimate the total nephron numbers
in the mouse kidneys. The physical disector method is a three-dimensional
sampling method that enables the user to sample structures in an unbiased way,
by comparing pairs of parallel sections (termed reference section and look-up
section) at a distance of approximately one third of the diameter of the structures
in question (NYENGAARD, 1999; STERIO, 1984). Five mice per group were selected
for analysis with the help of random numbers. Serial sections (n=100) with a
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nominal thickness of 1.0µm were cut from 3-6 kidney slices per kidney. Exactly
every 10th section (with a distance of 9µm) was mounted and stained with HE.
Two more sections were randomly selected for section thickness measurements.
Particular care was taken to ensure similar environmental conditions during the
sectioning and only one experienced person handled the Microm HM 360 rotary
microtome (Microm, Germany) for all serial cutting of GMA/MMA sections. Using
random numbers, pairs of reference and look-up sections with a disector height
of 20µm (distance 19µm, each containing several kidney sections), were chosen
for each kidney. A systematic meander sampling was set up with the help of a
computer-assisted stereology system (VisiomorphTM with newCASTTM software,
Visiopharm Integrator System, Denmark) at 100x magnification. The efficiency was
increased by interchanging the roles of reference and look-up sections. Glomeruli
that showed up on the reference section, but disappeared on the look-up section
(defined by counting frames, (GUNDERSEN, 1978)), were counted (
∑
Q−). The area
(A) covered by kidney tissue within the counting frame was determined by point-
counting. The sampled kidney volume was calculated by multiplying the area of
the analysed kidney sections by the disector height (h). The numerical volume
density (Nv) of glomeruli in the kidneys was calculated by dividing Q− by the
sampled tissue volume (NYENGAARD, 1999). By multiplying Nv by the reference
volume (VRef ), in this case the kidney volume, the total number of glomeruli (N)
was calculated. An average of 57±6 (52-67) Q− for wild-type mice and 53±2 (51-56)
Q− for transgenic mice were counted.
Equation 2:
Nv(Glom/Kid) =
∑
Q−
(Glom)
2×h×∑A × f 3s
Nv(Glom/Kid): estimated numerical volume density of glomeruli in the kidney
(tissue shrinkage corrected)∑
Q−(Glom): number of glomeruli counted within the sum of disectors
h: disector height (20µm)∑
A: area of kidney tissue within the counting frame
fs: linear tissue shrinkage correction factor for murine kidney tissue embedded in
GMA/MMA (0.91, (WANKE, 1996))
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Equation 3:
N(Glom,Kid) = Nv(Glom/Kid)(s) × VKid
N(Glom,Kid): number of glomeruli in both kidneys
Nv(Glom/Kid)(s) : estimated numerical volume density of glomeruli in the kidney
(tissue shrinkage corrected)
V(Kid): volume of both kidneys
3.4.3 Estimation of the total glomerular volume in both kidneys
To estimate the total glomerular volume in both kidneys, 6-10 randomly selected
HE stained GMA/MMA embedded kidney sections per mouse were examined at a
200x magnification. First, the volume fraction of glomeruli per kidneys (Vv(Glom/Kid))
was determined by point-counting with the computer-assisted stereology system
(VisiomorphTM with newCASTTM software, Visiopharm Integrator System, Den-
mark) By multiplying the volume fraction of glomeruli per kidneys (Vv(Glom/Kid)) by
the kidney volume (V(Kid)), the total glomerular volume in both kidneys (V(Glom,Kid))
was calculated. Between 157±25 (102-207) points hitting glomerular profiles and
6431±364 (6022-7286) points hitting kidney tissue were counted.
Equation 4:
V(Glom,Kid) = Vv(Glom/Kid) × V(Kid)
V(Glom,Kid): total glomerular volume of all glomeruli in the kidneys
Vv(Glom/Kid): volume fraction of glomeruli in the kidneys
V(Kid): volume of both kidneys
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3.4.4 Estimation of the mean glomerular volume
To determine the mean glomerular volume (v¯(Glom)), a commonly used model-based
method (WEIBEL and GOMEZ, 1962) was used. PAS stained GMA/MMA slides
were analysed with a computer-based digital image analysis system (Videoplan R©,
Zeiss Kontron, Germany) and an attached microscope (Orthoplan, Leitz, Germany)
with a video camera (CCTV WV-CD132E, Matsushita, Japan) at a 400x magnifica-
tion. The system was calibrated, using an object micrometer (Zeiss, Germany). A
systematic meander sampling (GUNDERSEN, 1978) was applied to select 182±11
(163-219) glomerular tuft profiles for area measurements per case. Their outlines
were traced with a cursor on a digitising tablet. According to the equations by
Weibel and Gomez (1962), the mean glomerular volume was calculated with the
help of the arithmetic mean area. A shape coefficient (β) for spheres was divided
by a size distribution coefficient (K), assuming a coefficient of variation of 15%. The
result was multiplied with the mean glomerular profile by the power of 1.5 and
then corrected for tissue shrinkage.
Equation 5:
v¯(Glom) =
β
k×(a¯Glom)1.5
f3s
v¯(Glom): mean glomerular volume (tissue shrinkage corrected)
a¯Glom: arithmetic mean of the areas of analysed glomerular tuft profiles
β: shape coefficient (1.4, WANKE, 1996)
k: size distribution coefficient (1.04, WANKE, 1996)
fs: linear tissue shrinkage correction factor for murine kidney tissue embedded in
GMA/MMA (0.91)
3.4.5 Estimation of the podocyte number per glomerulus
The number of podocytes per glomerulus (N(Pod,Glom)) was calculated by multi-
plying the numerical volume density of podocytes per glomerulus (Nv(Pod/Glom))
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by the mean glomerular volume (v¯(Glom)) (WANKE, 1996). The numerical volume
density Nv(Pod/Glom) was determined using the physical disector method (STERIO,
1984). Ten serial semithin sections with a nominal section thickness of 0.5µm were
cut from glycid ether embedded kidney cortex tissue with an Ultracut E microtome
(Leica, Germany). The first section was discarded, the remaining nine sections were
stained according to protocol. One set of three sections with a distance of 1.5µm
was chosen using random numbers. Glomerular tuft profiles, present on all three
sections, were photographed at a 400x magnification with a Leica DFC 320 (Leica,
Germany), connected to a light microscope (Orthoplan, Leitz, Germany). Every
set of glomerular tuft profiles was counted in both directions, first to second and
second to third section, making for a total of four disectors analysed per sample.
Podocyte nuclei appearing in the reference section, but not in the look-up section,
were counted as Q−(Pod) (Figure 3.6, p.62). The pictures taken of the glomeruli
were printed at 1000x magnification. An object micrometer (Zeiss, Germany) was
photographed and printed under the same conditions for calibration. The areas of
the glomerular tuft were measured planimetrically, using a computer-based digital
image analysis system (Videoplan R©, Zeiss Kontron, Germany) on printed pages, as
previously described. Twelve glomeruli per animal were analysed. On average,
73±20 (42-107) Q−(Pod) were counted.
Equation 6:
Nv(Pod/Glom) =
∑
Q−
(Pod)
h×A(Glom) × f
3
s
Nv(Pod/Glom): estimated numerical volume density of podocytes in the glomerulus
(tissue shrinkage corrected)
Q−(Pod): number of podocyte nuclei counted in the disector
A(Glom): area of the glomerular cross section
h: disector height (distance between reference and look-up section; 1.5µm)
fs: linear tissue shrinkage correction factor for murine kidney tissue embedded in
epon (0.95, (WANKE, 1996))
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Equation 7:
N(Pod,Glom) = Nv(Pod/Glom) × v¯(Glom)
N(Pod,Glom): number of podocytes per glomerulus
v¯(Glom): estimated mean glomerular volume
Figure 3.6 Stereological estimation of number of podocytes per glomerulus (physi-
cal disector method)
Reference section
* *
Look-up section
(*) marks Q-, in this case podocyte nuclei present in the reference section, but
missing in the look-up section. After all Q- have been counted, the reference section
becomes the look-up section and vice versa. Semithin sections, Azur II-Safranin,
bar = 10µm.
3.4.6 Estimation of the mean podocyte volume
Pictures of glomerular profiles (n=12 per animal), already taken for the estimation
of the podocyte number, were used to estimate the mean podocyte volume. The
pictures were superimposed with a 2x2mm point matrix to determine the volume
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fraction of podocytes per glomerulus (Vv(Pod/Glom)). It was differentiated between
points hitting the glomerular tuft area (p(Glom)) and the subset of points hitting
podocyte section profiles (p(Pod)). The volume fraction of podocytes per glomerulus
(Vv(Pod/Glom)) was calculated by dividing p(Pod) by p(Glom). The mean volume of
podocytes was calculated by dividing the volume fraction by the numerical volume
density of podocytes in the glomerulus (NYENGAARD, 1999). On average, 222±55
(153-346) podocyte hits were counted, and 913±321 (509-1574) points hitting the
glomerulus.
Equation 8:
Vv(Pod/Glom) =
∑
p(Pod)∑
p(Glom)
Vv(Pod/Glom): volume fraction of podocytes in the glomerulus
p(Pod): number of points hitting podocytes
p(Glom): number of points hitting the glomerular tuft profile
Equation 9:
v¯(Pod) =
Vv(Pod/Glom)
Nv(Pod/Glom)
v¯(Pod): estimated mean podocyte volume
Vv(Pod/Glom): volume fraction of podocytes per glomerulus
Nv(Pod/Glom): numerical volume density of podocytes in the glomerulus
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3.4.7 Estimation of the mean mesangial and capillary volume
per glomerulus
The volume fractions of the mesangium (Vv(Mes/Glom)) and the glomerular capillaries
(Vv(Cap/Glom)) were determined at 400x magnification in PAS stained GMA/MMA
sections with a computed-assisted system (VisiomorphTM with newCASTTM soft-
ware, Visiopharm Integrator System, Denmark). A systematic meander sampling of
kidney cortex tissue was performed to select glomerular tuft profiles. A point grid
was superimposed over all glomerular tuft profiles within the sampling frame. The
points hitting the mesangium and the capillaries respectively were divided by the
total number of points hitting the glomerular tuft profile. The mean mesangial and
capillary volume per glomerulus were derived by multiplying the corresponding
volume fractions with the mean glomerular volume (v¯(Glom); (WANKE, 1996)). An
average of 59±5 (52 - 78) glomerular tuft profiles were analysed. In FVB/N mice,
1446±142 (975 - 1794) points hitting the glomerular tuft area were counted. 883±93
(713 - 1107) points hitting the glomerular tuft area were counted in C57BL/6J
mice.
Equation 10:
V¯(x,Glom) = Vv(x/Glom) × v¯(Glom)
V(x,Glom): estimated mean volume of x (mesangium or capillaries) per glomerulus
Vv(x/Glom): volume fraction of x in the glomerulus
v¯(Glom): estimated mean glomerular volume
3.4.8 Estimation of the capillary length density in the glomeruli
A systematic meander sampling was set up with a stereology system (VisiomorphTM
with newCASTTM software, Visiopharm Integrator System, Denmark), and HE
stained GMA/MMA sections were analysed at 400x magnification. The number
of capillary profiles (Q(Cap)) in 54±2 (51-68) glomerular profiles was counted and
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related to the cumulative area of the corresponding glomerular profiles, which
were measured planimetrically. The resulting quotient was multiplied by two and
corrected for tissue shrinkage (WANKE, 1996).
Equation 11:
Lv(Cap/Glom) = 2×
∑
Q(Cap)∑
A(Glom)
× f 2s
Lv(Cap/Glom): estimated capillary length density in the glomerulus (tissue shrinkage
corrected)∑
Q(Cap): sum of glomerular capillary profiles in the investigated glomeruli∑
A(Glom): sum of areas of glomerular tuft cross sections in the investigated
glomeruli
fs: linear tissue shrinkage correction factor for murine kidney tissue embedded in
GMA/MMA (0.91)
3.4.9 Estimation of the mean capillary length per glomerulus
The mean capillary length per glomerulus was obtained by multiplying the capil-
lary length density per glomerulus (Lv(Cap/Glom)) by the mean glomerular volume.
Equation 12:
L(Cap,Glom) = Lv(Cap/Glom) × v¯(Glom)
L(Cap,Glom): estimated capillary length per glomerulus
Lv(Cap/Glom): estimated capillary length density in the glomerulus (tissue shrinkage
corrected)
v¯(Glom): estimated mean glomerular volume
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3.4.10 Determination of the filtration slit frequency (FSF)
To determine the filtration slit frequency, five mice per group were randomly
selected for electron microscopic analysis. Six glomerular profiles per mouse,
each from a different tissue sample, were selected from Azur II-Safranin stained
semithin sections (3.2.5) using random numbers. The glycid ether embedded tissue
samples containing the selected glomeruli were prepared for electron microscopy
as previously described (3.2.5). Electron microscopic images of ultrathin sections
(eight peripheral capillary loops per glomerulus) were taken with a Zeiss EM
10 transmission electron microscope (Zeiss, Germany) at a 8000x magnification
in a predetermined manner by half turns of the stagehandle. A standard cross-
grating grid (S107, TAAB, USA) with 2160 lines/mm was photographed at the
same magnification for calibration. All images were printed with identical settings.
The filtration slit frequency (FSF) was determined by counting the total number
of filtration slits and dividing it by the total length of the peripheral capillary
wall at the epithelial interface (JANI et al., 2002; REMUZZI et al., 1995). Length
measurements were performed with a computer-assisted image analysis system
(Videoplan R©, Zeiss Kontron, Germany). On average, 1205±297 (593-1588) filtration
slits per animal were counted.
3.4.11 Estimation of the true harmonic mean thickness of the
glomerular basement membrane (GBM)
The previously printed electron microscopy pictures were used to determine the
thickness of the glomerular basement membrane (GBM), using the orthogonal
intercept method (EL-AOUNI et al., 2006; GUO et al., 2005; RAMAGE et al., 2002).
A grid (2.5 x 2.5cm) was superimposed over the prints. At the intersections of
grid lines and GBM, the shortest distance between the endothelial cytoplasmatic
membrane and the outer edge of the lamina rara externa of the glomerular basement
membrane beneath the podocytes’ foot processes’ cytoplasmatic membrane was
measured with a transparent, logarithmic ruler. The logarithmic ruler, provided by
Ewald Freitag (Institute of Thermodynamics, TU Munich) in accordance with the
description by RAMAGE et al. (2002), uses the multiplier 0.75 for the harmonic value
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for the divisions The ruler is divided into an initial division (A = 2mm, harmonic
value: 1/A = 0.5mm), in which no measurement can be contained, and eleven
classes, into which the measurements fall (n observations, Fig. 3.7, p.68). The limits
of the classes are calculated as 1/(0.75n x 0.5), with n denoting the number of the
respective class. A midpoint for each class is calculated as the arithmetic mean
of the harmonic values of its limits (((1/lower limit of class n) + (1/lower limit of
class n+1))/2).
Equation 13:
Apparent harmonic mean thickness Ih (mm):
Ih =
∑
(n of observations)∑
(midpoints×n of observations)
Equation 14:
True harmonic mean thickness Th (nm):
Th =
8
3pi × 10
6
magnification (m) × Ih
3.4.12 Shrinkage in GMA/MMA and glycid ether embedded
kidney tissue and determination of thickness of
GMA/MMA sections
To reduce the bias caused by linear tissue shrinkage during the embedding pro-
cess, correction factors previously established for GMA/MMA and glycid ether
embedded murine kidney tissue were used (WANKE, 1996). Spectral reflectance
measurements (FILMETRICS-INC., 2012) of two sections per GMA/MMA block
were made to determine the average section thickness of serial sections for the
disector method. The sections were selected randomly during the consecutive
sectioning of GMA/MMA embedded kidneys. Sections were mounted on standard
glass slides (Menzel GmbH & Co KG, Germany) and reflected, absorbed and
transmitted light (380-1050nm wavelength) were measured by a F20 thin-film
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Figure 3.7 Estimation of the true harmonic mean thickness of the glomerular
basement membrane with a logarithmic ruler
E: endothelial cell, GBM: glomerular basement membrane, FP: podocyte foot
process, 1: intersection of a grid line (transparent 2.5x2.5cm grid) with the GBM,
2:shortest distance between the attachment of the endothelial cytoplasmatic mem-
brane and the outer lining of the lamina rara externa of the glomerular basement
membrane underneath the cytoplasmatic membrane of the epithelial foot process.
The GBM-thickness is read off in terms of classes, here class 6
Picture courtesy of Dr. Andreas Blutke, Institute of Veterinary Pathology, LMU
München
analyser (comprised of a regulated tungsten halogen light source, spectrometer
and computer with a specialized software; kindly provided by Filmetrics Europe
GmbH, Unterhaching).
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3.5 Statistical analyses
Shapiro-Wilk-test and Levene-test were performed to test for normal distribution
and equality of variance. For each parameter, either two-sample t-tests or Mann-
Whitney U-tests were performed to test for significant differences between wild-
type and GIPRdn-transgenic animals of the FVB/N and C57BL/6J strain respectively.
Strain-dependent differences between wild-type mice of the FVB/N background
compared to the C57BL/6J background were tested in the same manner. Differences
in the development of diabetes mellitus and diabetic nephropathy in GIPRdn-tg
mice on a FVB/N and C57BL/6 background were examined as well. Parametric
data was tested for statistical significance by Student’s t-test for independent
samples in cases of equal variances. Welch-test was used in cases of non-equal
variances. Non-parametric data sets were analysed with the Mann-Whitney U test.
Analyses were performed with the statistical analysis software SPSS Statistics 21
(IBM, USA).
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Table 3.1 Outline of performed analyses
Parameter Number of examined animals
FVB/N C57BL/6J
GIPRdn-tg wt GIPRdn-tg wt
Blood pressure 8 8 8 8
Blood glucose conc.
Fasting blood glucose 8 8 8 8
Casual blood glucose 8 8 8 8
Serum parameters
Serum albumin conc. 5 5 5 5
Serum creatinin conc. 5 5 5 5
Serum cystatin c conc. 5 5 5 5
Serum total protein conc. 5 5 5 5
Serum triglycerides conc. 5 5 5 5
Serum sodium conc. 5 5 5 5
Serum chloride conc. 5 5 5 5
Urine parameters
Urine albumin conc. 8 8 8 8
Urine creatinine conc. 5 5 5 5
Urine sodium conc. 5 5 5 5
Urine chloride conc. 5 5 5 5
Body weight 8 8 8 8
Food consumption 8 8 8 8
Water consumption 8 8 8 8
Urine volume 8 8 8 8
Immunohistochemistry
Laminin 3 3 3 3
Fibronectin 3 3 3 3
Collagen IV 3 3 3 3
TGF β1 3 3 3 3
Glomerulosclerosis index 8 8 8 8
Total kidney volume 8 8 8 8
Total nephron number 5 5 5 5
Total glom. vol. per kidneys 8 8 8 8
Total mean glom. volume 8 8 8 8
Podocyte number per glom. 8 8 8 8
Mean podocyte vol. per glom. 8 8 8 8
Mean glom. mesangial vol. 8 8 8 8
Mean glom. capillary vol. 8 8 8 8
Cap. length density per glom. 8 8 8 8
Mean cap. length per glom. 8 8 8 8
Filtration slit frequency 5 5 5 5
Thickness of the GBM 5 5 5 5
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4 Results
4.1 Clinical parameters
4.1.1 Body weight
There is no statistically significant difference in the body weights of GIPRdn-tg
FVB/N vs. FVB/N-wt mice or GIPRdn-tg C57BL/6J vs. C57BL/6J-wt mice. Nor do
GIPRdn-tg FVB/N vs. GIPRdn-tg C57BL/6J or FVB/N-wt vs. C57BL/6J-wt mice
display any statistically significant differences in body weight.
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Figure 4.1 Body weight
Data are depicted as means ± SD, n=8. Significance calculated with Student’s
t-test. Level of significance is displayed as ∗ = p ≤ 0.05, ∗∗ = p ≤ 0.01 and
∗ ∗ ∗ = p ≤ 0.001. “A” marks significant differences between GIPRdn-tg FVB/N and
GIPRdn-tg C57BL/6J animals, “B” between FVB/N-wt and C57BL/6J-wt animals.
wt: non-transgenic wild-type littermate controls, GIPRdn-tg: GIPRdn-transgenic
mice
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4.1.2 Food consumption per day
The food consumption per day of GIPRdn-tg FVB/N mice is statistically significantly
increased by 38% compared to FVB/N-wt mice. The food consumption per day of
GIPRdn-tg C57BL/6J mice is statistically significantly increased by 45% compared to
C57BL/6J-wt mice. Compared to GIPRdn-tg C57BL/6J mice, the food consumption
of GIPRdn-tg FVB/N mice is increased by 30%. In FVB/N-wt mice, the food
consumption per day is increased by 36% compared to C57BL/6J-wt mice.
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Figure 4.2 Food consumption per day
Data are depicted as means ± SD, n=8. Significance calculated with Student’s
t-test. Level of significance is displayed as ∗ = p ≤ 0.05, ∗∗ = p ≤ 0.01 and
∗ ∗ ∗ = p ≤ 0.001. “A” marks significant differences between GIPRdn-tg FVB/N and
GIPRdn-tg C57BL/6J animals, “B” between FVB/N-wt and C57BL/6J-wt animals.
wt: non-transgenic wild-type littermate controls, GIPRdn-tg: GIPRdn-transgenic
mice
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4.1.3 Food consumption per day and body weight
The food consumption per day and body weight of GIPRdn-tg FVB/N mice is
statistically significantly increased by factor 1.6 compared to FVB/N-wt mice.
The food consumption per day and body weight of GIPRdn-tg C57BL/6J mice is
statistically significantly increased by factor 1.5 compared to C57BL/6J-wt mice.
There is no statistically significant difference in the food consumption of GIPRdn-tg
FVB/N vs. GIPRdn-tg C57BL/6J or FVB/N-wt vs. C57BL/6J-wt mice.
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Figure 4.3 Food consumption per day and body weight
Data are depicted as means ± SD, n=8. Significance calculated with Student’s
t-test. Level of significance is displayed as ∗ = p ≤ 0.05, ∗∗ = p ≤ 0.01 and
∗ ∗ ∗ = p ≤ 0.001. “A” marks significant differences between GIPRdn-tg FVB/N and
GIPRdn-tg C57BL/6J animals, “B” between FVB/N-wt and C57BL/6J-wt animals.
wt: non-transgenic wild-type littermate controls, GIPRdn-tg: GIPRdn-transgenic
mice
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4.1.4 Water consumption per day
The water consumption per day of GIPRdn-tg FVB/N mice is statistically signifi-
cantly increased by factor 3.8 compared to FVB/N-wt mice. In GIPRdn-tg C57BL/6J
mice, the water consumption per day is statistically significantly increased by factor
1.9 compared to C57BL/6J-wt mice. The water consumption per day of GIPRdn-tg
FVB/N mice is statistically higher by factor 2.2 compared to GIPRdn-tg C57BL/6J
mice. No statistically significant difference appears in the water consumption of
FVB/N-wt vs. C57BL/6J-wt mice.
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Figure 4.4 Water consumption per day
Data are depicted as means ± SD, n=8. Significance calculated with Student’s
t-test. Welch’s correction was used for GIPRdn-tg FVB/N vs. FVB/N-wt. Level of
significance is displayed as ∗ = p ≤ 0.05, ∗∗ = p ≤ 0.01 and ∗ ∗ ∗ = p ≤ 0.001. “A”
marks significant differences between GIPRdn-tg FVB/N and GIPRdn-tg C57BL/6J
animals, “B” between FVB/N-wt and C57BL/6J-wt animals. wt: non-transgenic
wild-type littermate controls, GIPRdn-tg: GIPRdn-transgenic mice
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4.1.5 Water consumption per day and body weight
The water consumption per day and body weight of GIPRdn-tg FVB/N mice is
statistically significantly increased by factor 4.3 compared to FVB/N-wt mice. In
GIPRdn-tg C57BL/6J mice, the water consumption per day and body weight is
statistically significantly increased by factor 2 compared to C57BL/6J-wt mice.
The water consumption per day and body weight of GIPRdn-tg FVB/N mice
is statistically higher by factor 2.2 compared to GIPRdn-tg C57BL/6J mice. No
statistically significant difference appears in the water consumption of FVB/N-wt
vs. C57BL/6J-wt mice.
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Figure 4.5 Water consumption per day and body weight
Data are depicted as means ± SD, n=8. Significance calculated with Student’s
t-test. Welch’s correction was used for GIPRdn-tg FVB/N vs. FVB/N-wt. Level of
significance is displayed as ∗ = p ≤ 0.05, ∗∗ = p ≤ 0.01 and ∗ ∗ ∗ = p ≤ 0.001. “A”
marks significant differences between GIPRdn-tg FVB/N and GIPRdn-tg C57BL/6J
animals, “B” between FVB/N-wt and C57BL/6J-wt animals. wt: non-transgenic
wild-type littermate controls, GIPRdn-tg: GIPRdn-transgenic mice
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4.1.6 Daily urine volume
In GIPRdn-tg FVB/N mice, the urine volume per day is statistically significantly
increased by factor 6.2 compared to FVB/N-wt mice. Compared to C57BL/6J-
wt mice, the urine volume per day of GIPRdn-tg C57BL/6J mice is statistically
significantly increased by factor 3.8. The urine volume per day of GIPRdn-tg FVB/N
mice is statistically significantly increased by factor 3.3 compared to GIPRdn-tg
C57BL/6J mice. There is no statistically significant difference in the urine volume
of FVB/N-wt vs. C57BL/6J-wt mice.
4.1.7 Blood pressure
The systolic blood pressure of GIPRdn-tg FVB/N mice is statistically significantly
increased by 21% compared to FVB/N-wt mice. No statistically significant in-
crease in systolic blood pressure of GIPRdn-tg C57BL/6J vs. C57BL/6J-wt mice
is observed. The systolic blood pressure of GIPRdn-tg FVB/N mice is statistically
significantly higher by 36% compared to GIPRdn-tg C57BL/6J mice. In FVB/N-
wt mice, the systolic blood pressure is statistically significantly higher by 29%
compared to C57BL/6J-wt mice. There is no statistically significant difference
in the diastolic blood pressure of GIPRdn-tg FVB/N vs. FVB/N-w, GIPRdn-tg
C57BL/6J vs. C57BL/6J-wt or GIPRdn-tg FVB/N vs. GIPRdn-tg C57BL/6J mice.
A by 12% statistically significantly higher diastolic blood pressure is observed in
FVB/N-wt mice compared to C57BL/6J-wt mice.
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Figure 4.6 24h-urine volume
Data are depicted as means ± SD, n=8. Significance calculated with Student’s
t-test. Welch’s correction was used for GIPRdn-tg FVB/N vs. FVB/N-wt, GIPRdn-tg
C57BL/6J vs. C57BL/6J-wt and FVB/N-wt vs. C57BL/6J-wt. Level of significance
is displayed as ∗ = p ≤ 0.05, ∗∗ = p ≤ 0.01 and ∗ ∗ ∗ = p ≤ 0.001. “A” marks
significant differences between GIPRdn-tg FVB/N and GIPRdn-tg C57BL/6J animals,
“B” between FVB/N-wt and C57BL/6J-wt animals. wt: non-transgenic wild-type
littermate controls, GIPRdn-tg: GIPRdn-transgenic mice
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Figure 4.7 Blood pressure
Data are depicted as means ± SD, n=8. Significance calculated with Student’s
t-test. Welch’s correction was used for systolic blood pressure FVB/N-wt vs.
C57BL/6J-wt. Level of significance is displayed as ∗ = p ≤ 0.05, ∗∗ = p ≤ 0.01 and
∗ ∗ ∗ = p ≤ 0.001. “A” marks significant differences between GIPRdn-tg FVB/N and
GIPRdn-tg C57BL/6J animals, “B” between FVB/N-wt and C57BL/6J-wt animals.
wt: non-transgenic wild-type littermate controls, GIPRdn-tg: GIPRdn-transgenic
mice
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4.1.8 Blood glucose concentration
A statistically significant increase of the casual blood glucose concentration by
the factor 4.3 is present in GIPRdn-tg FVB/N mice compared to FVB/N-wt mice.
The casual blood glucose concentration of GIPRdn-tg C57BL/6J mice is statistically
significantly increased by factor 2.8 compared to C57BL/6J-wt mice. In GIPRdn-tg
FVB/N mice, the casual blood glucose concentration is statistically significantly
higher by factor 1.7 compared to GIPRdn-tg C57BL/6J mice. The casual blood
glucose concentration of FVB/N-wt is slightly, but statistically significantly lower
compared to C57BL/6J-wt mice.
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Figure 4.8 Blood glucose concentrations
Data are depicted as means ± SD, n=8. Significance calculated with Student’s
t-test. Welch’s correction was used for casual blood glucose GIPRdn-tg FVB/N
vs. FVB/N-wt and GIPRdn-tg C57BL/6J vs. C57BL/6J-wt. Level of significance
is displayed as ∗ = p ≤ 0.05, ∗∗ = p ≤ 0.01 and ∗ ∗ ∗ = p ≤ 0.001. “A” marks
significant differences between GIPRdn-tg FVB/N and GIPRdn-tg C57BL/6J animals,
“B” between FVB/N-wt and C57BL/6J-wt animals. wt: non-transgenic wild-type
littermate controls, GIPRdn-tg: GIPRdn-transgenic mice
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4.1.9 Serum parameters
Serum creatinine concentration
A statistically significant increase of 99% is observed in the serum creatinine
concentration of GIPRdn-tg FVB/N mice compared to FVB/N-wt mice. The serum
creatinine concentration GIPRdn-tg C57BL/6J mice is statistically significantly in-
creased by 46% compared to C57BL/6J-wt mice. Compared to GIPRdn-tg C57BL/6J
mice, the serum creatinine concentration of GIPRdn-tg FVB/N mice is statistically
significantly increased by 26%. There is no statistically significant difference in the
serum creatinine concentration of FVB/N-wt vs. C57BL/6J-wt mice.
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Figure 4.9 Serum creatinine concentration
Data are depicted as means ± SD, n=5. Significance calculated with Student’s
t-test. Welch’s correction was used for FVB/N-wt vs. C57BL/6J-wt. Level of
significance is displayed as ∗ = p ≤ 0.05, ∗∗ = p ≤ 0.01 and ∗ ∗ ∗ = p ≤ 0.001. “A”
marks significant differences between GIPRdn-tg FVB/N and GIPRdn-tg C57BL/6J
animals, “B” between FVB/N-wt and C57BL/6J-wt animals. wt: non-transgenic
wild-type littermate controls, GIPRdn-tg: GIPRdn-transgenic mice
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Serum urea concentration
There is no statistically significant difference in serum urea concentrations of
GIPRdn-tg FVB/N vs. FVB/N-wt, GIPRdn-tg C57BL/6J vs. C57BL/6J-wt, GIPRdn-tg
FVB/N vs. GIPRdn-tg C57BL/6J or FVB/N-wt vs. C57BL/6J-wt mice.
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Figure 4.10 Serum urea concentration
Data are depicted as means ± SD, n=5. Significance calculated with Student’s
t-test (GIPRdn-tg FVB/N vs. FVB/N-wt and FVB/N-wt vs. C57BL/6J-wt) and
Mann-Whitney u-test (GIPRdn-tg C57BL/6J vs. C57BL/6J-wt and GIPRdn-tg FVB/N
vs. GIPRdn-tg C57BL/6J). Level of significance is displayed as ∗ = p ≤ 0.05, ∗∗ =
p ≤ 0.01 and ∗ ∗ ∗ = p ≤ 0.001. “A” marks significant differences between
GIPRdn-tg FVB/N and GIPRdn-tg C57BL/6J animals, “B” between FVB/N-wt and
C57BL/6J-wt animals. wt: non-transgenic wild-type littermate controls, GIPRdn-tg:
GIPRdn-transgenic mice
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Serum triglyceride concentration
There is no statistically significant difference in serum triglyceride concentration of
GIPRdn-tg FVB/N vs. FVB/N-wt mice. The serum triglyceride concentration of
GIPRdn-tg C57BL/6J mice is statistically significantly increased by 52% compared to
C57BL/6J-wt mice. In GIPRdn-tg FVB/N mice, the serum triglyceride concentration
is statistically significantly higher by factor 2.7 compared to GIPRdn-tg C57BL/6J
mice. Compared to C57BL/6J-wt mice, the serum triglyceride concentration of
FVB/N-wt mice is statistically significantly higher by 3.6.
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Figure 4.11 Serum triglyceride concentration
Data are depicted as means ± SD, n=5. Significance calculated with Student’s
t-test. Welch’s correction was used for GIPRdn-tg FVB/N vs. GIPRdn-tg C57BL/6J
and FVB/N-wt vs. C57BL/6J-wt. Level of significance is displayed as ∗ = p ≤
0.05, ∗∗ = p ≤ 0.01 and ∗∗∗ = p ≤ 0.001. “A” marks significant differences between
GIPRdn-tg FVB/N and GIPRdn-tg C57BL/6J animals, “B” between FVB/N-wt and
C57BL/6J-wt animals. wt: non-transgenic wild-type littermate controls, GIPRdn-tg:
GIPRdn-transgenic mice
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Serum total protein concentration
There is no statistically significant difference in serum total protein concentrations of
GIPRdn-tg FVB/N vs. FVB/N-wt mice. GIPRdn-tg C57BL/6J vs. C57BL/6J-wt mice
show no statistically significant difference in serum total protein concentrations
either. GIPRdn-tg FVB/N vs. GIPRdn-tg C57BL/6J or FVB/N-wt vs. C57BL/6J-wt
mice do not significantly differ in respect to their serum total protein concentra-
tions.
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Figure 4.12 Serum total protein concentration
Data are depicted as means ± SD, n=5. Significance calculated with Mann-Whitney
u-test. Level of significance is displayed as ∗ = p ≤ 0.05, ∗∗ = p ≤ 0.01 and
∗ ∗ ∗ = p ≤ 0.001. “A” marks significant differences between GIPRdn-tg FVB/N and
GIPRdn-tg C57BL/6J animals, “B” between FVB/N-wt and C57BL/6J-wt animals.
wt: non-transgenic wild-type littermate controls, GIPRdn-tg: GIPRdn-transgenic
mice
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Serum albumin concentration
The serum albumin concentration of GIPRdn-tg FVB/N mice is statistically signif-
icantly decreased by 23% compared to FVB/N-wt mice. In GIPRdn-tg C57BL/6J
mice, the serum albumin concentration is statistically significantly decreased by
16% compared to C57BL/6J-wt mice. The serum albumin concentration of GIPRdn-
tg FVB/N mice is statistically significantly lower by 17% compared to GIPRdn-tg
C57BL/6J mice. There is no statistically significant difference of serum albumin
concentrations of FVB/N-wt vs. C57BL/6J-wt mice.
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Figure 4.13 Serum albumin concentration
Data are depicted as means ± SD, n=5. Significance calculated with Student’s
t-test. Welch’s correction was used for FVB/N-wt vs. C57BL/6J-wt. Level of
significance is displayed as ∗ = p ≤ 0.05, ∗∗ = p ≤ 0.01 and ∗ ∗ ∗ = p ≤ 0.001. “A”
marks significant differences between GIPRdn-tg FVB/N and GIPRdn-tg C57BL/6J
animals, “B” between FVB/N-wt and C57BL/6J-wt animals. wt: non-transgenic
wild-type littermate controls, GIPRdn-tg: GIPRdn-transgenic mice
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Serum cystatin C concentration
There is no statistically significant difference in serum cystatin C concentrations of
GIPRdn-tg FVB/N vs. FVB/N-wt, GIPRdn-tg C57BL/6J vs. C57BL/6J-wt, GIPRdn-tg
FVB/N vs. GIPRdn-tg C57BL/6J or FVB/N-wt vs. C57BL/6J-wt mice.
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Figure 4.14 Serum cystatin C concentration
Data are depicted as means ± SD, n=5. Significance calculated with Student’s t-test
(GIPRdn-tg C57BL/6J vs. C57BL/6J-wt and FVB/N-wt vs. C57BL/6J-wt) and Mann-
Whitney u-test (GIPRdn-tg FVB/N vs. FVB/N-wt and GIPRdn-tg FVB/N vs. GIPRdn-
tg C57BL/6J). Level of significance is displayed as ∗ = p ≤ 0.05, ∗∗ = p ≤ 0.01 and
∗ ∗ ∗ = p ≤ 0.001. “A” marks significant differences between GIPRdn-tg FVB/N and
GIPRdn-tg C57BL/6J animals, “B” between FVB/N-wt and C57BL/6J-wt animals.
wt: non-transgenic wild-type littermate controls, GIPRdn-tg: GIPRdn-transgenic
mice
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Serum sodium concentration
There is no statistically significant difference in the serum sodium concentration
of GIPRdn-tg FVB/N vs. FVB/N-wt mice. The serum sodium concentration of
GIPRdn-tg C57BL/6J is slightly, but statistically significantly decreased compared
to C57BL/6J-wt mice. No statistically significant difference in the serum sodium
concentration of GIPRdn-tg FVB/N vs. GIPRdn-tg C57BL/6J mice was apparent. The
serum sodium concentration of FVB/N-wt is slightly, but statistically significantly
higher compared to C57BL/6J-wt mice.
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Figure 4.15 Serum sodium concentration
Data are depicted as means ± SD, n=5. Significance calculated with Student’s t-test.
Welch’s correction was used for FVB/N-wt vs. C57BL/6-wt. Level of significance
is displayed as ∗ = p ≤ 0.05, ∗∗ = p ≤ 0.01 and ∗ ∗ ∗ = p ≤ 0.001. “A” marks
significant differences between GIPRdn-tg FVB/N and GIPRdn-tg C57BL/6J animals,
“B” between FVB/N-wt and C57BL/6J-wt animals. wt: non-transgenic wild-type
littermate controls, GIPRdn-tg: GIPRdn-transgenic mice
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Serum chloride concentration
There is no statistically significant difference in the serum chloride levels of GIPRdn-
tg FVB/N vs. FVB/N-wt, GIPRdn-tg FVB/N vs. GIPRdn-tg C57BL/6J or FVB/N-wt
vs. C57BL/6J-wt mice. The serum chloride concentration of GIPRdn-tg C57BL/6J
mice is slightly, but significantly decreased compared to C57BL/6J-wt mice.
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Figure 4.16 Serum chloride concentration
Data are depicted as means ± SD, n=5. Significance calculated with Student’s
t-test. Level of significance is displayed as ∗ = p ≤ 0.05, ∗∗ = p ≤ 0.01 and
∗ ∗ ∗ = p ≤ 0.001. “A” marks significant differences between GIPRdn-tg FVB/N and
GIPRdn-tg C57BL/6J animals, “B” between FVB/N-wt and C57BL/6J-wt animals.
wt: non-transgenic wild-type littermate controls, GIPRdn-tg: GIPRdn-transgenic
mice
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4.1.10 Urine analyses
Urine creatinine concentration
Compared to FVB/N-wt mice, the urine creatinine levels of GIPRdn-tg FVB/N
mice are statistically significantly decreased by 90% The urine creatinine levels of
GIPRdn-tg C57BL/6J mice are statistically significantly decreased by 71% compared
to C57BL/6J-wt mice. In GIPRdn-tg FVB/N mice, the urine creatinine levels are
statistically significantly lower by 82% compared to GIPRdn-tg C57BL/6J mice. The
urine creatinine levels of FVB/N-wt mice are statistically significantly lower by
47% compared to C57BL/6J-wt mice.
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Figure 4.17 Urine creatinine concentration
Data are depicted as means ± SD, n=5. Significance calculated with Student’s
t-test. Welch’s correction was used for GIPRdn-tg FVB/N vs. FVB/N-wt and
GIPRdn-tg FVB/N vs. GIPRdn-tg C57BL/6J. Level of significance is displayed as
∗ = p ≤ 0.05, ∗∗ = p ≤ 0.01 and ∗ ∗ ∗ = p ≤ 0.001. “A” marks significant differences
between GIPRdn-tg FVB/N and GIPRdn-tg C57BL/6J animals, “B” between FVB/N-
wt and C57BL/6J-wt animals. wt: non-transgenic wild-type littermate controls,
GIPRdn-tg: GIPRdn-transgenic mice
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Estimated glomerular filtration rate (eGFR)
There is no statistically significant difference in the eGFR of GIPRdn-tg FVB/N vs.
FVB/N-wt, GIPRdn-tg FVB/N vs. GIPRdn-tg C57BL/6J or FVB/N-wt vs. C57BL/6J-
wt mice. The eGFR of GIPRdn-tg C57BL/6J is slightly, but statistically significantly,
decreased compared to C57BL/6J-wt mice.
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Figure 4.18 Estimated glomerular filtration rate (eGFR)
Data are depicted as means ± SD, n=5. Significance calculated with Student’s
t-test. Welch’s correction was used for GIPRdn-tg C57BL/6J vs. C57BL/6J-wt and
GIPRdn-tg FVB/N vs. GIPRdn-tg C57BL/6J. Level of significance is displayed as
∗ = p ≤ 0.05, ∗∗ = p ≤ 0.01 and ∗ ∗ ∗ = p ≤ 0.001. “A” marks significant differences
between GIPRdn-tg FVB/N and GIPRdn-tg C57BL/6J animals, “B” between FVB/N-
wt and C57BL/6J-wt animals. wt: non-transgenic wild-type littermate controls,
GIPRdn-tg: GIPRdn-transgenic mice
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Urine urea concentration
Sample concentrations of several animals exceed the range of the autoanalyzer.
Graphically, there appears to be no significant difference between the means of the
accepted samples.
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Figure 4.19 Urine urea concentration
Each dot represents one animal, n=8. wt: non-transgenic wild-type littermate
controls, GIPRdn-tg: GIPRdn-transgenic mice
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Urine sodium concentration
The urine sodium concentrations of a number of samples fall below the testing
range of the autoanalyzer. The urine sodium concentration of GIPRdn-tg FVB/N
mice appears to be decreased compared to FVB/N-wt mice and the urine sodium
concentration of GIPRdn-tg C57BL/6J mice appears to be decreased compared to
C57BL/6J-wt mice.
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Figure 4.20 Urine sodium concentration
Each dot represents one animal, n=8. wt: non-transgenic wild-type littermate
controls, GIPRdn-tg: GIPRdn-transgenic mice
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Urine chloride concentration
In GIPRdn-tg FVB/N mice, the urine chloride concentrations are statistically sig-
nificantly decreased by 76% compared to FVB/N-wt mice. The urine chloride
concentrations of GIPRdn-tg C57BL/6J mice are statistically significantly decreased
by 74% compared to C57BL/6J-wt mice. There is no statistically significant differ-
ence between the urine chloride concentrations of GIPRdn-tg FVB/N vs. GIPRdn-tg
C57BL/6J or FVB/N-wt vs. C57BL/6J-wt mice.
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Figure 4.21 Urine chloride concentration
Data are depicted as means ± SD, n=5. Significance calculated with Student’s t-test.
Welch’s correction was used for GIPRdn-tg FVB/N vs. FVB/N-wt and FVB/N-wt vs.
C57BL/6J-wt. Level of significance is displayed as ∗ = p ≤ 0.05, ∗∗ = p ≤ 0.01 and
∗ ∗ ∗ = p ≤ 0.001. “A” marks significant differences between GIPRdn-tg FVB/N and
GIPRdn-tg C57BL/6J animals, “B” between FVB/N-wt and C57BL/6J-wt animals.
wt: non-transgenic wild-type littermate controls, GIPRdn-tg: GIPRdn-transgenic
mice
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Urine albumin concentration
A statistically significantly increase of 98% in the urine albumin concentration is dis-
played by GIPRdn-tg FVB/N mice compared to FVB/N-wt mice. The urine albumin
concentration of GIPRdn-tg C57BL/6J mice is statistically significantly decreased by
77% compared to C57BL/6J-wt mice. The urine albumin concentration of GIPRdn-
tg FVB/N mice is statistically significantly increased by factor 9.6 compared to
GIPRdn-tg C57BL/6J-mice. There is no statistically significant difference in the
urine albumin concentration of FVB/N-wt vs C57BL/6J-wt mice.
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Figure 4.22 Urine albumin concentration
Data are depicted as means ± SD, n=8. Significance calculated with Student’s t-test
(GIPRdn-tg FVB/N vs FVB/N-wt and FVB/N-wt vs. C57BL/6J-wt) and Mann-
Whitney u-test (GIPRdn-tg C57BL/6J vs. C57BL/6J-wt and GIPRdn-tg FVB/N vs.
GIPRdn-tg C57BL/6J). Level of significance is displayed as ∗ = p ≤ 0.05, ∗∗ =
p ≤ 0.01 and ∗ ∗ ∗ = p ≤ 0.001. “A” marks significant differences between
GIPRdn-tg FVB/N and GIPRdn-tg C57BL/6J animals, “B” between FVB/N-wt and
C57BL/6J-wt animals. wt: non-transgenic wild-type littermate controls, GIPRdn-tg:
GIPRdn-transgenic mice
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Daily albumin excretion
The albumin excretion per day of GIPRdn-tg FVB/N mice is statistically signif-
icantly increased by the factor 11.9 compared to FVB/N-wt mice. There is no
statistically significant difference in the albumin excretion per day of GIPRdn-tg
C57BL/6J vs. C57BL/6J-wt mice. The albumin excretion per day is statistically
significantly higher by the factor 33.0 in GIPRdn-tg FVB/N mice compared to
GIPRdn-tg C57BL/6J mice. Compared to C57BL/6J-wt mice, the albumin excretion
per day of FVB/N-wt mice is statistically significantly higher by the factor 2.0.
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Figure 4.23 Albumin excretion
Data are depicted as means ± SD, n=8. Significance calculated with Student’s
t-test. Level of significance is displayed as ∗ = p ≤ 0.05, ∗∗ = p ≤ 0.01 and
∗ ∗ ∗ = p ≤ 0.001. “A” marks significant differences between GIPRdn-tg FVB/N and
GIPRdn-tg C57BL/6J animals, “B” between FVB/N-wt and C57BL/6J-wt animals.
wt: non-transgenic wild-type littermate controls, GIPRdn-tg: GIPRdn-transgenic
mice
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Urine albumin creatinine ratio (UACR)
The UACR of GIPRdn-tg FVB/N mice is statistically significantly increased by
the factor 8.3 compared to FVB/N-wt mice. There is no statistically significant
difference in the UACR of GIPRdn-tg C57BL/6J vs. C57BL/6J-wt mice. Compared
to GIPRdn-tg C57BL/6J mice, the UACR of GIPRdn-tg FVB/N mice is statistically
significantly higher by the factor 24.0. The UACR of FVB/N-wt mice is statistically
significantly higher by the factor 2.1 compared to C57BL/6J-wt mice.
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Figure 4.24 Urine albumin creatinine ratio
Data are depicted as means ± SD, n=5. Significance calculated with Student’s t-test
(FVB/N-wt vs. C57BL/6-wt) and Mann-Whitney u-test (GIPRdn-tg FVB/N vs.
FVB/N-wt, GIPRdn-tg C57BL/6J vs. C57BL/6J-wt, GIPRdn-tg FVB/N vs. GIPRdn-tg
C57BL/6J). Level of significance is displayed as ∗ = p ≤ 0.05, ∗∗ = p ≤ 0.01 and
∗ ∗ ∗ = p ≤ 0.001. “A” marks significant differences between GIPRdn-tg FVB/N and
GIPRdn-tg C57BL/6J animals, “B” between FVB/N-wt and C57BL/6J-wt animals.
wt: non-transgenic wild-type littermate controls, GIPRdn-tg: GIPRdn-transgenic
mice
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4.2 Qualitative histological findings
4.2.1 Glomerular tuft profiles of GIPRdn-tg mice
HE stained glomerular tuft profiles
Typical glomerular tuft profiles of wild-type and GIPRdn-tg FVB/N and C57BL/6J
mice are displayed. Subjectively, mice on the FVB/N background appear to display
a larger glomerular tuft areas compared to mice on the C57BL/6J background. In
GIPRdn-tg FVB/N mice in this study, dilated and distorted glomerular capillaries
were a common finding, No significant number of dilated capillaries could be
found in GIPRdn-tg C57BL/6J mice.
FVB/N-wt
*
*
GIPRdn-tg FVB/N
C57BL/6-wt GIPRdn-tg C57BL/6
Figure 4.25 Glomerular histology of GIPRdn-tg FVB/N and C57BL/6J mice in HE
stained GMA/MMA-embedded kidney tissue. * Distorted capillaries. Bar 30µm.
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PAS-MS stained glomerular tuft profiles
In the present study, FVB/N-wt and C57BL/6J-wt mice only occasionally mild
glomerulosclerotic lesions. The glomerular tuft profiles of GIPRdn-tg C57BL/6J
mice sometimes display mild mesangial expansion, but do not differ significantly
from those of C57BL/6J-wt mice. A number of glomerular tuft profiles of GIPRdn-tg
FVB/N mice shows segmental glomerulosclerosis or mesangial expansion.
FVB/N-wt GIPRdn-tg FVB/N
C57BL/6-wt GIPRdn-tg C57BL/6
Figure 4.26 Kidney histology in PAS-MS stained GMA/MMA-embedded tissue of
GIPRdn-tg FVB/N and C57BL/6J mice. Bar 30µm.
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4.2.2 Immunohistochemical detection of glomerular
extracellular matrix proteins and TGF-β1
Immunohistochemical detection of collagen IV
GIPRdn-tg FVB/N mice display increased glomerular immunostaining for collagen
IV compared to FVB/N-wt mice. GIPRdn-tg C57BL/6J mice display an only
slightly increased immunostaining for collagen IV in the glomerulus compared to
C57BL/6J-wt mice. GIPRdn-tg FVB/N mice display more accumulation of collagen
IV in the glomerulus than GIPRdn-tg C57BL/6J mice. There is no difference in
glomerular collagen immunostaining of FVB/N-wt vs. C57BL/6J-wt mice.
FVB/N-wt GIPRdn-tg FVB/N
C57BL/6J-wt GIPRdn-tg C57BL/6J
Figure 4.27 Immunohistochemical detection of collagen IV in paraffin-embedded
tissue of GIPRdn-tg mice. Bar 30µm.
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Immunohistochemical detection of laminin
GIPRdn-tg FVB/N display increased glomerular immunostaining of laminin com-
pared to FVB/N-wt mice. GIPRdn-tg C57BL/6J display increased glomerular im-
munostaining of laminin compared to C57BL/6J-wt mice. There is no difference in
glomerular laminin immunostaining of GIPRdn-tg FVB/N vs. GIPRdn-tg C57BL/6J
or FVB/N-wt vs. C57BL/6J-wt mice.
FVB/N-wt GIPRdn-tg FVB/N
C57BL/6J-wt GIPRdn-tg C57BL/6J
Figure 4.28 Immunohistochemical detection of laminin in paraffin-embedded tissue
of GIPRdn-tg mice. Bar 30µm.
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Immunohistochemical detection of fibronectin
GIPRdn-tg FVB/N display increased immunostaining of fibronectin in the glomeru-
lus compared to FVB/N-wt mice. GIPRdn-tg C57BL/6J mice display increased
glomerular immunostaining of fibronectin compared to C57BL/6J-wt mice. GIPRdn-
tg FVB/N mice display more intense immunostaining of fibronectin in the glomeru-
lus compared to GIPRdn-tg C57BL/6J. There is no difference in the fibronectin
immunostaining intensity in the glomeruli of FVB/N-wt vs. C57BL/6J-wt mice.
FVB/N-wt GIPRdn-tg FVB/N
C57BL/6J-wt GIPRdn-tg C57BL/6J
Figure 4.29 Immunohistochemical detection of fibronectin in paraffin-embedded
tissue of GIPRdn-tg mice. Bar 30µm.
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Immunohistochemical detection of TGF-β1 in the glomerulus
Podocytes of GIPRdn-tg FVB/N display TGF-β1 immunostaining, unlike FVB/N-
wt, GIPRdn-tg C57BL/6J and C57BL/6J-wt mice.
FVB/N-wt GIPRdn-tg FVB/N
C57BL/6J-wt GIPRdn-tg C57BL/6J
Figure 4.30 Immunohistochemical detection of TGF-β1 in paraffin-embedded tissue
of GIPRdn-tg mice. Bar 30µm.
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4.3 Glomerulosclerosis index
The glomerulosclerosis index of GIPRdn-tg FVB/N mice is statistically significantly
increased by the factor 3.5 compared to FVB/N-wt mice. The glomerulosclerosis
index of GIPRdn-tg FVB/N mice is statistically significantly higher by the factor
3.8 compared to GIPRdn-tg C57BL/6J mice. There is no statistically significant
difference in the glomerulosclerosis index of GIPRdn-tg C57BL/6J vs. C57BL/6J-wt
or FVB/N-wt vs. C57BL/6J-wt mice.
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Figure 4.31 Glomerulosclerosis index
Data are depicted as means ± SD, n=8. Significance calculated with Student’s
t-test. Welch’s correction was used for GIPRdn-tg C57BL/6J vs. C57BL/6J-wt,
GIPRdn-tg FVB/N vs. GIPRdn-tg C57BL/6J and FVB/N-wt vs. C57BL/6J-wt. Level
of significance is displayed as ∗ = p ≤ 0.05, ∗∗ = p ≤ 0.01 and ∗∗∗ = p ≤ 0.001. “A”
marks significant differences between GIPRdn-tg FVB/N and GIPRdn-tg C57BL/6J
animals, “B” between FVB/N-wt and C57BL/6J-wt animals. wt: non-transgenic
wild-type littermate controls, GIPRdn-tg: GIPRdn-transgenic mice
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4.4 Quantitative stereological parameters
4.4.1 Total volume of both kidneys
Compared to FVB/N-wt mice, the total volume of both kidneys of GIPRdn-tg
FVB/N mice is statistically significantly increased by 29%. In GIPRdn-tg C57BL/6J
mice, the total volume of both kidneys is statistically significantly increased by 12%
compared to C57BL/6J-wt mice. The total volume of both kidneys of GIPRdn-tg
FVB/N mice is statistically significantly increased by 65% compared to GIPRdn-tg
C57BL/6J mice, while the kidney volume-to-body weight ratio is increased by
64%, compared to GIPRdn-tg C57BL/6J mice. The total volume of both kidneys
of FVB/N-wt mice is statistically significantly increased by 42%, compared to
C57BL/6J-wt mice. The kidney volume-to-body weight ratio is increased by 33%
in FVB/N-wt mice compared to C57BL/6J-wt mice.
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Figure 4.32 Total volume of both kidneys
Data are depicted as means ± SD, n=8. Significance calculated with Student’s
t-test. Level of significance is displayed as ∗ = p ≤ 0.05, ∗∗ = p ≤ 0.01 and
∗ ∗ ∗ = p ≤ 0.001. “A” marks significant differences between GIPRdn-tg FVB/N and
GIPRdn-tg C57BL/6J animals, “B” between FVB/N-wt and C57BL/6J-wt animals.
wt: non-transgenic wild-type littermate controls, GIPRdn-tg: GIPRdn-transgenic
mice
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4.4.2 Total number of nephrons in both kidneys
There is no statistically significant difference in the total nephron number in both
kidneys of GIPRdn-tg FVB/N vs. FVB/N-wt, GIPRdn-tg C57BL/6J vs. C57BL/6J-wt,
GIPRdn-tg FVB/N vs. GIPRdn-tg C57BL/6J or FVB/N-wt vs. C57BL/6J-wt mice.
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Figure 4.33 Total nephron number in both kidneys
Data are depicted as means ± SD, n=5. Significance calculated with Student’s t-test.
Welch’s correction was used for GIPRdn-tg C57BL/6J vs. C57BL/6J-wt. Level of
significance is displayed as ∗ = p ≤ 0.05, ∗∗ = p ≤ 0.01 and ∗ ∗ ∗ = p ≤ 0.001. “A”
marks significant differences between GIPRdn-tg FVB/N and GIPRdn-tg C57BL/6J
animals, “B” between FVB/N-wt and C57BL/6J-wt animals. wt: non-transgenic
wild-type littermate controls, GIPRdn-tg: GIPRdn-transgenic mice
106
CHAPTER 4. RESULTS
4.4.3 Volume fraction of glomeruli in the kidneys
A statistically significant increase by 0.82 percentage points (more than one fourth)
is displayed by GIPRdn-tg FVB/N mice compared to the volume fraction of
glomeruli in the kidneys of FVB/N-wt mice There is no statistically significant
difference in the volume fraction of GIPRdn-tg C57BL/6J vs. C57BL/6J-wt mice.
The volume fraction of glomeruli in the kidneys of GIPRdn-tg FVB/N mice is
statistically significantly lower by 0.37 percentage points compared to GIPRdn-tg
C57BL/6J mice. The volume fraction of glomeruli in the kidneys of FVB/N-wt
mice is statistically significantly higher by 0.83 percentage points compared to
C57BL/6J-wt mice.
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Figure 4.34 Volume fraction of glomeruli in both kidneys
Data are depicted as means ± SD, n=8. Significance calculated with Student’s
t-test. Level of significance is displayed as ∗ = p ≤ 0.05, ∗∗ = p ≤ 0.01 and
∗ ∗ ∗ = p ≤ 0.001. “A” marks significant differences between GIPRdn-tg FVB/N and
GIPRdn-tg C57BL/6J animals, “B” between FVB/N-wt and C57BL/6J-wt animals.
wt: non-transgenic wild-type littermate controls, GIPRdn-tg: GIPRdn-transgenic
mice
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4.4.4 Total glomerular volume in both kidneys
The total glomerular volume pertaining to both kidneys of GIPRdn-tg FVB/N mice
is statistically significantly increased by 84% compared to FVB/N-wt mice. The
total glomerular volume pertaining to both kidneys of GIPRdn-tg FVB/N mice is
statistically significantly increased by 91% compared to GIPRdn-tg C57BL/6 mice.
There is no statistically significant difference in the total glomerular volume of
GIPRdn-tg C57BL/6 vs. C57BL/6-wt or FVB/N-wt vs. C57BL/6-wt mice.
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Figure 4.35 Total glomerular volume in both kidneys
Data are depicted as means ± SD, n=8. Significance calculated with Student’s
t-test. Welch’s correction was used for GIPRdn-tg C57BL/6 vs. C57BL/6-wt and
GIPRdn-tg FVB/N vs. GIPRdn-tg C57BL/6J. Level of significance is displayed as
∗ = p ≤ 0.05, ∗∗ = p ≤ 0.01 and ∗ ∗ ∗ = p ≤ 0.001. “A” marks significant differences
between GIPRdn-tg FVB/N and GIPRdn-tg C57BL/6J animals, “B” between FVB/N-
wt and C57BL/6J-wt animals. wt: non-transgenic wild-type littermate controls,
GIPRdn-tg: GIPRdn-transgenic mice
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4.4.5 Total glomerular volume to body weight ratio
In GIPRdn-tg FVB/N mice, the total glomerular volume per body weight is sta-
tistically significantly increased by the factor two compared to FVB/N-wt mice.
There is no statistically significant difference in the total glomerular volume per
body weight in GIPRdn-tg C57BL/6J vs. C57BL/6J-wt mice or FVB/N-wt vs.
C57BL/6J-wt mice. The total glomerular volume per body weight is statistically
significantly increased by 93% in GIPRdn-tg FVB/N mice, compared to GIPRdn-tg
C57BL/6J mice.
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Figure 4.36 Total glomerular volume to body weight ratio
Data are depicted as means ± SD, n=8. Significance was calculated with Student’s
t-test for GIPRdn-tg FVB/N vs. FVB/N-wt and FVB/N-wt vs. C57BL/6J-wt mice.
Welch’s correction was used for GIPRdn-tg C57BL/6J vs. C57BL/6J mice and
GIPRdn-tg FVB/N vs. GIPRdn-tg C57BL/6J mice. Level of significance is displayed
as ∗ = p ≤ 0.05, ∗∗ = p ≤ 0.01 and ∗ ∗ ∗ = p ≤ 0.001. “A” marks significant
differences between GIPRdn-tg FVB/N and GIPRdn-tg C57BL/6J animals, “B”
between FVB/N-wt and C57BL/6J-wt animals. wt: non-transgenic wild-type
littermate controls, GIPRdn-tg: GIPRdn-transgenic mice
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4.4.6 Mean glomerular volume
The mean glomerular volume of GIPRdn-tg FVB/N mice is statistically significantly
increased by the factor 1.6 compared to FVB/N-wt mice. In GIPRdn-tg C57BL/6J
mice, the mean glomerular volume is statistically significantly increased by the
factor 1.2 compared to C57BL/6J-wt mice. The mean glomerular volume of GIPRdn-
tg FVB/N mice is statistically significantly higher by the factor 2.3 compared to
GIPRdn-tg C57BL/6J mice. Compared to C57BL/6J-wt mice, the mean glomerular
volume of FVB/N-wt mice is statistically significantly higher by the factor 1.8.
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Figure 4.37 Mean glomerular volume
Data are depicted as means ± SD, n=8. Significance calculated with Student’s
t-test. Welch’s correction was used for FVB/N-wt vs. C57BL/6J-wt. Level of
significance is displayed as ∗ = p ≤ 0.05, ∗∗ = p ≤ 0.01 and ∗ ∗ ∗ = p ≤ 0.001. “A”
marks significant differences between GIPRdn-tg FVB/N and GIPRdn-tg C57BL/6J
animals, “B” between FVB/N-wt and C57BL/6J-wt animals. wt: non-transgenic
wild-type littermate controls, GIPRdn-tg: GIPRdn-transgenic mice
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4.4.7 Mean glomerular volume to body weight ratio
The mean glomerular volume per body weight in GIPRdn-tg FVB/N mice is
statistically significantly increased by the factor 1.8 compared to FVB/N-wt mice.
GIPRdn-tg C57BL/6J mice display an by 30% statistically significantly increased
mean glomerular volume per body weight compared to C57BL/6J-wt mice. In
GIPRdn-tg FVB/N vs. GIPRdn-tg C57BL/6J mice, the mean glomerular volume per
body weight is statistically significantly higher by the factor 2.3. FVB/N-wt vs.
C57BL/6J-wt mice display a by the factor 1.7 statistically significantly higher mean
glomerular volume per body weight.
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Figure 4.38 Mean glomerular volume to body weight ratio
Data are depicted as means ± SD, n=8. Significance calculated with Student’s t-test.
Welch’s correction was used for FVB/N-wt vs. C57BL/6J-wt Level of significance
is displayed as ∗ = p ≤ 0.05, ∗∗ = p ≤ 0.01 and ∗ ∗ ∗ = p ≤ 0.001. “A” marks
significant differences between GIPRdn-tg FVB/N and GIPRdn-tg C57BL/6J animals,
“B” between FVB/N-wt and C57BL/6J-wt animals. wt: non-transgenic wild-type
littermate controls, GIPRdn-tg: GIPRdn-transgenic mice
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4.4.8 Numerical volume density of podocytes in the
glomerulus
GIPRdn-tg FVB/N mice display a numerical volume density of podocytes in the
glomerulus, that is approximately half as high as that of FVB/N-wt mice. In
GIPRdn-tg C57BL/6J vs. C57BL/6J-mice, no statistically significant difference is
apparent. The glomerular numerical volume density of GIPRdn-tg FVB/N mice is
statistically significantly lower compared to GIPRdn-tg C57BL/6J mice. FVB/N-
wt mice display a statistically significantly lower numerical volume density of
podocytes in the glomerulus compared to C57BL/6J-wt mice.
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Figure 4.39 Numerical volume density of podocytes in the glomerulus
Data are depicted as means ± SD, n=8. Significance calculated with Student’s
t-test (GIPRdn-tg C57BL/6J vs. C57BL/6J-wt mice, FVB/N-wt vs. C57BL/6J-wt
mice). Welch’s correction was used for GIPRdn-tg FVB/N vs. FVB/N-wt mice
and GIPRdn-tg FVB/N vs. GIPRdn-tg C57BL/6J mice. Level of significance is
displayed as ∗ = p ≤ 0.05, ∗∗ = p ≤ 0.01 and ∗ ∗ ∗ = p ≤ 0.001. “A” marks
significant differences between GIPRdn-tg FVB/N and GIPRdn-tg C57BL/6J animals,
“B” between FVB/N-wt and C57BL/6J-wt animals. wt: non-transgenic wild-type
littermate controls, GIPRdn-tg: GIPRdn-transgenic mice
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4.4.9 Podocyte number per glomerulus
The number of podocytes per glomerulus is statistically significantly reduced
by 27% in GIPRdn-tg FVB/N mice compared to FVB/N-wt mice. There is no
statistically significant difference in the number of podocytes per glomerulus in
GIPRdn-tg C57BL/6J vs. C57BL/6J-wt mice. A by 46% statistically significantly
lower number of podocytes per glomerulus is presented by GIPRdn-tg FVB/N mice
compared to GIPRdn-tg C57BL/6J mice. The number of podocytes per glomerulus
is statistically significantly lower by 26% in FVB/N-wt mice compared to C57BL/6J-
wt mice.
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Figure 4.40 Podocyte number per glomerulus
Data are depicted as means ± SD, n=8. Significance calculated with Student’s
t-test. Welch’s correction was used for GIPRdn-tg FVB/N vs. FVB/N-wt and
GIPRdn-tg FVB/N vs. GIPRdn-tg C57BL/6J. Level of significance is displayed as
∗ = p ≤ 0.05, ∗∗ = p ≤ 0.01 and ∗ ∗ ∗ = p ≤ 0.001. “A” marks significant differences
between GIPRdn-tg FVB/N and GIPRdn-tg C57BL/6J animals, “B” between FVB/N-
wt and C57BL/6J-wt animals. wt: non-transgenic wild-type littermate controls,
GIPRdn-tg: GIPRdn-transgenic mice
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4.4.10 Volume fraction of podocytes in the glomerulus
There is no statistically significant difference in the volume fraction of podocytes
in the glomerulus of GIPRdn-tg FVB/N vs. FVB/N-wt or GIPRdn-tg C57BL/6J vs.
C57BL/6J-wt mice. The volume fraction of GIPRdn-tg FVB/N mice is statistically
significantly lower by 11.13 percentage points compared to GIPRdn-tg C57BL/6J
mice. Compared to C57BL/6J-wt mice, the volume fraction of FVB/N-wt mice is
statistically significantly lower by 6.39 percentage points.
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Figure 4.41 Volume fraction of podocytes in the glomerulus
Data are depicted as means ± SD, n=8. Significance calculated with Student’s
t-test. Level of significance is displayed as ∗ = p ≤ 0.05, ∗∗ = p ≤ 0.01 and
∗ ∗ ∗ = p ≤ 0.001. “A” marks significant differences between GIPRdn-tg FVB/N and
GIPRdn-tg C57BL/6J animals, “B” between FVB/N-wt and C57BL/6J-wt animals.
wt: non-transgenic wild-type littermate controls, GIPRdn-tg: GIPRdn-transgenic
mice
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4.4.11 Mean podocyte volume
The mean podocyte volume of GIPRdn-tg FVB/N mice is statistically significantly
increased by 93% compared to FVB/N-wt mice. In GIPRdn-tg C57BL/6J mice, the
mean podocyte volume is statistically significantly increased by 31% compared
to C57BL/6J-wt mice. the mean podocyte volume of GIPRdn-tg FVB/N mice is
statistically significantly higher by the factor 2.1 Compared to GIPRdn-tg C57BL/6J
mice, the mean podocyte volume of GIPRdn-tg FVB/N mice is statistically signifi-
cantly higher by the factor 2.1. The mean podocyte volume of FVB/N-wt mice is
statistically significantly higher by 44% compared to C57BL/6J-wt mice.
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Figure 4.42 Mean podocyte volume
Data are depicted as means ± SD, n=8. Significance calculated with Student’s
t-test. Level of significance is displayed as ∗ = p ≤ 0.05, ∗∗ = p ≤ 0.01 and
∗ ∗ ∗ = p ≤ 0.001. “A” marks significant differences between GIPRdn-tg FVB/N and
GIPRdn-tg C57BL/6J animals, “B” between FVB/N-wt and C57BL/6J-wt animals.
wt: non-transgenic wild-type littermate controls, GIPRdn-tg: GIPRdn-transgenic
mice
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4.4.12 Volume fraction of mesangium in the glomerulus
In GIPRdn-tg FVB/N mice, the volume fraction of mesangium in the glomerulus is
statistically significantly increased by 3.7 percentage points compared to FVB/N-
wt mice. The volume fraction of mesangium in the glomerulus of GIPRdn-tg
C57BL/6J mice is statistically significantly increased by 3.5 percentage points
compared to C57BL/6J-wt mice. Compared to GIPRdn-tg C57BL/6J mice, the
volume fraction of mesangium in the glomerulus of GIPRdn-tg FVB/N mice is
statistically significantly higher by 4.4 percentage points. The volume fraction of
mesangium in the glomerulus of FVB/N-wt mice is statistically significantly higher
by 4.2 percentage points compared to C57BL/6J-wt mice.
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Figure 4.43 Volume fraction of mesangium in the glomerulus
Data are depicted as means ± SD, n=8. Significance calculated with Student’s
t-test. Level of significance is displayed as ∗ = p ≤ 0.05, ∗∗ = p ≤ 0.01 and
∗ ∗ ∗ = p ≤ 0.001. “A” marks significant differences between GIPRdn-tg FVB/N and
GIPRdn-tg C57BL/6J animals, “B” between FVB/N-wt and C57BL/6J-wt animals.
wt: non-transgenic wild-type littermate controls, GIPRdn-tg: GIPRdn-transgenic
mice
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4.4.13 Mean mesangial volume per glomerulus
The mean mesangial volume per glomerulus of GIPRdn-tg FVB/N mice is statisti-
cally significantly increased by 73% compared to FVB/N-wt mice. In GIPRdn-tg
C57BL/6J mice, the mean mesangial volume per glomerulus is statistically signif-
icantly increased by 14% compared to C57BL/6J-wt mice. The mean mesangial
volume per glomerulus of GIPRdn-tg FVB/N mice is statistically significantly higher
by the factor 3.7 compared to GIPRdn-tg C57BL/6J mice. Compared to C57BL/6J-wt
mice, the mean mesangial volume per glomerulus of FVB/N-wt mice is statistically
significantly higher by the factor 2.2.
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Figure 4.44 Mean glomerular mesangial volume
Data are depicted as means ± SD, n=8. Significance calculated with Student’s
t-test. Welch’s correction was used for GIPRdn-tg FVB/N vs. GIPRdn-tg C57BL/6J
and FVB/N-wt vs. C57BL/6J-wt. Level of significance is displayed as ∗ = p ≤
0.05, ∗∗ = p ≤ 0.01 and ∗∗∗ = p ≤ 0.001. “A” marks significant differences between
GIPRdn-tg FVB/N and GIPRdn-tg C57BL/6J animals, “B” between FVB/N-wt and
C57BL/6J-wt animals. wt: non-transgenic wild-type littermate controls, GIPRdn-tg:
GIPRdn-transgenic mice
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4.4.14 Volume fraction of capillaries in the glomerulus
There is no statistically significant difference in the volume fraction of capillaries
per glomerulus in GIPRdn-tg FVB/N vs. FVB/N-wt mice. The volume fraction
of capillaries in the glomerulus of GIPRdn-tg C57BL/6J mice is statistically sig-
nificantly decreased by 2.4 percentage points compared to C57BL/6J-wt mice.
In GIPRdn-tg FVB/N mice, the volume fraction of capillaries per glomerulus is
statistically significantly increased by 3.6 percentage points compared to GIPRdn-tg
C57BL/6J mice. There is no statistically significant difference in the volume fraction
of capillaries per glomerulus in FVB/N-wt vs. C57BL/6J-wt mice.
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Figure 4.45 Volume fraction of capillaries per glomerulus
Data are depicted as means ± SD, n=8. Significance calculated with Student’s
t-test. Level of significance is displayed as ∗ = p ≤ 0.05, ∗∗ = p ≤ 0.01 and
∗ ∗ ∗ = p ≤ 0.001. “A” marks significant differences between GIPRdn-tg FVB/N and
GIPRdn-tg C57BL/6J animals, “B” between FVB/N-wt and C57BL/6J-wt animals.
wt: non-transgenic wild-type littermate controls, GIPRdn-tg: GIPRdn-transgenic
mice
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4.4.15 Mean capillary volume per glomerulus
The mean glomerular capillary volume per glomerulus of GIPRdn-tg FVB/N mice
is statistically significantly increased by 51% compared to FVB/N-wt mice. There
is no statistically significant difference in the mean capillary volume of GIPRdn-tg
C57BL/6J vs. C57BL/6J-wt mice. A by the factor 2.8 statistically significantly
higher mean glomerular capillary volume per glomerulus compared to GIPRdn-tg
C57BL/6J mice, is displayed by GIPRdn-tg FVB/N mice. The mean glomerular
capillary volume per glomerulus of FVB/N-wt mice is statistically significantly
higher by the factor 1.8 compared to C57BL/6J-wt mice.
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Figure 4.46 Mean glomerular capillary volume
Data are depicted as means ± SD, n=8. Significance calculated with Student’s t-test.
Welch’s correction was used for GIPRdn-tg FVB/N vs. FVB/N-wt and FVB/N-wt vs.
C57BL/6J-wt. Level of significance is displayed as ∗ = p ≤ 0.05, ∗∗ = p ≤ 0.01 and
∗ ∗ ∗ = p ≤ 0.001. “A” marks significant differences between GIPRdn-tg FVB/N and
GIPRdn-tg C57BL/6J animals, “B” between FVB/N-wt and C57BL/6J-wt animals.
wt: non-transgenic wild-type littermate controls, GIPRdn-tg: GIPRdn-transgenic
mice
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4.4.16 Capillary length density in the glomerulus
The capillary length density per glomerulus of GIPRdn-tg FVB/N mice is statisti-
cally significantly decreased by 28% compared to FVB/N-wt mice. Compared to
GIPRdn-tg C57BL/6J mice, the capillary length density per glomerulus of GIPRdn-tg
FVB/N mice is statistically significantly lower by 31%. There is no statistically
significant difference in the capillary length density in the glomerulus of GIPRdn-tg
C57BL/6J vs. C57BL/6J-wt or FVB/N-wt vs. C57BL/6J-wt mice.
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Figure 4.47 Capillary length density in the glomerulus
Data are depicted as means ± SD, n=8. Significance calculated with Student’s
t-test (GIPRdn-tg FVB/N vs. FVB/N-wt and FVB/N-wt vs. C57BL/6J-wt) and
Mann-Whitney u-test (GIPRdn-tg C57BL/6J vs. C57BL/6J-wt and GIPRdn-tg FVB/N
vs. GIPRdn-tg C57BL/6J). Level of significance is displayed as ∗ = p ≤ 0.05, ∗∗ =
p ≤ 0.01 and ∗ ∗ ∗ = p ≤ 0.001. “A” marks significant differences between
GIPRdn-tg FVB/N and GIPRdn-tg C57BL/6J animals, “B” between FVB/N-wt and
C57BL/6J-wt animals. wt: non-transgenic wild-type littermate controls, GIPRdn-tg:
GIPRdn-transgenic mice
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4.4.17 Mean capillary length per glomerulus
In GIPRdn-tg FVB/N mice, the mean capillary length per glomerulus is statistically
significantly increased by 16% compared to FVB/N-wt mice. The mean capillary
length per glomerulus of GIPRdn-tg C57BL/6J mice is statistically significantly
increased by 25% compared to C57BL/6J-wt mice. The mean capillary length
per glomerulus of GIPRdn-tg FVB/N mice is statistically significantly higher by
63% compared to GIPRdn-tg C57BL/6J mice. The mean capillary length per
glomerulus of FVB/N-wt mice is statistically significantly higher by 77% compared
to C57BL/6J-wt mice.
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Figure 4.48 Mean capillary length per glomerulus
Data are depicted as means ± SD, n=8. Significance calculated with Student’s
t-test. Welch’s correction was used for GIPRdn-tg C57BL/6J vs. C57BL/6J-wt
and FVB/N-wt vs. C57BL/6J-wt. Level of significance is displayed as ∗ = p ≤
0.05, ∗∗ = p ≤ 0.01 and ∗∗∗ = p ≤ 0.001. “A” marks significant differences between
GIPRdn-tg FVB/N and GIPRdn-tg C57BL/6J animals, “B” between FVB/N-wt and
C57BL/6J-wt animals. wt: non-transgenic wild-type littermate controls, GIPRdn-tg:
GIPRdn-transgenic mice
121
CHAPTER 4. RESULTS
4.4.18 Filtration slit frequency
There is no statistically significant difference in the filtration slit frequency of
of GIPRdn-tg FVB/N vs. FVB/N-wt, GIPRdn-tg C57BL/6J vs. C57BL/6J-wt or
GIPRdn-tg FVB/N vs. GIPRdn-tg C57BL/6J mice. The filtration slit frequency
in FVB/N-wt mice is slightly, but statistically significantly lower compared to
C57BL/6J-wt mice.
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Figure 4.49 Filtration slit frequency
Data are depicted as means ± SD, n=5. Significance calculated with Student’s
t-test. Level of significance is displayed as ∗ = p ≤ 0.05, ∗∗ = p ≤ 0.01 and
∗ ∗ ∗ = p ≤ 0.001. “A” marks significant differences between GIPRdn-tg FVB/N and
GIPRdn-tg C57BL/6J animals, “B” between FVB/N-wt and C57BL/6J-wt animals.
wt: non-transgenic wild-type littermate controls, GIPRdn-tg: GIPRdn-transgenic
mice
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4.4.19 True harmonic mean thickness of the glomerular
basement membrane (GBM)
The glomerular basement membrane thickness of GIPRdn-tg FVB/N mice is
statistically significantly increased by 7% compared to FVB/N-wt mice. There
is no statistically significant difference in the glomerular basement membrane
thickness of GIPRdn-tg C57BL/6J vs. C57BL/6J-wt mice. The glomerular basement
membrane thickness of GIPRdn-tg FVB/N mice is statistically significantly greater
by 17% compared to GIPRdn-tg C57BL/6J mice.s In FVB/N-wt mice, the glomerular
basement membrane thickness is statistically significantly greater by 11% compared
to C57BL/6J-wt mice.
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Figure 4.50 Glomerular basement membrane thickness
Data are depicted as means ± SD, n=5. Significance calculated with Student’s
t-test. Level of significance is displayed as ∗ = p ≤ 0.05, ∗∗ = p ≤ 0.01 and
∗ ∗ ∗ = p ≤ 0.001. “A” marks significant differences between GIPRdn-tg FVB/N and
GIPRdn-tg C57BL/6J animals, “B” between FVB/N-wt and C57BL/6J-wt animals.
wt: non-transgenic wild-type littermate controls, GIPRdn-tg: GIPRdn-transgenic
mice
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5 Discussion
5.1 General aspects
The present study was performed to examine the influence of the genetic back-
ground on the development and severity of diabetes mellitus and associated renal
lesions in GIPRdn-transgenic mice. Kidney architecture, blood pressure, blood
glucose concentration and other factors that are suspected of playing a role in the
development of renal lesions, were evaluated in the FVB/N and C57BL/6J strain
and in GIPRdn-tg mice of both backgrounds. The presence and severity of diabetes
mellitus was evaluated in GIPRdn-tg FVB/N and GIPRdn-tg C57BL/6J mice. The
results were interpreted in respect to strain-dependent differences between the
FVB/N and C57BL/6J strain in general and their possible influence on the severity
of diabetic lesions in GIPRdn-tg mice. While genetic factors obviously play a role in
determining phenotype, the identification of those factors was not an objective of
the current study. The copy number and insertation place of the transgene were
not examined, nor are differences between the different genetic backgrounds to
be expected in this respect. To investigate differences in the severity of diabetes
mellitus and susceptibility to diabetes-associated renal lesions, eight male GIPRdn-
tg mice on a FVB/N and C57BL/6J background and eight male wild-type FVB/N
and C57BL/6J mice were monitored until the age of six months.
Age is still a central factor in mouse models of diabetic nephropathy. At 180 days
of age, GIPRdn transgenic mice on the CD1 background display many features of
diabetic nephropathy (HERBACH et al., 2009), including podocyte hypertrophy,
glomerular hypertrophy, glomerulosclerosis and thickening of the glomerular
basement membrane. Only male mice were used in the present study, due to the
well documented fact that male mice display more severe symptoms of diabetic
nephropathy compared to their female litter mates (INADA et al., 2007; GURLEY
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et al., 2006). One factor leading to this discrepancy might be the higher blood
glucose levels and blood pressure displayed by male mice. The influence of the
degree of hyperglycemia on the severity of diabetic nephropathy is well established
in humans (UKPDS-GROUP, 1998; DCCT, 1995; WARRAM et al., 1995). Several
small studies seem to suggest that this applies to mice as well (CAO et al., 2014;
REDDI et al., 1990).
The FVB/N and C57BL/6J strains were chosen because of their popularity and
wide-spread use as a genetic background for transgenic animal models of diseases,
both in diabetes research and in medical research in general. Diabetic FVB/N mice
have been noted for their high albumin excretion (XU et al., 2010). Most models
of diabetic nephropathy do not reach the goal of a tenfold or higher increase in
albumin levels, making the FVB/N background especially interesting for research.
On the other hand, C57BL/6J mice are noted for their resistance to the development
of diabetes-associated renal lesions (MA and FOGO, 2003; SHARMA et al., 2003;
ZHENG et al., 1998).
Most comparable stereological studies use a sample size of 5-8 animals per group
(SHEA et al., 2013; HARTNER et al., 2004; BUZELLO, 2000). To optimize the infor-
mative value of the performed analysis, the sample size was set at n=8 for most
quantitative stereological evaluations. The analyzed data confirms that the sample
size was sufficient to draw valid conclusions.
5.2 Diabetes mellitus in GIPRdn-tg FVB/N and
C57BL/6J mice
In the present study, GIPRdn-tg FVB/N mice develop severe diabetes mellitus,
while GIPRdn-tg C57BL/6J mice develop a much milder diabetes. Both groups
of transgenic mice display elevated casual glucose concentrations. In humans,
high blood glucose levels correlate with an increased risk to develop DN, while
strict management of hyperglycemia can postpone or prevent the development
of DN. The severity of hyperglycemia can, but does not have to, contribute to the
progression and severity of DN in mice (GURLEY et al., 2006). The blood glucose
concentrations of db/db-transgenic C57BL/6J mice and of high fat diet diabetic
C57BL/6J mice (NOONAN and BANKS, 2000; HUMMEL et al., 1972) remain below
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the level defined as a diabetic condition (200-300mg/dl, (MARRERO et al., 2013;
FOX, 2007)) and can be interpreted as a pre-diabetic state. Other models of diabetes
mellitus, like STZ-induced diabetes mellitus type 1 or Ins2Akita/+-mutants on a
C57BL/6J background show markedly higher casual blood glucose concentrations
of 300-500mg/dl, but still develop only mild diabetes-associated renal lesions. In
summary, the blood glucose levels of C57BL/6J mice are dependent on the method
of diabetes induction, and GIPRdn-tg mice develop only mildly elevated blood
glucose levels on the C57BL/6J background. GIPRdn-tg FVB/N mice, on the other
hand, display hyperglycemia consistent with diabetes mellitus. FVB/N mice seem
to develop considerable hyperglycemia irrespective of the method of diabetes
induction (CHANG et al., 2012; ZHENG et al., 2004). Solely db/db transgenic
FVB/N mice display comparatively mild hyperglycemia with casual blood glucose
concentrations of only 300-400mg/dl (Table 2.2, p.31). This suggests that the
propensity towards developing severe hyperglycemia might be a characteristic trait
of the FVB/N genetic background. In comparison, GIPRdn-tg CD1 and BALB/c
mice develop similar casual blood glucose concentrations of ca. 700mg/dl (POPPER,
2013). The difference in the level of hyperglycemia displayed by diabetic GIPRdn-tg
mice are important strain-specific features of the FVB/N and C57BL/6J background.
The blood glucose concentrations of GIPRdn-tg FVB/N and GIPRdn-tg C57BL/6J
mice may influence the development and severity of renal alterations in these mice.
In addition to hyperglycemia, hypertension is an important feature in the de-
velopment of DN in human patients. Many mouse models of DN, including
GIPRdn-tg C57BL/6J mice fail to develop significant hypertension. Blood pressure
measurements in conscious mice using tail cuff systems have been shown to be
reasonably accurate (KREGE et al., 1995a,b), and as such were chosen as the least
stressful option. FVB/N mice display an altogether increased systolic blood pres-
sure compared to C57BL/6J mice, and GIPRdn-tg FVB/N mice display increased
systolic blood pressure compared to FVB/N-wt mice. GIPRdn-tg CD1 and CD1-wt
mice presented with systolic blood pressures of 100-120mmHg, GIPRdn-tg BALB/c
and BALB/c-wt with 130-150mmHg, with no significant increase in transgenic vs.
wild-type mice (POPPER, 2013). This strain-dependent difference in systolic blood
pressure might contribute to the progression of DN and the severity of renal lesions
displayed by GIPRdn-tg FVB/N mice.
Polyuria and polydipsia are cardinal symptoms of diabetes mellitus. Persistent
hyperglycemia and increased filtration of glucose lead to a capacity overload of the
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sodium-glucose linked transporter 2 (SGLT2) in the proximal tubule. The resulting
glucosuria leads to osmotic diuresis, causing the polyuria and secondary polydipsia
observed in GIPRdn-tg FVB/N and C57BL/6J mice (GERICH, 2010). The water
consumption and urine production is drastically increased in GIPRdn-transgenic
FVB/N and C57BL/6J mice compared to FVB/N-wt and C57BL/6J-wt mice. Water
consumption and urine volume are considerably higher in GIPRdn-tg FVB/N mice
compared to GIPRdn-tg C57BL/6J mice, reflecting the background-specific higher
degree of hyperglycemia displayed by GIPRdn-tg FVB/N animals. The severely
hyperglycemic GIPRdn-tg CD1 mice show an even higher water consumption and
urine volume compared to GIPRdn-tg FVB/N, with GIPRdn-tg BABL/c mice falling
in between GIPRdn-tg FVB/N and GIPRdn-tg C57BL/6J (POPPER, 2013).
Polyphagia accompanied by failure to gain weight or even weight loss is another
common occurrence in diabetes in humans (GELLING, 2006). Though the average
body weight of wild-type mice is slightly higher than that of diabetic mice, the
difference is not statistically significant for either FVB/N or C57BL/6J mice. In spite
of their unaltered body weight, GIPRdn-tg mice consume a considerably higher
amount of food. Additionally to hyperphagia and hyperglycemia, diabetics usually
show changes in fat metabolism with increased blood triglyceride concentrations
and, consequently, reduced high density lipoprotein cholesterol levels and ele-
vated low density lipoprotein cholesterol levels (diabetic dyslipidemia). Diabetic
dyslipidemia is associated with a higher risk for cardiovascular disease in human
diabetes mellitus patients. Not all mouse models of diabetes mellitus develop
diabetic dyslipidemia. However, the concentration of triglycerides in the blood
of GIPRdn-tg FVB/N and C57BL/6J mice is higher than that of their respective
wild-type controls, with FVB/N mice displaying altogether higher levels than
C57BL/6J mice. The increase of serum triglyceride concentrations in GIPRdn-tg
might be the result of the mutated GIP receptor expressed by this animal model of
diabetes mellitus (PATEL et al., 2014; FARR and ADELI, 2012), compare 2.4.8.
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5.3 Influence of the genetic background on the
development of diabetic nephropathy in
GIPRdn-tg FVB/N and C57BL/6J mice
5.3.1 Kidney function of diabetic GIPRdn-tg FVB/N and
C57BL/6J mice
In healthy individuals, the kidney regulates osmolality, acid-base homeostasis
and excretes products of metabolism. Serum and urine parameters, including
albumin and creatinine, were measured in six months old mice in the present study.
Total serum protein concentrations of GIPRdn-tg FVB/N and C57BL/6J mice are
slightly, but not significantly, decreased. Causative might be a lower albumin serum
concentration, while the serum globulin concentration remains stable. Albumin is
usually excreted in a healthy kidney in only negligible quantities, due to a balance
of filtration and tubular reabsorption (RUSSO et al., 2007). Due to its small molecular
weight of approximately 65kD, it is able to cross the filtration barrier formed by
the glomerular basement membrane and the podocyte foot processes (COMPER,
2014; TOJO and KINUGASA, 2012). As an alternate filtration pathway, transport of
albumin through the podocyte cell bodies has been proposed (KINUGASA et al.,
2011; TOJO et al., 2008). The ability of albumin to cross the filtration barrier has been
controversially discussed previously. Albumin excretion in mice has been shown
to vary greatly in a both strain and gender dependent manner (GURLEY et al., 2010,
2006; BREYER et al., 2005a). Strains that have been noted for above average albumin
excretion are FVB/N mice in general and DBA/2N and BALB/c in STZ-induced
diabetes. C57BL/6J mice show the lowest urinary albumin excretion compared
to other strains in models of DN, i.e. STZ or Ins2Akita/+ (compare Table 2.2, p.31).
Male diabetic mice show higher levels of albumin excretion in all investigated
strains, and are more predisposed to develop DN in general, probably due to their
physiologically higher blood pressure and blood glucose levels (GURLEY et al.,
2010, 2006).
In case of alterations of the glomerular filtration barrier, the increased filtration of
albumin may exceed the capacity for tubular reabsorption. Another study suggests,
that the tubular reabsorption may be decreased in DN, leading to an increased
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albumin excretion even in the absence of alterations of the filtration barrier (TOJO
et al., 2001). At present, it is not known which level of albuminuria correlates
with glomerular disease, as albumin excretion is so heavily dependent on age,
sex and genetic background. Projecting from the situation in humans, mice are
currently considered to display signs of glomerular disease, if albumin levels are
tenfold higher compared to a control group with the same genetic background
and gender (BROSIUS et al., 2009). Because of the polyuria displayed by GIPRdn-tg
C57BL/6J mice, the albumin concentration in the urine of GIPRdn-tg C57BL/6J mice
is significantly lower compared to C57BL/6J-wt mice. The renal loss of albumin
in GIPRdn-tg FVB/N is so great, that even though they develop severe polyuria,
the urine albumin concentration is still almost twice as high as that of wild-type
FVB/N. GIPRdn-tg FVB/N display a twelve fold increase in daily albumin excretion
compared to wild-type FVB/N mice. The FVB/N background appears to be prone
to albuminuria in general, whereas models using C57BL/6J mice fail to develop
increased albuminuria. GIPRdn-tg CD1 and BALB/c mice fall in between GIPRdn-tg
FVB/N and C57BL/6J mice, with GIPRdn-tg CD1 displaying an approximately
6-fold increase and GIPRdn-tg BALB/c an approximately 2-fold increase in daily
albumin excretion (POPPER, 2013). The strain-specific predisposition to develop
proteinuria could compound renal lesions in GIPRdn-tg FVB/N, due to the toxicity
of misfiltrated protein to renal tissue (ABBATE et al., 2006; REMUZZI, 1999; MAR-
SHALL and WILLIAMS, 1998).
Another integral part of phenotyping mouse models of diabetic nephropathy is
the determination of serum and urine creatinine concentrations. Studies have
shown that the measurement of creatinine serum concentrations in autoanalyzers
through creatinase activity overestimates the creatinine concentration approxi-
mately twofold (DUNN et al., 2004; MEYER et al., 1985). However, if evaluated
in conjunction with serum urea concentrations, the enzymatic determination of
creatinine concentration is thought to be suitable as a screening method for renal
function (BROSIUS et al., 2009). Increased serum creatinine levels in the absence of
elevated serum urea nitrogen levels speak against significant renal impairment in
GIPRdn-tg mice on both the FVB/N and C57BL/6J genetic background. Creatinine
measurements are also commonly used as a method to determine glomerular
filtration rate (GFR) in mice, by measuring creatinine clearance. In the presence
of elevated creatinine serum levels, the only reliable method to determine GFR in
mice is by measuring FITC-inulin clearance (QI et al., 2004). Part of the problem
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is the overestimation of creatinine serum concentrations by most measurement
techniques. But even using the gold standard for measuring serum creatinine
concentrations in mice, the high pressure liquid chromatography (HPLC), GFR
calculation using creatinine yields unsatisfactory results. While creatinine is mostly
filtrated in the glomerulus, it can also be secreted in the tubulus (SPITHOVEN et al.,
2013). And as creatinine is being produced in muscle tissue, decreased muscle mass
in subadult, old, female or sedentary mice and strain-dependent differences in
muscle endowment influence serum creatinine levels, making formulas calculating
GFR from serum creatinine unsuitable (HORIO, 2014). However, it is still useful as a
simple way to detect considerable changes in GFR. The estimated glomerular
filtration rate of GIPRdn-tg FVB/N and C57BL/6J is lower than that of their
respective wild-type controls. though only the difference between GIPRdn-tg
C57BL/6J and wild-type C57BL/6J mice is statistically significant. This points
toward the possibility of a slight renal impairment. To either confirm or exclude the
possibility of a renal impairment, serum cystatin C concentrations were measured
in all animals. Cystatin C is a small, 120-amino-acid protein produced at a constant
rate in all cell nuclei (FILLER et al., 2005; ABRAHAMSON et al., 1990; GRUBB and
LOFBERG, 1982), that belongs to the family of cysteine proteinase inhibitors. Due
to its low molecular weight of approximately 13.3 kilodaltons, it is able to pass
through the filtration slits formed by the podocyte foot processes (GRUBB, 2010).
Though cystatin C is then almost entirely reabsorbed by the tubulus epithelial
cells, it does not re-enter the bloodstream, as it is instantly catabolized (JACOBSSON
et al., 1995). No other elimination pathway is currently known (GRUBB, 2010;
FILLER et al., 2005). Though recent studies have shown that cystatin C serum
concentration is indeed dependent on such factors as muscle mass, gender and age,
the effects on cystatin C serum levels are low compared to serum creatinine levels.
This test is especially effective in the detection of mild renal impairment and has
been shown to be superior to the assessment of renal function through creatinine
serum concentrations or blood urea nitrogen concentrations in mice (SONG et al.,
2009). GIPRdn-tg FVB/N and C57BL/6 show no statistically significant differences
in serum cystatin C concentrations and consequently are not renally impaired at
the age of six months. Equally, six month old GIPRdn-tg CD1 and BALB/c mice
displayed no difference in serum cystatin C concentrations (POPPER, 2013) or any
other sign of renal insufficiency.
In addition to albumin and creatinine, sodium and chloride concentrations were
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measured in both serum and urine. Adverse effects of sodium on blood pressure
and the role of increased dietary sodium uptake on hypertension in human patients
have been discussed controversially. Reduced sodium uptake may have beneficial
effects on blood pressure and kidney function (CAMPBELL et al., 2014) in at
least some forms of hypertension. FVB/N-wt mice display both higher serum
sodium concentrations and higher blood pressure compared to C57BL/6J-wt mice.
However, the higher blood pressure seen in GIPRdn-tg FVB/N mice compared to
FVB/N-wt and GIPRdn-tg C57BL/6J mice does not correlate with an increase in
serum sodium concentration and there are no differences in dietary sodium uptake
between the different groups of mice. There does not appear to be a causality
between the higher sodium serum concentrations of FVB/N-wt vs. C57BL/6J-wt
mice and the more severe presentation of DN in GIPRdn-tg FVB/N compared
to GIPRdn-tg C57BL/6J mice. High urinary sodium excretion combined with
albuminuria has been associated with increased mortality in human patients with
chronic kidney disease (MCQUARRIE et al., 2014). However, measurable urine
sodium and chloride concentrations are substantially lower in transgenic mice
compared to their respective wild type controls, with a number of samples falling
below the testing range for urinary sodium. The total urinary sodium excretion
of GIPRdn-tg FVB/N mice is not increased compared to FVB/N-wt, C57BL/6J-wt
mice or GIPRdn-tg C57BL/6J mice, and as such is not considered a determining
factor in the progression of renal lesions in this mouse model of diabetes mellitus.
5.3.2 Semiquantitative analysis and quantitative stereological
analyses of kidneys
Reduction of non-stereological bias through tissue preparation, embedding
and linear tissue shrinkage correction factors
Different forms of bias can greatly influence the quality of quantitative stereology.
Unlike design-based methods, model-based stereological methods are often asso-
ciated with stereological bias. This bias can often be reduced by using correction
factors, but design-based methods should be preferred. Non-stereological bias
includes artifacts of tissue preparation like tissue shrinkage and recognition bias
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through incomplete stain penetration, and can be reduced through optimal tissue
preparation. The purpose of vascular perfusion is the best possible preservation
of the natural state and architecture of tissues, similar to the situation in a living
animal (TRACHSEL et al., 2011). Prevention of the collapse of blood vessels enables
accurate measurements of the glomerulus. Removing the erythrocytes from the
blood vessels also simplifies the counting of glomerular components. The prompt
fixation of the tissue avoids autolytical artifacts.
Tissue shrinkage and tissue deformation are important factors to be considered
in choosing an appropriate embedding method for stereological investigations
(DORPH-PETERSEN et al., 2001). Paraffin embedding, while offering many advan-
tages, produces the greatest degree of tissue shrinkage and deformation. Section
thickness of paraffin sections varies greatly, even when cut in one session from the
same block, which makes paraffin embedding unsuitable for the measurement of
certain parameters (SCHNEIDER and OCHS, 2014). GMA/MMA embedding is far
more time-consuming, but has the benefit of retaining the tissue architecture and
producing regular, even sections with little variation in section height (SCHNEIDER
and OCHS, 2014; BADDELEY et al., 2006). One of the best embedding method for
stereological purposes is embedding in glycid ether, which causes only minimal
tissue shrinkage and deformation compared to other embedding media. Nominal
and actual section thickness of glycid ether embedded kidney slices differ only
slightly. Negative aspects of this embedding method are the high expenditure of
time, technical difficulty and high cost of supplies. The estimation of podocyte
number and mean podocyte volume in the glomerulus, glomerular basement
membrane thickness and filtration slit frequency were performed on glycid ether
embedded tissue samples, to provide maximum effectivity. Additionally, well
established correction factors for linear tissue shrinkage in a variety of embedding
materials (WANKE, 1996), were used to minimize bias. The physical disector
method, currently the gold standard in design-based stereological methods for
particle counting, was used to determine particle numbers. The physical disector
method relies on correct section thickness to produce reliable results. So far, it
has been common practice to calculate particle numbers with the disector method
using the nominal section thickness without verifying the actual section thickness.
By measuring the actual section thickness of a number of sections of GMA/MMA-
embedded murine kidney tissue, an average section thickness of slightly over 1µm
was calculated.
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Glomerulosclerosis index of FVB/N, C57BL/6J and GIPRdn-tg mice
In the present study, the glomerulosclerosis index was determined according to
the method of EL NAHAS et al. (1991), as a measure of the severity of diabetes-
associated renal lesions. Glomerulosclerosis is one of the defining pathological
changes of DN. The combined silver methenamine and PAS staining method for
extracellular matrix ensures maximum specificity by facilitating the differentiation
of extracellular matrix from cell cytoplasm (BROSIUS et al., 2009), while still
allowing for an assessment of glomerular morphology. With a glomerulosclerosis
index increased more than threefold in this study, GIPRdn-tg FVB/N mice have
shown significant glomerular alterations consistent with diabetic nephropathy in
mice. Correspondently, the capillary length density in the glomerulus is statistically
significantly decreased in GIPRdn-tg FVB/N mice. The glomerulosclerosis index of
GIPRdn-tg C57BL/6J is not statistically significantly increased compared to wild-
type mice on the C57BL/6J and FVB/N background. As GIPRdn-tg C57BL/6J
do not develop severe hyperglycemia or albuminuria, this failure to develop
glomerulosclerotic lesions is not surprising. Whether this failure to develop
glomerulosclerotic lesions is due to the insufficient hyperglycemia or is strain-
specific to C57BL/6J mice, has been shown by a combined model of Leprdb/db and
Sur1-/- transgenic C57BL/6J mice (C57BL/6JSur1-/-,db/db). The sulfonylurea receptor
1 (Sur1) is a subunit of the adenosintriphosphat-sensitive potassium channel in beta
cells. The loss of Sur1 in Sur1-/- mice causes a defective insulin secretion (SEGHERS
et al., 2000). Unlike C57BL/6Jdb/db mice, these C57BL/6JSur1-/-,db/db mice displayed
severe obesity and hyperglycemia similar to FVB/Ndb/db mice. The degree of
glomerulosclerosis displayed by the C57BL/6JSur1-/-,db/db mice was not increased
compared to C57BL/6db/db mice with only mild hyperglycemia (CHUA et al., 2010).
The results of this study and a previous study on susceptibility loci to nephropathy
in mice seem to suggest that the resistance to the development of glomerulosclerosis
is a trait inherent to the C57BL/6J background, and attributable to a dominant
locus on chromosome 5 (CHUA et al., 2010; PAPETA et al., 2009). The study also
identified a major locus on chromosome 8, which appeared to influence the higher
susceptibility to nephropathy in FVB/N mice (CHUA et al., 2010). Comparing the
results of the present study with a similar study (POPPER, 2013) using different
genetic backgrounds, it appears that the glomerulosclerosis index of GIPRdn-tg
CD1 mice is higher compared to GIPRdn-tg FVB/N mice, possibly a consequence
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of the higher blood glucose concentrations displayed by GIPRdn-tg CD1 mice. The
glomerulosclerosis index of GIPRdn-tg BALB/c falls in between that of GIPRdn-tg-
FVB/N and GIPRdn-tg C57BL/6J mice (POPPER, 2013).
Quantitative stereological analyses of kidneys of FVB/N, C57BL/6J and
GIPRdn-tg mice
To investigate differences in kidney morphology and their effect on the suscepti-
bility to diabetes-associated renal lesions, multiple stereological parameters were
determined in wild-type FVB/N and C57BL/6J mice and GIPRdn-tg mice of both
backgrounds. The total kidney volume of GIPRdn-tg animals was significantly
higher than that of their respective wild-type controls, a common finding associated
with diabetes mellitus and DN in both humans and mice (BLANTZ and SINGH,
2014; HABIB, 2013). Most of the increase in kidney volume of diabetic patients may
be attributable to tubular hyperplasia and hypertrophy, and interstitial expansion
(SEYER-HANSEN et al., 1980). Possibly, heightened filtration and active reabsorption
of glucose and fluids play a role in increasing kidney volume (BILOUS, 2001). There
is a strain-dependent difference in kidney volume, with FVB/N-wt mice presenting
with altogether bigger kidneys compared to C57BL/6J-wt mice, in spite of similar
body weight. A higher percental increase of kidney volume in GIPRdn-tg FVB/N
mice compared to GIPRdn-tg C57BL/6J mice implicates a more severe reaction to
hyperglycemia and higher susceptibility to the development of renal disease.
Many recent studies have emphasized the influence of low congenital nephron
number on the development and progression of kidney disease in various species
(CEBRIAN et al., 2014; BOUBRED et al., 2013; SCHLOTE et al., 2013; BRENNER and
MACKENZIE, 1997). Rats with unilateral renal agenesis and reduced nephron
numbers in the remaining kidney show more severe glomerular hypertrophy than
a uninephrectomized control group (WANG et al., 2014). Prematurely delivered CD1
mice showed approximately 26% lower nephron number, lower GFR, higher blood
pressure and increased urinary albumin excretion compared to CD1 mice delivered
full-term (STELLOH et al., 2012). However, there is no statistically significant
difference in the nephron endowment of FVB/N-wt and C57BL/6J-wt mice. Causes
discussed for decreased congenital nephron numbers include maternal and fetal
malnutrition, premature birth and maternal diabetes. None of those factors apply
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to the animals used in the present study. The nephron number determined in this
study for FVB/N and C57BL/6J mice agrees with previously published data for
C57BL/6J and C3H/HeJ mice, and appears to be unexceptional for laboratory
mice (MURAWSKI et al., 2010). GIPRdn-tg status appears to have no negative effect
on kidney development and nephron number. The differences in kidney lesions
between GIPRdn-tg FVB/N and C57BL/6J mice appear to be unrelated to changes
in nephron number and no significant loss of nephrons at the age of six months
can be observed. The mechanisms through which low congenital nephron number
influences the progression of renal disease are currently still under discussion,
but increased blood pressure appears to play an integral role (BRENNER et al.,
1988). The increase in blood pressure can potentially be attributed to changes
in sodium re-absorption in the tubule instead of directly to the lower number of
nephrons (BAUMANN et al., 2003). The idea, that low nephron number leads to a
higher GFR per nephron and subsequent scarring of the glomerulus, has also been
proposed (MILLER et al., 1991). Other studies noted that the kidney compensates
for the decreased number of glomeruli through glomerular hypertrophy, leading
to podocytopathy (BENZ et al., 2011; MANALICH et al., 2000). While FVB/N-wt
mice display average nephron endowment, a higher mean glomerular volume and
higher blood pressure are present.
Another parameter suspected of influencing susceptibility to DN is the mean
glomerular volume. A high mean glomerular volume is considered a risk factor
for glomerular injury in humans. Pima Indians, the majority of whom develop
diabetes mellitus, and people of african or hispanic origin display a higher mean
glomerular volume compared to caucasians or asians (LEMLEY, 2003; LAWSON
et al., 1996; SCHMIDT et al., 1992; BILOUS et al., 1989). Compared to diabetes
patients of caucasian descent, a higher percentage of these ethnic groups devel-
ops DN and the progression of the disease is more severe (DREYER et al., 2013;
LEMLEY, 2008). The mean glomerular volume of FVB/N-wt mice is almost twice
as high as that of C57BL/6-wt mice, which is a considerable strain-dependent
difference. While there is no significant difference in the total glomerular volume
of FVB/N-wt and C57BL/6J-wt mice, the volume fraction of glomeruli per kidney
is considerably higher in C57BL/6J-wt mice. Volume fraction of glomeruli in
the kidney, total glomerular volume and mean glomerular volume of GIPRdn-tg
FVB/N are increased at more than 25-50% compared to FVB/N-wt mice, whereas
GIPRdn-tg C57BL/6J mice only display a slight increase in mean glomerular volume
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compared to C57BL/6J-wt mice. Summarized, FVB/N-wt mice possess larger
kidneys with larger glomeruli and a lower volume fraction of glomeruli in the
kidneys compared to C57BL/6J mice, without showing a difference in total nephron
number. Glomerular hypertrophy, as displayed by GIPRdn-tg FVB/N mice, is one
of the hallmarks of DN (FOGO and ICHIKAWA, 1991). A study by POPPER (2013)
examined kidney morphology in GIPRdn-tg CD1 and BALB/c mice. Subsequently,
the results of the present study are compared to those of POPPER (2013). CD1-
wt and GIPRdn-tg CD1 mice display a slightly lower mean glomerular volume
compared to FVB/N-wt and GIPRdn-tg FVB/N mice respectively, while BALB/c-wt
and GIPRdn-tg BALB/c mice display a slightly higher mean glomerular compared
to C57BL/6-wt and GIPRdn-tg C57BL/6 mice (POPPER, 2013). GIPRdn-tg CD1
display a comparable percental increase in mean glomerular volume compared to
CD1-wt mice as GIPRdn-tg FVB/N to FVB/N-wt mice. A similar percental increase
in mean glomerular volume is present in GIPRdn-tg mice on the BALB/c and
C57BL/6J backgrounds compared to their wild-type control groups. The presumed
higher risk for renal alterations associated with a high mean glomerular volume
seems to apply to the situation in GIPRdn-tg FVB/N mice, as they develop more
severe albuminuria and glomerulosclerotic lesions than C57BL/6J mice. The low
mean glomerular volume of C57BL/6J mice seems to confer a resistance to the
development of renal lesions irrespective of the state of hyperglycemia.
The mean capillary volume in the glomerulus of GIPRdn-tg C57BL/6J mice does not
differ significantly from that of wild-type C57BL/6J controls. The volume fraction
of capillaries in the glomerulus is slightly decreased in GIPRdn-tg C57BL/6J mice.
This is probably due to the mild mesangial expansion and podocyte hypertrophy
displayed by GIPRdn-tg C57BL/6J mice, instead of a collapse of glomerular cap-
illaries, which was not observed in the present studies. In contrast, the volume
fraction of capillaries in the glomerulus in GIPRdn-tg FVB/N mice is not decreased
compared to FVB/N-wt mice, and their mean capillary volume in the glomerulus
is increased by the factor 1.5 compared to FVB/N-wt mice. To differentiate
between a de novo growth of capillaries and capillary dilation and distortion
due to mesangial failure, capillary length density and mean capillary length per
glomerulus were assessed in GIPRdn-tg FVB/N, FVB/N-wt, GIPRdn-tg C57BL/6J
and C57BL/6J-wt mice. The mean capillary length per glomerulus is increased in
GIPRdn-tg mice of both the FVB/N and the C57BL/6J background compared to
their respective wild-type control mice.. However, the capillary length density is
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decreased by 28% in GIPRdn-tg FVB/N mice compared to FVB/N-wt mice, while no
significant differences between FVB/N-wt, C57BL/6-wt and GIPRdn-tg C57BL/6J
mice can be observed. Mechanical stress due to high intraglomerular pressure
can damage the mesangium’s connection to the GBM and promote mesangial
expansion. Consequently, the normal glomerular architecture can no longer be
maintained and capillaries dilate and may display ballooning (LEMLEY et al., 1992;
SAKAI et al., 1992). Distorted and dilated capillaries can be observed in the majority
of glomeruli in GIPRdn-tg FVB/N mice, suggesting that mesangial failure due
to increased intraglomerular pressure may be present in GIPRdn-tg FVB/N mice.
Due to the kidney’s ability to regulate blood flow through the organ (Bayliss
myogenic response) and tubuloglomerular feedback, the increased intraglomerular
pressure apparently present in GIPRdn-tg FVB/N is not necessarily a consequence
of the increased systolic blood pressure displayed by GIPRdn-tg FVB/N mice. The
existence of differences in hemodynamics specific to the FVB/N background can
not be precluded at this time. GIPRdn-tg CD1 and GIPRdn-tg BALB/c display
similarly decreased capillary length densities compared to GIPRdn-tg FVB/N mice
and distorted capillaries are present as well. The capillary length density of CD1-wt
and BALB/c-wt mice is comparable to FVB/N-wt and C57BL/6J-wt mice (POPPER,
2013).
Laminin, fibronectin and collagen IV are the three most significant extracellular
glomerular matrix proteins associated with mesanigal expansion, which marks
the beginning of glomerulosclerosis (PUGLIESE et al., 1997). Detection of collagen
IV through immunohistochemistry allows the assessment of extracellular matrix
components in the glomerulus and clearly marks basement membranes in the
interstitium (BROSIUS et al., 2009). Immunohistochemical detection of laminin,
fibronectin and collagen IV shows an increased accumulation of matrix proteins
in GIPRdn-tg FVB/N and GIPRdn-tg C57BL/6J mice compared to their wild-type
controls. Transforming growth factor β1 has been shown to play a pivotal role
in the development of mesangial expansion and interstitial fibrosis. It increases
the synthesis of extracellular matrix proteins and prevents matrix degradation
(ZIYADEH, 2004; SHARMA and ZIYADEH, 1994; ZIYADEH et al., 1994). TGF-β1
accumulation detected trough IHC is increased in GIPRdn-tg FVB/N, but not in
GIPRdn-tg C57BL/6J mice. Stereological analysis of the mean mesangial volume
per glomerulus shows considerable mesangial expansion of over 70% volume
increase in GIPRdn-tg FVB/N mice vs. FVB/N-wt mice, compared to a 14%
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increase in GIPRdn-tg C57BL/6J vs. C57BL/6J-wt mice. That difference in the
increase of the mean mesangial volume per glomerulus is reflected in the higher
glomerulosclerosis index shown by GIPRdn-tg FVB/N mice compared to GIPRdn-tg
C57BL/6J. The mean mesangial volume per glomerulus of wild-type FVB/N is
considerably higher than that of wild-type C57BL/6J mice, another important
difference between the two strains that may contribute to the higher susceptibility
of the FVB/N background to the development of diabetes-associated renal lesions.
The higher volume fraction of mesangium per glomerulus of GIPRdn-tg FVB/N
mice compared to GIPRdn-tg C57BL/6J mice proves that the observed difference in
mean mesangial volume per glomerulus is not simply due to the higher mean
glomerular volume displayed by FVB/N mice, but is indeed a strain-related
difference.
Podocytes play an integral role in kidney function and the development and
progression of renal diseases. Their foot processes form part of the filtration barrier
and are indispensable for homeostasis. Mature podocytes are unable to replicate
and detach from the glomerular capillary wall once their lifespan ends. Parietal
podocytes present on the Bowman’s capsule migrate to the glomerulus to replace
the lost podocytes (SCHULTE et al., 2014), but if the body’s capacity to recruit new
podocytes to the glomerulus is exceeded, the number of mature podocytes forming
filtration slits begins to drop. Podocyte hypertrophy and podocyte loss are features
of diabetic nephropathy and are fundamental processes in the development of
chronic kidney insufficiency. Several different mechanisms leading to podocyte
loss in the diabetic kidney have been discussed, among them apoptosis, insufficient
production of podocyte-protective substances and mechanical detachment through
high pressure and glomerular hypertrophy (BROSIUS and COWARD, 2014; KRIZ
and LEMLEY, 2014). In the progression of diabetic nephropathy, the glomerular
hypertrophy and ongoing loss of podocytes leads to podocyte hypertrophy, as
the remaining podocytes grow in size to cover the emerging gaps in the filtration
barrier. Traditionally, fewer and larger podocytes are regarded as a contributing
factor in the development of diabetic nephropathy in humans (LEMLEY, 2003).
Hyperglycemia is thought to have direct effects on podocyte growth as well (HOSHI
et al., 2002). Their foot processes broaden, stop to interlock, separate from the GMB
and proteinuria develops (WHITE and BILOUS, 2004). The podocyte numbers of
FVB/N-wt mice are already considerably lower compared to C57BL/6J-wt mice,
and GIPRdn-tg FVB/N show significantly lower podocyte numbers compared to
138
CHAPTER 5. DISCUSSION
FVB/N-wt mice, which can be interpreted as podocyte loss. Alternatively, if the
increase in the mean podocyte volume of GIPRdn-tg FVB/N mice is independent of
podocyte loss, fewer podocytes might be required to cover the glomerular basement
membrane as the volume of the podocytes increases over time. No significantly
decrease in the number of podocytes per glomerulus is observable in GIPRdn-tg
C57BL/6J mice compared to C57BL/6J-wt mice.
The volume fraction of podocytes per glomerulus is strain-dependently lower in
FVB/N-wt mice compared to C57BL/6J-wt mice. The podocyte volume shows
strain-specific differences as well, with FVB/N-wt mice displaying a higher mean
podocyte volume compared to C57BL/6J-wt mice. An increase in podocyte volume
can be observed in transgenic mice of both strains, but the degree of hypertrophy is
considerably greater in GIPRdn-tg FVB/N compared to GIPRdn-tg C57BL/6J mice.
Subsequently, the results of the present study were compared with the results of a
previous study by POPPER (2013), in which the kidney morphology of GIPRdn-tg
CD1 mice, GIPRdn-tg BALB/c mice and their respective wild-type control mice
were studied. CD1-wt, BALB/c-wt, GIPRdn-tg CD1 and GIPRdn-tg BALB/c display
podocyte numbers comparable to FVB/N-wt mice. The mean podocyte volume
of CD1-wt and BALB/c-wt mice is comparable to the mean podocyte volume
of C57BL/6J-wt mice. GIPRdn-tg BALB/c mice display podocyte hypertrophy
comparable to GIPRdn-tg C57BL/6J mice. GIPRdn-tg CD1 mice develop more severe
podocyte hypertrophy compared to GIPRdn-tg C57BL/6J and GIPRdn-tg BALB/c,
but their podocytes only reach approximately a third of the mean podocyte volume
of GIPRdn-tg FVB/N mice (POPPER, 2013). In view of the severe albuminuria and
increased glomerulosclerosis index displayed by GIPRdn-tg FVB/N, the results
seem to concur with the hypothesis that few, large podocytes can be considered as
a risk factor in the development of nephropathies. The higher podocyte number
and lower podocyte volume of the C57BL/6J background on the other hand, may
have a protective effect on the development of proteinuria and glomerulosclerosis
(STEFFES et al., 2001). Recently, a study on podocyte volumes and numbers in
GLUT4-deficient mice noted that they showed less signs of diabetic nephropathy
in spite of displaying larger and fewer podocytes (GUZMAN et al., 2014) than their
wild-type controls, with podocyte number having been determined by counting
WT1 positive nuclei. These findings implicate, that while low podocyte number
and high podocyte volume can be associated with an increased risk for developing
DN or a more severe progression of DN, several other predisposing factors are
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probably required for the development of severe DN. The strain-dependent severe
hyperglycemia, hypertension and high mean glomerular volume of FVB/N mice
are such other predisposing factors and could explain the severity of lesions
developed by diabetic FVB/N mice. C57BL/6J mice only display strain-specific
kidney characteristics associated with a suspectedly low risk of contracting DN,
and do not develop anything but mild renal changes in most models of diabetes
mellitus (SHARMA et al., 2003; ZHENG et al., 1998; HUMMEL et al., 1972), including
the GIPRdn mouse model.
The filtration slit frequency of FVB/N-wt mice is slightly, but statistically signifi-
cantly lower compared to C57BL/6J-wt mice, but no other statistically significant
differences are apparent. The glomerular basement membrane shows an increase
in thickness in GIPRdn-tg FVB/N mice compared to FVB/N-wt mice, but not
in GIPRdn-tg C57BL/6J mice compared to C57BL/6J-wt mice. Correspondingly,
GIPRdn-tg CD1, but not GIPRdn-tg BALB/c, display an increased GBM thickness
(POPPER, 2013). As thickening of the GBM has been shown to go hand in hand
with a change in GBM architecture that leads to increased permeability (ISOGAI
et al., 1999), this correlates well with the differences in proteinuria displayed by
GIPRdn-tg mice of the FVB/N, C57BL/6J, CD1 and BALB/c genetic backgrounds.
5.4 Conclusions
The hypothesis that the genetic background influences the severity of the diabetic
metabolic state and the susceptibility to diabetic nephropathy (BREYER and QI, 2010;
BROSIUS et al., 2009), and that strain-dependent differences in kidney composition
play a role in the differences in susceptibility to diabetic nephropathy, is supported
by the findings of this study. The way genetic factors determine the quantitative
traits investigated in this study is still unclear and their identification is not
the aim of this study. GIPRdn-transgenic mice on a FVB/N background display
severe hyperglycemia, hypertension, polyuria and severe albuminuria. GIPRdn-
transgenic mice on a C57BL/6J background, on the other hand, display only
mildly elevated blood glucose levels, no hypertension or albuminuria, and mild
polyuria. The degree of hyperglycemia, hypertension and albuminuria displayed
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by GIPRdn-tg FVB/N and C57BL/6J mice may be influenced by differences specific
to the respective background strain. The higher degree of hyperglycemia and
hypertension displayed by GIPRdn-tg FVB/N mice may influence the development
of renal lesions, but other mouse models of diabetes have demonstrated, that a
higher blood glucose concentraion and higher blood pressure do not have to lead to
more severe lesions in the absence of other risk factors. The kidneys of FVB/N-wt
mice are characterized by large glomeruli, a low number of podocytes and larger
podocytes compared to C57BL/6J-wt mice. The combination of these features
may contribute to the development of albuminuria and renal lesions that share
some aspects with human DN. The kidneys of C57BL/6J-wt mice contain small
glomeruli with a higher number of podocytes, which are comparatively small,
possibly explaining their apparent resistance to injury. FVB/N-wt and C57BL/6J-
wt mice display a comparable nephron endowment, and GIPRdn-tg FVB/N and
C57BL/6J mice do not show a lower nephron number compared to FVB/N-wt or
C57BL/6J-wt mice. While GIPRdn-FVB/N mice can be considered a suitable model
of human DN and the use of the FVB/N strain as a genetic background in models
of diabetes and diabetic nephropathy can be recommended, the C57BL/6J strain
appears to be not ideally suited for research on diabetes-associated kidney lesions
in this model of disease. As a model to study resistance to kidney lesions, however,
it may be highly interesting.
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6 Summary
Diabetic nephropathy is one of the most important sequelas of diabetes mellitus.
The pathogenically relevent processes underlying this disease are only insufficiently
understood, and existing mouse models fail to recreate the human disease in all
its aspects. Therefore, much effort has been put into the development of novel
mouse models of DN. Recently, the impact of the genetic background on the
development of renal lesions has come into the focus of research. Transgenic mice
expressing a dominant negative glucose-dependent insulinotropic polypeptide
receptor (GIPRdn-tg mice), controlled by the rat proinsulin 2 promotor, were chosen
as a model of diabetes. To investigate strain dependent morphological differences
and their possible influence on susceptibility to develop DN, GIPRdn-tg mice were
investigated on a genetic background prone to albuminuria (FVB/N) and on a
background noted for its relative resistance to the development of renal injury
(C57BL/6J).
Eight male GIPRdn-tg FVB/N, GIPRdn-tg C57BL/6J mice and their respective wild-
type controls at the age of six months were analysed. Clinical parameters were
investigated, and morphological kidney parameters were analysed quantitative
stereologically, semiquantitatively and qualitatively.
Clinically, GIPRdn-tg FVB/N mice developed severe hyperglycemia, polydypsia,
polyuria and showed elevated systolic blood pressure levels compared to wild-type
FVB/N mice. The GIPRdn-tg FVB/N mice displayed an increase in daily albumin
excretion of approximately 12 times compared to wild-type FVB/N. Compared
to C57BL/6J-wt mice, GIPRdn-tg C57BL/6J mice developed only mildly increased
casual blood glucose concentrations and polyuria. Albuminuria or elevated blood
pressure in GIPRdn-tg C57BL/6J mice compared to wild-type C57BL/6J were
not observed. The results of the present study indicate that pronounced strain-
dependent differences in the diabetic metabolic state exist between GIPRdn-tg
FVB/N and GIPRdn-tg C57BL/6J mice.
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FVB/N-wt mice displayed a higher kidney volume, comparable nephron en-
dowment, higher mean and total glomerular volume, higher mean podocyte
volume and lower podocyte number compared to C57BL/6J-wt mice, showing
that statistically significant differences in kidney morphology are present between
the FVB/N and C57BL/6J strain. GIPRdn-tg mice on the FVB/N background
showed pronounced glomerulosclerosis, renal hypertrophy and glomerular hy-
pertrophy with mesangial expansion, dilated and distorted glomerular capillaries,
podocyte hypertrophy, reduced podocyte numbers and GBM thickening compared
to FVB/N-wt mice. GIPRdn-tg mice on the C57BL/6J background displayed an
only slightly increased kidney and mean glomerular volume and mild podocyte
hypertrophy compared to C57BL/6J-wt mice. Reduced podocyte numbers, dilation
of glomerular capillaries or GBM thickening compared to C57BL/6J-wt mice were
not observed. GIPRdn-tg FVB/N mice displayed a higher glomerulosclerosis index,
higher mean and total glomerular volume, higher mean podocyte volume, lower
podocyte number and higher glomerular basement thickness compared to GIPRdn-
tg C57BL/6J mice. The differences already present in quantitative morphological
kidney parameters between wild-type mice of the both strains are exacerbated by
the presence of diabetes. The strain-dependent differences in clinical parameters
like hyperglycemia, blood pressure and albuminuria may influence susceptibility
to renal lesions, but strain-dependent variations in mean glomerular volume,
podocyte volume and podocyte number also appear to play a role in both genetic
backgrounds. The mild presentation of renal lesions in GIPRdn-tg C57BL/6J may
be partially attributable to the lower casual blood glucose concentrations, but
other models of diabetes have reported similar findings in diabetic C57BL/6J
mice displaying higher blood glucose concentrations. This suggests that kidney
morphology is also at least partially responsible for the low susceptibility to the
development of renal lesions in the C57BL/6J strain.
In summary, this study demonstrates the importance of choosing the right genetic
background for murine models of DN, based on its susceptibility to develop severe
renal lesions. In the light of the predisposing factors displayed by FVB/N mice
and the correspondingly more severe renal lesions displayed by diabetic FVB/N
mice, GIPRdn-tg FVB/N mice can be endorsed as a useful mouse model of DN.
GIPRdn-tg C57BL/6J mice are less suitable as a model of DN due to the C57BL/6J
genetic background’s apparent resistance to the development of DN, but may offer
valuable insight into the mechanisms of resistance to diabetes and renal disease.
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7 Zusammenfassung
Die diabetische Nephropathie stellt eine der bedeutendsten Folgeerkrankungen
von Diabetes dar. Die der Erkrankung zugrunde liegenden pathogenen Prozesse
sind bisher nur unzureichend bekannt und derzeitige Mausmodelle sind nicht
in der Lage, die Erkrankung des Menschen vollständig darzustellen. Daher
wird viel Aufwand in die Entwicklung neuer Mausmodelle für die diabetische
Nephropathie investiert. In letzter Zeit rückte vor allem der Einfluss des genet-
ischen Hintergrundes in den Fokus der Forschung. Transgene Mäuse, die einen
dominant-negativen glukoseabhängigen insulinotropen Polypeptidrezeptor unter
der Kontrolle des Ratten Proinsulin 2 Promotors exprimieren (GIPRdn-tg Mäuse)
wurden als Diabetesmodell ausgewählt. Um Licht auf stammabhängige Unter-
schiede in der quantitativen Morphologie der Niere und deren möglichen Einfluss
auf die Empfänglichkeit für die Entwicklung von diabetische Nephropathie zu
werfen, wurden GIPRdn-tg Mäuse auf einem zu Albuminurie neigenden (FVB/N)
und einem für Nierenläsionen eher unempfindlichen (C57BL/6J) genetischen
Hintergrund untersucht.
Die Analysen erfolgten an je acht sechs Monate alten GIPRdn-tg FVB/N-Mäusen,
GIPRdn-tg C57BL/6J-Mäusen und den zugehörigen Wildtyp-Kontrolltieren und
umfassten klinische und klinisch-chemische sowie qualitative, semiquantitative
und quantitativ-morphologische Untersuchungen der Nieren.
Klinisch zeigten GIPRdn-tg FVB/N-Mäuse hochgradige Hyperglykämie, Poly-
dypsie, Polyurie, erhöhten Blutdruck, sowie eine gegenüber FVB/N-wt Mäusen
um den Faktor zwölf erhöhte täglich ausgeschiedene Albuminmenge im Urin.
GIPRdn-tg C57BL/6J-Mäuse zeigten nur geringfügig erhöhte Blutglukosespiegel
und geringgradige Polyurie im Vergleich zu C57BL/6J-wt Mäusen. Die Ergebnisse
dieser Studie zeigen, dass zwischen GIPRdn-tg FVB/N- und C57BL/6J-Mäusen
erhebliche stammabhängige Unterschiede in der diabetischen Stoffwechsellage
bestehen.
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FVB/N-Mäuse wiesen im Vergleich zu C57BL/6J-Mäusen eine ähnliche Glomeru-
lumanzahl, ein höheres Nieren-, Glomerulum- und Podozytenvolumen und eine
niedrigere Podozytenzahl auf. Dies zeigt, das signifikante stammabhängige Un-
terschiede in der Nierenmorphologie zwischen FVB/N- und C57BL/6J-Mäusen
bestehen. GIPRdn-tg FVB/N-Mäuse zeigten im Vergleich zu FVB/N-wt Mäusen
Glomerulosklerose, renale, glomeruläre und podozytäre Hypertrophie, dilatierte
glomeruläre Kapillaren, eine erniedrigte Podozytenzahl und einer Verdickung
der glomerulären Basalmembran (GBM). Dagegen wiesen GIPRdn-tg C57BL/6J vs.
C57BL/6-wt Mäuse nur wenig erhöhte Nieren-, Glomerulum- und Podozytenvolu-
mina auf. Im Vergleich zu GIPRdn-tg C57BL/6J wiesen GIPRdn-tg FVB/N Mäuse
einen höheren Glomeruloskleroseindex, ein höheres mittleres Glomerulum- und
Podozytenvolumen, eine niedrigere Podozytenzahl und eine höhere GBM-Dicke
auf. Die zwischen den Wildtyp-Mäusen beider Stämme bestehenden renalen
morphologischen Unterschiede werden bei Vorhandensein von Diabetes noch aus-
geprägter. Die stammabhängigen Unterschiede in Parametern wie Hyperglykämie,
Blutdruck und Albuminurie können möglicherweise die Empfänglichkeit gegenüber
renalen Veränderungen beeinflussen, aber auch stammabhängige Differenzen im
mittleren Glomerulum- und Podozytenvolumen und der Podozytenzahl scheinen
eine Rolle in beiden genetischen Hintergründen zu spielen. Die geringfügige
Ausprägung der renalen Alterationen in GIPRdn-tg C57BL/6J Mäusen mag teil-
weise in den niedrigeren Blutglukosekonzentrationen begründet sein. Andere
Diabetesmodelle liefern jedoch trotz höherer Blutglukosekonzentrationen ver-
gleichbare Ergebnisse für C57BL/6J-Mäuse. Dies legt die Vermutung nahe, dass
die Nierenmorphologie ebenfalls einen Einfluss auf die niedrigere Empfänglichkeit
des C57BL/6J-Stammes für die Entwicklung von Nierenläsionen hat.
Zusammenfassend kann festgestellt werden, dass die Auswahl eines für Nieren-
läsionen prädisponierten genetischen Hintergrundes für Mausmodelle diabet-
ischer Nephropathie eine wichtige Rolle spielt. Angesichts der Faktoren, die
FVB/N-Mäuse für diabetische Nephropathie zu prädisponieren scheinen und der
entsprechend schwereren Nierenläsionen, können GIPRdn-tg FVB/N-Mäuse als
Modell für DN empfohlen werden. Dagegen erscheinen GIPRdn-tg C57BL/6J-
Mäuse auf Grund der relativen Unempfindlichkeit des genetischen Hintergrundes
gegenüber Nierenläsionen als Modell für DN weniger geeignet, sie sind allerdings
als Modell für die Untersuchung von Resistenzfaktoren gegenüber Diabetes oder
Nephropathien von Interesse.
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Appendix
Summary of results On the following pages, the most important results of both
the clinical analyses, the glomerulosclerosis and the quantitative stereological anal-
yses have been compiled. Statistically significant differences have been marked.
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Table A.1 Summary of results of clinical analyses
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Table A.2 Summary of results of clinical analyses 2
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Table A.3 Summary of results of morphological analyses
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